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Abstract 
The burden of Diabetes Mellitus (DM) is increasing worldwide and it is estimated to 
reach indefinite proportions of about 450 million by year 2030. Patients with type 2 
diabetes mellitus (T2DM) have a significantly increased risk of developing 
cardiovascular diseases (CVD). Moreover, CVD is the major cause of mortality and 
morbidity (75%) in T2DM patients. DM itself has been long recognised as an 
independent risk factor for several forms of CVD including coronary heart disease 
(CHD), peripheral arterial disease, cardiomyopathy and congestive heart failure in both 
men and women. It is well-known that T2DM is associated with several factors 
including hyperglycaemia, hypertension, dyslipidemia, obesity all of which contribute 
to CVD. In order to prevent CVD, early intervention on cardiovascular risk factors is 
vital during clinical assessment of T2DM patients. A major role of inflammation has 
been well described in the development of CVD in T2DM patients. Inflammatory 
process and factors which contribute to CVD in T2DM patients have recently become a 
focus in diabetic research. Elucidation of common patho-physiological mechanisms 
among T2DM patients might emphasize the role of inflammation in CVD. 
The main purpose of this study was to investigate any patho-physiological changes in 
red blood cells (RBC), white blood cells (neutrophils and lymphocytes) and plasma, 
measuring RBC membrane fragility and proteins, intracellular free calcium 
concentrations [Ca
2+
]i and several cations including Na
+,
 Mg
2+
, Ca
2+
, Fe
2+
, Zn
2+
 and 
Cu
2+
, biochemical parameters and inflammatory mediators which normally serve as 
independent predisposing risk factors for CVD among T2DM patients compared to age-
match healthy controls. 
The results have shown that fura-2 loaded neutrophils and lymphocytes in blood from 
T2DM patients contain significantly (p<0.05) less [Ca
2+
]i  than neutrophils and 
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lymphocytes from healthy subjects upon stimulation with  physiological doses of either 
fMLP or thapsigargin indicating a derangement in cellular calcium homeostasis during 
T2DM. Similarly, RBC membranes from T2DM patients contained significantly 
(p<0.05) more spectrin, ankyrin, band 3, band 4.1, glycophorin etc compared to RBC 
membranes from age-matched healthy control subjects. The results also show that the 
RBCs from T2DM patients were more fragile compared to RBC from healthy controls. 
Measurement of protein glycation in plasma have revealed significantly (p<0.05) more 
fluorescence in proteins form T2DM patients compared to control. In relation to plasma 
cations and intracellular markers and mediators, the results show that plasma from 
T2DM patients contain significantly (p<0.05) more Na
+,
 Mg
2+
 , Ca
2+
, Fe
2+
, Zn
2+
 and 
Cu
2+ 
compared to plasma levels from age-match healthy controls. Similarly, the 
concentrations of kidney and liver function markers such as urea, creatinine, alkaline 
phosphatase, ALT, AST, GGT, total protein and albumin increased significantly 
(p<0.05) compared to healthy controls. The same is also true for glucose, total 
cholesterol, triglycerides, CRP, HbA1c, WBC where the blood from T2DM patients 
contained elevated concentrations compared to blood from healthy age-matched control 
patients. 
Together, the results of this study have clearly demonstrated marked and significant 
changes in cellular calcium homeostasis in white blood cells, RBC membrane proteins 
and fragility, plasma protein glycation and in plasma levels of cations, intracellular 
markers and mediators of T2DM patients compared to healthy controls. Therefore, it is 
proposed that an early integrated and multi-factorial intervention of risk factors and 
inflammatory markers must be done in order to reduce the risk of CVD and possible 
mortality of T2DM patients.    
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Introduction 
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1.1 Scope of this study 
Diabetes mellitus (DM) is the most widespread complex metabolic disorder among the 
world‘s population currently affecting around 250 million people globally (Srinivasan et 
al., 2008). In early 1930‘s, Himsworth documented that two types of diabetes existed 
(Himsworth, 1936). This complicated metabolic syndrome is due to either insulin 
insufficiency or impaired action of the insulin hormone or both (American Diabetes 
Association, 2004). This disease is classified as insulin- dependent or type 1 diabetes 
mellitus (T1DM) and non-insulin dependent diabetes mellitus or type 2 diabetes 
mellitus (T2DM) of which both types of are associated with high levels of morbidity 
and mortality (Alberti et al., 2004). The epidemic of diabetes mellitus is accompanied 
by an increase in the incidence of diabetic complications including cardiovascular 
disease (CVD), retinopathy, nephropathy and microangiopathy, neuropathy and several 
other complications (Kumar and Clark, 2007). 
It is well understood that CVD are the leading cause of mortality and morbidity in 
T2DM patients as there is an increased risk of CVD in this particular population. Some 
of the types of cardiovascular risk encountered in diabetic patients include coronary 
heart disease (CHD), small vessel coronary artery disease (CAD), cerebrovascular 
disease, peripheral vascular disease, hypertension and congestive heart failure (Grundy 
et al., 1999). Diabetes-induced CVD is due to several conditions which are associated 
with increased concentration of glucose in the blood often referred to as 
hyperglycaemia. Dyslipidemia, hyperglycaemia and inflammation could also lead to 
insulin resistance (DSouza et al., 2009; Mooradian, 2009).  
There is strong evidence that inflammation forms the basis in the pathophysiology of 
both insulin resistance and CVD among T2DM patients (Sobel and Schneider, 2005) 
CVD has several underlying risk factors including the conventional hypertension, 
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hyperglycemia, increased levels of total cholesterol and low density cholesterol (LDL) 
and several other factors like race, origin, gender and smoking, lack of exercise, DM, 
genetics (Al-Ozairi et al.,2006)  as well as the non-conventional risk factors like 
considerable variations in the levels of inflammatory markers including C-reactive 
protein (CRP), Interleukine-6 (L-6), Tumour necrosis factor (TNF-a), C-peptide and 
fatty acid binding protein (FABP) are all involved in the pathogenesis of insulin 
resistance (Erdmann, 2005; DSouza et al., 2009).  
The main aim of this study was to identify and evaluate the levels of various 
biochemical parameters and inflammatory markers, which serve as predisposition 
factors and govern the susceptibility to CVD in T2DM patients of different ages 
compared to healthy age-matched controls.  
Chapter 1 of this study contains a general introduction of the subject area. Chapter 2 
summarizes materials and methods involved in tackling the scientific problems. Chapter 
3 of this thesis describes measurement of intracellular free calcium [Ca
2+
]i in 
neutrophils and lymphocytes of T2DM patients and healthy controls. Chapter 4 is an 
analysis of red blood cell membrane proteins in T2DM patients compared to healthy 
controls using SDS-PAGE and Chapter 5 of this thesis is an analysis of various 
biochemical parameters in T2DM patients and healthy controls. Chapter 6 involves 
analysis of low molecular weight advanced glycation end products (AGEs), anti-oxidant 
status and osmotic fragility of red blood cells (RBC) in T2DM patients compared with 
healthy age-matched controls. Chapter 7 is a general discussion of this study followed 
by conclusion, the scope for future studies, the references, appendix and presentations. 
1.2 Type 2 Diabetes Mellitus (T2DM) 
Diabetes mellitus (DM) can be described as a metabolic disorder which is caused by the 
deficiency of insulin hormone secreted by the pancreatic beta cells (Rosenbloom et al., 
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2008). The hormone is responsible for the uptake of glucose from the blood mainly into 
muscle and fat cells of the body and it also inhibits hepatic glucose production, and 
therefore regulates the concentration of blood glucose at normal levels of 4-6 mmol/l 
(Kumar and Clark, 2007). 
1.2.1 Classification of diabetes 
Generally, there are two types of DM namely, T1DM and T2DM. T1DM is also called 
insulin dependent or early onset diabetes, which is diagnosed during childhood and 
accounts for about 5-10% of DM. T1DM is due to autoimmune destruction of 
pancreatic β cells in islets of Langerhans resulting in a decrease of insulin production. 
T1DM is commonly associated with microvascular complications including 
nephropathy and retinopathy and it also predisposes to CHD (Adler et al., 2003). 
T2DM is also called non-insulin dependent DM (NIDDM) or late onset diabetes and it 
is the most prevalent form of diabetes which usually makes its appearance later in life. It 
is due to a combination of defective secretion of insulin by pancreatic β cells and 
impairment of insulin- mediated glucose disposal, which is called insulin resistance. 
This accounts for 90-95% of DM (Kumar and Clark, 2007; DSouza et al., 2009; Ripsin 
et al., 2009; Ahmed, 2010). 
The World Health Organisation classified diabetes in 1980 and revised it in 1985 into 
the two most common types which was insulin-dependent diabetes mellitus (IDDM) 
and non-insulin-dependent diabetes mellitus (NIDDM). Depending on the nutrition 
status, the WHO also categorized DM into other types like malnutrion-related diabetes, 
which is now omitted from the new classification due to its unknown aetiology, and 
diabetes, which is diagnosed during pregnancy as gestational diabetes. The WHO 
ultimately authorized the classification proposed by the American Diabetes Association 
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(ADA), which was based on aetiology in 1997 (Holt, 2004; Kumar and Clark, 2007; 
Ahmed, 2010).  
1.2.2 Symptoms 
Both types of diabetes have similar symptoms, but for T1DM the symptoms develop 
more rapidly in days or weeks. They include polyuria, polydipsia, unexplained weight 
loss, muscle wasting, fatigue, cramps, constipation, blurred vision and skin infections. 
Diabetes is often diagnosed from those complications of untreated patients like foot 
ulcers and eye problems. The various long term complications due to DM are classified 
as macrovascular, microvascular and nephropathic which cause different dysfunctions 
and are the major causes of morbidity and mortality in Diabetics (Kumar and Clark, 
2007; Song and Hardisty, 2008; Ahmed, 2010).  
1.2.2.1 Hypoglycaemia 
Hypoglycaemia occurs due to low blood glucose levels. It is caused by over medication, 
excessive exogenous insulin, and strenuous exercise. Sometimes it may even lead to 
seizures, coma and irreversible brain death as blood glucose regulates the functioning of 
body and organs including the brain. Symptoms due to hypoglycaemia include 
irritability, sweating, tingling lips, weakness, hunger and nausea (Kumar and Clark, 
2007; Ahmed, 2010). 
1.2.2.2 Hyperglycaemia 
Hyperglycaemia is due to an increase in blood glucose levels. It is due to many factors 
including not taking medication or exogenous insulin, or by not controlling the diet or 
taking exercise. It may also occur due to autoimmune destruction of β-cells of pancreas. 
Symptoms include increased thirst and urination, blurred vision, lethargy, weight loss, 
cramps and dehydration. Lack of insulin also releases ketones into the blood which in 
turn raise the acidity of the blood leading to a state called ketoacidosis. Both hypo and 
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hyperglycemia are reversible and can be treated (Kumar and Clark, 2007; DSouza et al, 
2009; Ahmed, 2010).  
1.2.2.3 Diet, physical activity and diabetes 
Since this study is concerned mainly with T2DM, much emphasis will be placed on this 
type of DM. T2DM results from an interaction between genetic and environmental 
factors. The rapidly changing incidence rates, however, suggest a predominantly 
significant role for the latter as well as a potential for stemming the tide of the global 
epidemic of the disease. The most remarkable increases in T2DM are occurring in 
societies in which there have been major changes in the type of diet consumed, 
reductions in physical activity, and increases in overweight and obesity (Aronne and 
Segal, 2002).  
The diets concerned are typically energy-dense, high in saturated fatty acids and 
depleted in non-starch polysaccharides (NSP). In all societies, overweight and obesity 
are associated with an increased risk of T2DM, especially when the excess adiposity is 
centrally distributed (Parker et al., 1993). Conventional body mass index (BMI) 
categories may not be an appropriate means of determining the risk of developing 
T2DM in individuals of all population groups because of ethnic differences in the 
composition of the body and because of the importance of the distribution of excess 
adiposity. While all life style-related and environmental factors, which contribute to 
excess weight gain, thus may be regarded as contributing factors to T2DM. The 
evidence that an individual‘s dietary factors have an effect, which is independent of 
their obesity promoting effect, is unconvincing. Evidence that saturated fatty acids 
increase risk of T2DM and that NSP are protective is more convincing than the 
evidence for several other nutrients, which have been implicated (Lindgarde et al., 
2006). The presence of maternal diabetes, including gestational diabetes and intrauterine 
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growth retardation appears to increase the risk of developing diabetes in future 
(Dabelea, 2007).  
The association between excessive weight gain, central adiposity and the development 
of T2DM is convincing. The relationship has been frequently demonstrated in 
longitudinal studies in diverse populations, with a striking gradient of risk apparent with 
increasing levels of BMI, adult weight gain, waist circumference and waist-to-hip ratio 
(Despres et al., 2001). Indeed, either waist circumference or waist-to-hip ratio 
(reflecting abdominal or visceral adiposity) is a more powerful determinant of 
subsequent risk of T2DM than BMI (Colditz, 1990). 
Central adiposity is also a vital determinant of insulin resistance, the underlying 
abnormality in most cases of T2DM (Hayashi et al., 2003). Voluntary weight loss 
improves insulin sensitivity (McAuley et al., 2002) and several randomized controlled 
trials have been shown to reduce the risk of progression from impaired glucose 
tolerance to T2DM (Tuomilehto et al., 2005).  
Longitudinal studies have clearly indicated that increased physical activity reduces the 
risk of developing T2DM regardless of the degree of adiposity (Myers et al., 2003). 
Vigorous exercise (i.e. training to an intensity of 80--90% of age-predicted maximum 
heart rate for at least 20 minutes, at least five times per week) has the potential to 
substantially enhance insulin sensitivity. Physical activity might decrease T2DM by 
increasing insulin sensitivity although the intensity and duration of physical activity 
required to improve insulin sensitivity has not been established (Jeon et al., 2007). 
Insulin sensitivity also increases with physical activity according to a study based on 
questionnaires (Mayer-Davis et al., 1998). Offspring of diabetic pregnancies (including 
gestational diabetes) are often large and heavier at birth, tend to develop obesity in 
childhood and are at high risk of developing T2DM at an early age in life (Cook & 
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Hurley, 1998). Those born to mothers after they have developed diabetes have a three-
fold higher risk of developing diabetes than those born before (Momiyama et al., 1999).  
A number of studies, mostly in developing countries, have suggested that intrauterine 
growth retardation and low birth weight are associated with subsequent development of 
insulin resistance (McCance et al., 1994). In countries where there has been 
malnutrition, insulin resistance may have been selectively advantageous in terms of 
surviving famine. In populations where energy intake has increased and lifestyles have 
become more sedentary, however, insulin resistance and the consequent risk of T2DM 
have been enhanced. In particular, rapid postnatal catch-up growth appears to further 
increase the risk of  T2DM in later life (Cook and Hurley, 1998). Appropriate strategies, 
which may help to reduce the risk of T2DM in this situation, include improving the 
nutrition of young children, promoting linear growth and preventing energy excess by 
limiting intake of energy-dense foods, controlling the quality of fat supply, and 
facilitating physical activity. At a population level, foetal growth may remain restricted 
until maternal height improves. This may take several generations to correct (Lindsay, 
2009). The prevention of T2DM in infants and young children may be facilitated by the 
promotion of exclusive breast feeding, avoiding overweight and obesity, and thus, 
promoting optimum linear growth.  
1.3 Epidemiology of T2DM 
T2DM is a multifaceted disorder due to both genetic, lifestyle and environmental factors 
and it accounts for up to 90-95% of total diabetes cases. In the United Kingdom, around 
2.4 million people have T2DM. Globally, over 250 million people have DM. The 
prevalence of diabetes has been increasing day by day and is expected to reach 
indefinite proportions by 2030 (Zimmet et al., 2003). The worldwide distribution and 
the prevalence of T2DM are increasing rapidly. It has been envisaged by the World 
 Page 9 
 
Health Organisation (WHO) that the number of people with diabetes will be doubled by 
the year 2030 reaching almost 500 million (Holt, 2004).  
The incidence of T2DM varies enormously from one population to the other. A major 
discrepancy in the frequency of this disease globally has been very well established by 
several prospective population-based studies. Much information on the incidence of 
T2DM is unavailable though it is the most common form of diabetes, which has no 
genetic factors associated with it. The Pima Native Americans of Arizona and those 
from South Pacific Island of Nauru are found to have the maximum rates of people with 
diabetes (Barnett, 2005). 
In the present world, diabetes has become one of the most expensive health conditions 
to treat. In the United Kingdom, for example, it costs the NHS £5 billion to diagnose, 
treat and care for diabetic patients and UK only has 2.5 million cases. If these numbers 
are extrapolated to the current 250 million people globally, then it will cost the 
Governments of the world £500 billion annually to diagnose, treat and care for diabetic 
patients. Its prevalence worldwide has been growing in most populations (King et al., 
1998). Due to its insidious onset and asymptomatic nature, diabetes remains 
undiagnosed in many people which makes them susceptible to life-threatening 
complications, and thus reducing the quality of life. 
1.4 Pathogenesis of T2DM 
The two main reasons underlying the pathophysiology of T2DM are impaired insulin 
secretion due to the dysfunction of pancreatic beta cells and impaired insulin action 
because of insulin resistance (Kumar and Clark, 2007). A breakdown of these two 
mechanisms consequently results in abnormal high levels of plasma glucose 
concentrations that are usually maintained at a definite range irrespective of the various 
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changes for the requirement and supply which is regulated by a dynamic process 
between tissue sensitivity and insulin (Kasim-Karakas, 2000).  
Inflammation and inflammatory cytokines have been very recently suggested to be the 
reason for the development of insulin resistance and T2DM. Insulin resistance develops 
from physical inactivity, obesity along with a substrate of genetic susceptibility. It is 
commonly accompanied by other cardiovascular risk factors like dyslipidemia, 
hypertension and pro-thrombotic factors (Al-Ozairi et al., 2006). These factors together 
in an individual are called the metabolic syndrome, which precedes T2DM (Kumar and 
Clark 2007, Ahmed, 2010). 
1.5 Diagnosis 
There was major perplexity regarding the criteria for diagnosis of diabetes mellitus 
before the 1970s. The WHO has put forward its first statement on the diagnosis of 
diabetes in 1965, which was later tailored and made simple. The ADA proposed its first 
diagnostic criteria following WHO, which emphasised on the concentration of fasting 
glucose. Consequently, WHO revised its old version. Figure 1.1 shows a flow diagram 
for the diagnosis and screening of T2DM including IGTT (Jonathan and Donald, 2003). 
Since the diagnosis of diabetes mellitus has major implications on social, legal and 
medical aspects of an individual, security for diagnosis is indispensable. The test for 
diagnosing diabetes should include a venous plasma sample that can be tested in an 
accredited laboratory. A recent report by WHO recommends the acceptability of 
glycated haemoglobin (HbA1c) as an additional test to diagnose diabetes.  
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Figure 1.1: Diagnosis and screening for T2DM and impaired glucose metabolism 
(Taken from Jonathan and Donald, 2003).     
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1.6 T2DM: genetic and environmental factors. 
T2DM is a multifactorial disease caused by the interaction of both genetic and 
environmental factors. Its strong genetic component is suggested by its familial 
aggregation and transmission patterns. Other factors include its high concordance rate in 
twins (60-100%), and its high prevalence in certain ethnic populations after controlling 
for lifestyle factors. The role of environmental factors is established in populations that 
are genetically similar, but have different living conditions (Kraine and Tisch, 1999). 
Predisposition to develop T2DM following a change in lifestyle of an individual can be 
explained by the "thrifty genotype" hypothesis. According to this theory, factors in early 
humans that favoured fat deposition during periods of abundant food conferred survival 
advantage during subsequent periods of hardship and perhaps starvation, leading to the 
selection of genes for insulin resistance (James, 1962). However, these factors may be 
unfavourable to the individual post-urbanisation, resulting in the development of 
diabetes during the normal ageing process or with the onset of obesity (McDermott, 
1998; Lee, 2001). Consequently, relative resistance to glucose uptake in skeletal muscle 
leads to increased adiposity contributing to the pathogenesis of diabetes and other 
metabolic abnormalities (Dube et al., 2006). 
In contrast, the "thrifty phenotype" theory proposes that the excess modem living is the 
major cause for insulin resistance (Hales and Barker, 2001). These excesses lead to 
reprogramming of carbohydrate metabolism and subsequent β cell dysfunction and 
insulin resistant tissues. Disparities in T2DM and its complications between ethnic 
groups suggest that T2DM may represent a selection of particular genotypes in response 
to different evolutionary pressures (Speakman, 2008). 
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1.7 Cellular basis for type 2 diabetes 
1.7.1 Introduction 
Insulin resistance and a deficiency in insulin secretion are the major cellular basis of 
T2DM (Mahler and Adler, 1999). The action of insulin is to lower the glucose levels in 
the blood and to stimulate the uptake of glucose principally in muscle and liver cells, 
thus involved in promoting glucose oxidation and glycogenesis (Johnson et al., 2008). 
Insulin also plays a major role in controlling the production of hepatic glucose and 
inhibits lipolysis, which is the process of breakdown of fat in adipose tissue (Barbetti, 
1996). The initiation of the insulin action takes place by its binding to the extracellular 
domain of the β subunit in the insulin receptor, leading to auto phosphorylation of 
several tyrosine residues in the intracellular domain of the β subunit. Activation of 
tyrosine kinase of the insulin receptor, by insulin, then directs to phosphorylation of 
tyrosine residues on the insulin receptor substrates 1 and 2 (IRS-I and IRS-2), shc, and 
various other intracellular proteins which are uncharacterised (Polonsky et al., 1996). 
Consequently, the insulin-signalling cascade is triggered when the phosphotyrosines of 
these proteins bind to SH2 domains on the other signal kinases. IRS proteins 
preferentially involve in different signal pathways for glucose uptake as well as 
glycogen synthesis. They also involve in stimulating protein synthesis by transferring 
both the growth promoting and mitogenic signals of insulin to the nucleus (Polonsky et 
al., 1996; Ahmed, 2010).  
1.7.2 Insulin resistance  
The presence of a very high and unusual amount of endogenous or exogenous insulin to 
obtain a normal biologic response is the state of insulin resistance (IR). In muscle, fat 
and liver cells, the resistance to endogenous insulin is compensated by the high levels of 
serum insulin in association with normal or high blood glucose concentrations. The 
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main cause underlying diabetes, hypertension and coronary heart disease is insulin 
resistance (Nosadini et al., 1993; Ahmed and Thornalley, 2007; DSouza et al., 2009).  
Different environmental factors and the diverse patterns of lifestyle habits are involved 
in the development of insulin resistance in a person. Glucose intolerance, 
hyperinsulinemia, dyslipidemia and hypertension are included in the insulin resistance 
syndrome. Insulin resistance may occur due to many reasons involved in the functioning 
of insulin which can be either at the stage of the binding of insulin to the receptor or 
after the level of downstream signalling (Kumar and Clark, 2007). These defects caused 
by mutations in the insulin receptor gene which may include alterations in the receptor 
number, structure and function in signalling resulting in insulin resistance (Nigro et al., 
2006). The high levels of circulating free fatty acids increase the release of glucose from 
the liver reducing the disposal of glucose in the skeletal muscle leading to insulin 
resistance. Substantial information have established that the increased levels of 
inflammatory markers in the insulin resistance state helps in predicting the progress of 
T2DM and cardiovascular diseases (Festa et al., 2003). 
Adipose tissue plays a major role in the state of insulin resistance by producing the 
complement factor B, adipsin, acylation-stimulating protein. In addition, the adipose 
tissue also help in triglyceride synthesis and they are also involved in the increase of 
paracrine signalling (DeFronzo, 2006).  
In T2DM, the inability of insulin to maintain normal glycaemic levels is caused by a 
combination of both insulin resistance and a fault in glucose-stimulated secretion. 
Insulin resistance has been a strong predictor of T2DM, which is identified as 
hyperinsulinemia 10 to 20 years preceding the diagnosis of the disease. 
 Page 15 
 
The major causes of insulin resistance in T2DM are defects in glucose oxidation and 
glycogen synthesis in skeletal muscle. It is observed that when adipocytes are taken 
from T2DM, they are found to have impaired insulin-stimulated glucose uptake and 
moreover, lipolysis is increased.  By reducing glucose oxidation through the glucose 
fatty acid cycle in the muscle, it is possible that the elevated levels of circulating free 
fatty acids will induce insulin resistance. Greater levels of free fatty acids can also 
induce insulin resistance by reducing hepatic clearance of insulin and by enhancing 
gluconeogenesis (Tang et al., 2001).  
It has been previously suggested that long chain fatty acids are actively involved in 
directly affecting the glycogen synthase activity and can also modulate the transcription 
of pancreatic β cell transcription factor HNF-4α. Increased expression of cytokines may 
also result in insulin resistance. When tumour necrosis factor (TNFα) is over expressed 
in obese people, it inhibits the phophorylation of insulin receptor and insulin receptor 
substrate (IRS-1), which in turn blocks the insulin-signalling cascade in the adipose 
tissue (Federici, 2004). In T2DM, the isoform of low affinity insulin receptor and 
hybrid receptors when over expressed are also proposed to contribute to insulin 
resistance (Kroder et al., 1996). 
Hybrid receptor is formed when fusion occurs in between the insulin and insulin growth 
factor (IGF) receptors (Sesti et al., 2005). The insulin receptor is found to be negatively 
correlated with insulin sensitivity in vivo as it has greater affinity for insulin like growth 
factor (ILGF) than insulin (Yamauchi et al., 1996). Recent studies have also suggested 
that insulin resistance is caused by poor foetal and postnatal nutrition, leading to β cell 
dysfunction and insulin resistant tissues and thus can be detected by low birth weight of 
the child.  According to "thrifty phenotype" hypothesis, these individuals have a greater 
chance of developing diabetes with the onset of diabetes during the later stages of life 
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(Hales & Barker, 2001). In contrast, the "thrifty genotype" theory also proposed that 
smaller birth weight would enable the foetus to store energy and fat more efficiently in 
an unfavourable intrauterine environment and this can be genetically determined 
(Dunger et al., 2007). 
1.7.3 Insulin secretion 
In response to increasing plasma glucose concentrations, pancreatic β cells are involved 
in the secretion of insulin. In subjects with T2DM, several abnormalities in β cell 
insulin secretion have been detected. Insulin response to intravenous glucose is 
decreased in patients with T2DM, with loss of the first phase insulin secretion response, 
defective pulsatile pattems, and hyper-proinsulinaemia (Gumbiner et al., 1996). 
T2DM is characterised by a 20-50% reduction in β cell mass and this could be an 
impulsive factor in defective insulin secretion. Progressive loss of β cell function is 
associated with insulin resistance in skeletal muscle, and in the formation of islet 
myeloid deposits in the pancreas. In turn, this can induce pancreatic β cell death in vitro 
(Westermark & Wilander, 1978). In early or first-phase insulin secretion, the pattern of 
loss is the initial defect followed by a reduction in glucose to potentiate non-glucose 
signals, and finally β cell failure that requires insulin treatment (Lorenzo et al., 1994). 
In mice, the development of islet amyloid has been attributed to a high fat diet and it is 
associated with hyperglycaemia. However, a 50% reduction in β cell mass alone is not 
enough to explain the fasting hyperglycaemia observed in these animals, suggesting that 
the amyloidogenic process may impair the function of islet cells prior to cell death and 
reduction in islet mass (Verchere et al., 1996).  
Mitochondrial DNA (mtDNA) may also affect insulin action. Mitochondria are the 
major site for Krebs cycle function, ATP synthesis and transfer of fatty acids (Ahmed, 
2010). Elevated ATP in the cytoplasm is necessary for the membrane-dependent 
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increase in cytosolic Ca
2+
, which in turn triggers insulin exocytosis by the β cell. 
Patients with T2DM are found to have approximately 35% less mtDNA in their 
peripheral blood leukocytes (Lee et al., 1998). This reduction has been observed to 
precede the onset of diabetes. Low copy numbers of mtDNA are inversely correlated to 
fasting plasma glucose levels in patients with T2DM, and are associated with insulin 
resistance and defective insulin secretion in the offspring of diabetic mice. Mothers with 
low mtDNA in their peripheral blood leukocytes, tend to have offspring‘s with low birth 
weight indicating that mtDNA content may be an significant characteristic of the 
heritable ―thrifty phenotype" (Lee, 2001).  
The relationship between low levels of mtDNA and diabetes is unknown. In vitro, β cell 
depletion of mitochondrial DNA results in altered mitochondrial morphology and 
inhibition of glucose-stimulated ATP production that is required for downstream insulin 
release by the islet β cell (Lee et al., 2005). Glucose toxicity may be another mechanism 
for defective insulin secretion. When β cells are exposed to high glucose levels for 
prolonged period, impaired insulin gene transcription can result in decreased insulin 
secretion. Chronic exposure to high levels of glucose can also cause defective K
+
 
channel function and a reduced expression of GLUT-2, which is responsible for glucose 
storage and transportation to the cell membrane (Maechler & Wollheim, 2000).  
Severe hyperglycaemia is correlated with increased insulin deficiency (DSouza et al., 
2009). Once hyperglycaemia has developed, glucose toxicity can induce insulin 
resistance and decreased pancreatic β cell function. It has been predicted that a 50% 
decrease in β cell function (i.e. decreased β cell function) in the presence of insulin 
resistance may induce hyperglycaemia (Chen et al., 1998).  
In addition, glucose responsive tissue resistance to insulin will increase as β cell 
function decreases (Gerich, 2003). Hyperglycaemia can be considerably improved by 
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insulin therapy or by sulfonylureas and treatment with diet, resulting in reduction of 
insulin resistance and glucose toxicity (Cook et al., 1993). Insulin secretion and 
resistance are hence interrelated at several levels; however, it is unclear which defect is 
primary in the aetiology of diabetes (Kahn and Porte, 1988). It has been envisaged that a 
50% decrease in β cell function in the presence of insulin resistance results in 
significant levels of hyperglycaemia (Halter et al., 1985). Once hyperglycaemia 
develops, glucose itself leads directly to a loss of glucose induced-insulin release and 
impairment in glucose disposal (glucose toxicity), resulting in exacerbation of the 
disease state (Meece, 2007).  
1.8 Genetics of type 2 diabetes mellitus 
Both the types of diabetes mellitus have a characteristic feature to run in a family, which 
indicates a genetic predisposition to the disease. Different genes are likely to be 
involved in each type of DM as they have major difference in their underlying 
aetiology. The wide spread distribution and the ever growing prevalence of T2DM in 
the modern society has urged the research community to investigate the underlying 
genetic defects of the disease. The statement that T2DM is principally caused by genetic 
factors is known for many years. Until recently, the identification of genetic variants, 
contributing to the difference among individual susceptibility to T2DM is characterised 
by very slow progress in spite of strenuous efforts (Kahn et al., 1996). 
With the advances in the techniques involved in gene expression, like genome-wide 
association analysis, there has been a remarkable transformation in the ability to mark 
the common genetic variants, which play a major role in contribution to the 
predisposition of complex metabolic disorders such as T2DM during the last few years. 
Around 20 common variants have been implicated in the susceptibility of T2DM 
through related studies (Shu et al., 2010). 
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The two main candidate gene associations claimed for T2DM are Pro12Al variant in the 
peroxisome proliferator-activated receptor gamma (PPARG) gene, which encodes the 
target for thiazolidinedione class of drugs and the Glu23Lys variant in KCNJ11, which 
encodes the target for sulphonylureas (Gouda et al., 2010). These are the two most 
common polymorphisms involved in influencing the risk of T2DM. Some rare 
mutations in both of these genes are also involved in other syndromes, which have 
severe metabolic disturbances as their characteristic feature (Gouda et al., 2010).  
It has been reviewed earlier that the variants in the PPARG, KCNJ11 and TCF7L2 
genes are confirmed as carriers of established T2DM susceptibility loci and studies have 
led to further identification and replication of novel T2DM-susceptibility loci (Chauhan 
et al., 2010). The discovery that the variants in the Transcription factor 7-like 2 gene 
(TCF7L2) have a great effect on the susceptibility to T2DM has paved the way to 
identification of genes related to T2DM including gene association studies. After 
several replication studies, it has been finally proven that, the variants in TCF7L2 have 
a powerful role than those of PPARG and KCNJ11. It has been reported that almost 
10% of Europeans carrying this homozygous allele have a greater risk of developing 
T2DM than those without it (Zeggini and McCarthy, 2007). Alterations in either 
TCF7L2 gene function or expression causes disturbance in the function of pancreatic 
islet cells thereby dysregulating the gene expression of proglucagon, which decreases 
the secretion of insulin and results in T2DM. The effort towards discovering the genes 
responsible for a disease is driven by expectations to generate key insights into its 
various mechanisms giving a chance for clinical translation (Zeggini and McCarthy, 
2007; Chauhan et al., 2010). Further knowledge of the various biochemical pathways 
involved in T2DM is required for future research to understand the genetic variation in 
populations. 
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1.8.1 Candidate genes for type 2 diabetes 
The aetiology and pathogenesis of insulin resistance involve multiple signalling 
proceedings and pathways, and therefore a number of target genes. See (Table 1.1). 
Numerous researchers have sought to identify a genetic determinant that may be 
sufficient to considerably impair one or more of the major transduction pathways. 
Linkage of diabetes to different genetic loci in diverse populations has been well 
demonstrated by whole genome studies (Kahn, 1988; Mahtani et al., 1996).  
On the other hand, mutations in individual genes resulting in defective insulin secretion 
and signalling leading to T2DM have been unidentified by the candidate gene approach, 
which tests the association of a particular gene to diabetes.  However, a single gene 
mutation is yet to be identified, with exception of monogenic form of diabetes (Hart et 
al., 1999).       
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Table 1.1: Candidate genes for insulin resistance and insulin secretion defects. 
 
Insulin resistance genes 
Insulin receptor     
Insulin receptor substrate- I    IRS-1 
Glucose transporter-4     GLUT-4 
Glycogen synthase     GYS 
Amylin      IAPP 
β -3-adrenergic receptor    β-3AR 
Fatty acid binding protein 2    FABP2 
Obesity      OB 
Prohormone convertase-2    PC-2 
Tumour necrosis factor- α    TNF- α 
Ras associated with diabetes    Rad 
Insulin secretion defects 
Glucose transporter-2     GLUT-2 
Maturity onset diabetes of the young   MODY1, 2,3,4,5 
NeuroD1/ β 2                                                    β 2 
Mitochondrial DNA     mtDNA 
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1.9 Cardiovascular diseases (CVD) 
The major cause of mortality and morbidity worldwide among diabetics is due to CVD 
which are expected to reach indefinite proportions very soon (Murray and Lopez, 1997). 
The burden of CVD is a major challenge for community health worldwide and this has 
been especially noticeable in developing countries. The WHO placed CHD in the sixth 
place for morbidity and mortality and it is believed that it which would reach first place 
in future (Hoang et al., 2003). CHD is caused because of accumulation of atheromatous 
plaques inside the arterial walls which supply the myocardium (Mensah, 2007). It has 
been suggested that healthy men and women have a chance of developing CVD at age 
40 and above (Rosamond et al., 2007).  
According to WHO, CVD had affected around 15 million people in 1990, which 
increased to 17 million in 1999 and this figure is expected to reach 25 million in 2020 
(Murray and Lopez, 1997). The fact that CVD is associated with the lifestyle habits of 
an individual including high fatty diet, smoking, lack of exercise has been well known 
for years. Increased urbanisation in developing world has brought about a major 
difference in the various aspects of life, ultimately making it sedentary. The prevention 
of CVD is an important social and economic issue as it costs the UK Government, £26 
billion per year (BHF, 2007). It is of paramount importance to identify individuals at 
higher risk of a cardiovascular event and to manage their lifestyle. Understanding the 
molecular mechanisms in the progression of CVD and developing novel approaches for 
prevention and treatment of CVD is urgently required at this moment in time. 
1.9.1 Development of atherosclerosis 
The presence of atherosclerotic lesions within the vasculature is virtually a pre-requisite 
for acute ischaemic events. Complex lesions within the coronary arteries can cause 
luminal occlusion leading to stable and unstable angina pectoris (Dsouza et al., 2009). 
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Either erosion or rupture of vulnerable lesions can cause to atherothrombotic 
complications leading to myocardial infarction (MI), stroke, renal failure, heart failure, 
sudden death and peripheral vascular disease (PVD) (Cohn, 2004). Indeed, 
atherosclerosis and atherothrombosis are generalised processes, although vascular 
pathology is usually discussed and managed on an organ-by-organ basis. Patients may 
only clinically present with arterial pathology in a specific area, but the disease is 
almost invariably ubiquitous, and it is the root cause of the associated morbidity and 
mortality. For example, in a study of 1500 patients with leg artery atherosclerosis 
(intermittent claudication), it was found that in a 4-10 year follow-up, 60% of deaths 
were cardiac, 17% were cerebrovascular, and 8% were due to other vascular causes and 
complications such as ruptured aortic aneurysm (Kahn, 1988; Laing S. et al., 1991). In 
addition, a recent study has established that the ankle brachial blood pressure index 
(ABI) (a marker of peripheral atherosclerosis and subclinical stenosis) is associated with 
the site and number of arterial beds affected by atherosclerosis in vascular patients and 
to a lesser extent with the patient risk factor profile. These studies show that the 
atherosclerosis underlying the claudication pathology and this is also by far the main 
cause of mortality in this patient group. 
It is therefore advantageous to fully comprehend the complex cellular and molecular 
interplay involved in the development of atherosclerosis, considering the ubiquitous 
nature of atherosclerosis in the Westernised population, and its diffused nature in the 
vasculature. The rationale is that individuals who are at risk of progressing to an event 
may be identified at an early stage. Equally, it is also possible to identify pathways of 
therapeutic intervention for these individuals.  
Until the mid-1970s, atherosclerosis was considered a bland lipid storage disease where 
lesion swelling and stenosis were thought to be the primary cause of luminal occlusion 
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leading to ischemic heart disease and stroke (Ross & Harker, 1976). Indeed, much 
historical and current evidence supports the role of plasma lipids (cholesterol and 
triglycerides) and lipoproteins (low-density lipoprotein [LDL] and very low density 
lipoprotein [VLDL]) in atherogenesis (Kannel, 1979; Martin et al., 1986). To suggest 
that lipid storage alone is the cause of atherogenesis is, however, an over-simplification. 
With the extent of atherosclerosis being proportional to sustained blood lipid 
concentration in most cases, it would be a reasonable assumption that the main driving 
force would be hyperlipidaemia, if atherosclerosis was purely a lipid storage disease 
(Lloyd-Jones et al., 2001). Though hyperlipidaemia is a major risk factor for future 
cardiovascular death, almost half of all coronary events occur in individuals without 
clinical hyperlipidaemia (Braunwald, 1997) and other risk factors such as smoking and 
blood pressure are of similar importance. Furthermore, hyperlipidaemia is only weakly 
related to ischemic stroke (Shahar et al., 2003).  
Adipocytes play a very important role in the process of development of atherosclerosis 
by producing inflammatory factors like tumour necrosis factor, interleukine-6, 
interleukine-8, interleukine-10, monocyte chemoattractant protein-1, plasminogen 
activator inhibitor-1 and also adipokines such as adiponectin, leptin, angiotensinogen 
and resistin all of which accelerate the progression of atherosclerotic events (Hattori et 
al., 2006). It has been shown very recently that leptin enhances cellular immune 
responses and it also takes part in the increase of blood pressure. It has been observed 
that leptin tends to decrease the sensitivity to insulin when injected in obese rats. In the 
presence of high levels of glucose, leptin is also involved in the accumulation of 
cholesterol by the macrophage (Piemonti et al., 2003).  
The development of atherosclerosis in vivo is currently thought to be a more complex 
process, requiring persistent lipid presence, endothelial dysfunction and inflammation 
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(Libby et al., 2002; Szmitko et al., 2003; Willerson and Ridker, 2004; Hansson, 2005) 
(See Figure 1.2). This model in Figure 1.2 gives inflammatory cells and cytokines a 
pivotal role in the development of the lesion. 
 
 
Figure 1.2: Schematic diagram showing the development of atherosclerosis 
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Low density-lipoprotein (LDL) infiltrates the arterial wall and is modified by oxidation 
processes. It is then phagocytosed by macrophages which become active inflammatory 
lipid-laden foam cells characteristic of early atherosclerotic fatty streaks. Activated 
local endothelium starts to produce P- and E- selectins and integrins such as vascular 
cell adhesion molecule-1 (VCAM-1). Monocytes and activated lymphocytes from the 
periphery roll adhere and extravasate into the tissue. Macrophages activated via toll like 
receptors (TLRs) produce inflammatory cytokines, chemokines, proteases, and free 
radicals which perpetuate inflammation and damage tissue. A Th1 type adaptive 
response becomes established and interferon- (IFN-) γ is produced. This stimulates 
further activation of macrophages and proliferation of smooth muscle cells (SMCs). A 
stable fatty lesion develops with the collagenous cap manufactured by the SMCs. 
Production of IL-6 and other cytokines (interleukin-1, TNFα) leads to stimulation of the 
hepatic acute phase response (APR) releasing acute phase reactants such as fibrinogen, 
serum amyloid A, and C-reactive protein (CRP) (Taken from Hansson, 2005). 
1.9.2. Role of inflammation in the pathogenesis of atherosclerosis 
Accumulating evidence from both basic and applied laboratories indicates that 
inflammation plays a critical role in several stages of atherogenesis, including acute 
plaque rupture as well as early initiation of foam cell deposits (Libby et al., 2002). The 
plaque is typically an advanced atherosclerotic lesion covered by a fibrous cap 
consisting of smooth muscle cells and connective tissue containing macrophages and T 
lymphocytes. Under the fibrous cap, the lipid-rich core is filled with macrophages, 
lipids, calcium and other materials. Unstable plaques often have activated macrophages 
and leukocytes on their ―shoulders‖. Certain characteristics may predispose a plaque to 
rupture. These characteristics include a softer lipid core, the presence of macrophages, 
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fewer smooth muscle cells, a thinner fibrous cap and increased inflammatory activity 
(Adams III and Vickie, 2001). Cytokines, which cause the de novo hepatic production 
of acute phase reactants, such as C-reactive protein, have been shown to increase in 
acute coronary syndromes (Liuzzo et al., 1994). 
1.9.3 Endothelial dysfunction 
Endothelial dysfunction is commonly described as a diminished ability of the 
endothelium to produce the vasorelaxing compound nitric oxide (NO), or a profound 
imbalance in the relative amounts of other vasoactive compounds such as angiotensin II 
and oxidants (Verma and Anderson, 2002). Using this definition, endothelial 
dysfunction is confined to unfolding inappropriate vasomotor constriction of the 
vasculature, consequently aggravating luminal occlusion caused by conventional 
atherosclerotic lesions.  
In atherosclerotic development, however, diminished NO production by the 
endothelium is an intricate player in the development of patho-physiological 
inflammatory and molecular processes in the vasculature (Szmitko et al., 2003).   
In addition to vasodilatory effects, NO also generates an anti-thrombotic environment 
by limiting platelet aggregation at the endothelium (Freedman et al., 1997), In turn, this 
prevents leukocyte adhesion to the endothelium by suppressing expression of adhesion 
molecules (Gauthier et al., 1995) and it maintains vascular smooth muscle in a non-
proliferative state (Cornwell et al., 1994). This is a delicate balance, and local changes 
in vascular environments (such as LDL cholesterol, free radicals, infectious 
microorganisms, low shear stress, and angiotensin II-induced hypertension) can cause 
endothelial activation, in part by reducing the intracellular concentration of NO (Sloop 
et al., 1999). 
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1.9.3.1 Initiation of the atherosclerotic lesion; where inflammation meets 
endothelial dysfunction 
Systemic risk factors such as elevated LDL, hypertension, high blood sugar, and by-
products of tobacco smoking help in the process of initiation and exacerbation of 
atherosclerosis. Atherosclerotic lesions develop preferentially at bifurcations, branch 
points, and inner curvatures of arteries, although the entire vascular endothelium is 
exposed to these stimuli, which suggests that local factors contribute to the 
susceptibility of the disease. It is widely established that the complex patterns of blood 
flow in these regions expose the endothelium to "disturbed" hemodynamic forces low 
shear stress (Lowe, 2004), which may in turn cause physical disruption of the 
endothelium and concomitant inflammation (Gimbrone et al., 1997). 
1.10 Diabetes-induced changes in myocardial fuel selection 
Remarkable changes occur in the concentration of various energy substrates within the 
circulation in T2DM, which in turn can control cardiac metabolism. The rate of 
substrate uptake and oxidation in cardiomyocytes is significantly affected due to an 
increase in the levels of both plasma glucose and fatty acids in diabetes. Fatty acid-
induced inhibition of sarcolemmal GLUT4 expression impairs the uptake of glucose in 
the diabetic heart. Increased supply of FA can also result in the activation of cardiac 
PPARα, which promotes the expression of genes involved in uptake of FA and 
oxidation. In diabetes mellitus, an abundance of fatty acid causes an increase in the 
uptake of fatty acid in the myocardium increasing the oxidative capacity of the heart. 
This in turn leads to an accumulation of triglycerols, fatty acid intermediates, and 
ceramides resulting in a state of lipotoxicity within the cardiomyocytes (DSouza et al., 
2009; Lopaschuk et al., 2010). 
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1.11 Metabolic syndrome 
WHO defined metabolic syndrome as a state, which includes central obesity, 
dyslipidemia, impaired glucose tolerance, high blood pressure and T2DM. An 
individual with a BMI of >30 kg/m
2
 (obese) carrying a minimum of two other risk 
factors like dyslipidemia and hypertension is required to meet the criteria for diagnosis 
of metabolic syndrome. 
1.12 Obesity- a major health concern 
One of the major health concerns in the 21
st
 Century is obesity. This is when a person 
has a BMI in excess of 25-30 and moreover, it can be defined as excess body weight 
with an abnormally high proportion of body fat. An imbalance between energy intake 
and energy expenditure can lead to obesity.  
Obesity occurs due to interplay of sedentary lifestyle habits, genetic factors, medical 
illness, microbiological aspects and social factors. Figure 1.3 depicts the relationship 
between obesity, diabetes and the development of heart diseases. 
1.12.1 Measurement of obesity 
Obesity is commonly defined as body mass index (BMI, weight in kilograms divided by 
height in meters squared) of 30 kg/m
2
 or higher. BMI (or Quetelet index) was 
introduced by the Belgian polymath Adolphe Quetelet between 1830 and 1850. The 
classification of body weight according to WHO is shown in table 1.2.    
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Table 1.2:  Classification of overweight in adults according to BMI
a 
Classification                           BMI (kg/m
2
)                  Risk of comorbidities 
 
Underweight    <18.5     Low  
Normal range    18.5--24.9     Average 
Overweight    ≥25.0 
Pre-obese    25.0-29.9    Increased 
Obese class I    30.0--34.9    Moderate 
Obese class II    35.0--39.9     Severe 
Obese class III   ≥40.0      Very severe 
a
These BMI values are age-independent and the same for both sexes. However, BMI 
may not correspond to the same degree of fatness in different populations due, in part, 
to differences in body proportions. The table shows a simplistic relationship between 
BMI and the risk of comorbidity, which can be affected by a range of factors, including 
the nature and the risk of comorbidity. In turn this can be affected by a range of factors, 
including the nature of the diet, ethnic group and activity level. The risks associated 
with increasing BMI are continuous and graded and begin at a BMI below 25. The 
interpretation of BMI gradings in relation to risk may differ for different populations. 
Both BMI and a measure of fat distribution (waist circumference or waist: hip ratio 
(WHR)) are important in calculating the risk of obesity comorbidities.    
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Figure 1.3: Flow chart showing potential mechanisms for the development of diabetic 
cardiomyopathy: ROS, reactive oxygen species; TNFα, tumor necrosis factor alpha; IL-
6, interleukin-6; AGE, advanced glycation end products.     
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1.13 Diabetes mellitus and cardiovascular disease  
As mentioned earlier that DM is classified as type 1 and type 2 DM. Lifestyle, dietary 
habits, obesity, fat distribution, and age are the main pre-disposition factors for DM. 
T1DM is mostly caused by genetic predisposition with a combination of autoimmune 
disorders and viral infections. The prevalence of type 2 diabetes is growing globally and 
is established to be related to morbidity and mortality due to cardiovascular events. 
T2DM patients are more prone to acute myocardial infarction and angina and their 
mortality in terms of cardiac events is found to be higher when compared to non-
diabetics. Ischaemic heart disease and diabetic cardiomyopathy are the two important 
patho-physiological processes leading to diabetes-related cardiovascular disease. 
Metabolic disturbances like hyperglycemia, hyperlipidemia, insulin resistance, 
myocardial fibrosis, oxidative stress, and pro-inflammatory cytokines are the various 
contributing factors to this complex process (DSouza et al., 2009). 
1.13.1 Epidemiology of CVD 
1.13.1.1 The concept of “risk factors” 
Epidemiological studies trying to determine the various factors responsible for chronic 
diseases associated with infection and nutritional deficiency in the past have put forward 
the concept of ―risk factors‖. Research focussing on this type of disorders has been 
subsequently tailored with the improval of public health sector and when chronic 
diseases related to aging such as cancer and cardiovascular disease have become very 
common (Kannel et al.,, 1961). 
Therefore, the diverse factors linked to a disease have been statistically evaluated using 
epidemiological methods. The concept of ‗risk factors‘ in cardiovascular disease was 
initially popularised by the Framingham Heart Study (Kannel et al., 1961) which 
originated from the latin verb ―facere‖ meaning ―to make‖. According to the definition, 
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a risk factor has to be the fundamental behind the progression of a disease and the term 
should be employed where it has been associated with increasing the risk of a disease 
but yet to be proved as casual even though they are often interchangeably used. In some 
cases like infection (e.g. HIV virus infection giving rise to the acquired 
immunodeficiency syndrome, AIDS.), which have  particular pathogens that lead to 
clinical symptoms and disease states, the cause is very clear whereas in cardiovascular 
disease, however, the root cause is very unclear (Black, 1992).  
Development of atherosclerosis involves the interplay of complex molecular and 
cellular pathways and several factors that contribute to the disease before clinical 
presentation of an end event. The major concern is the determination of these factors in 
terms of major influence over the progression of the disease for use as a clinical marker 
in the prediction of the disease or for development of therapeutic interventions. 
 
 
Table 1.3:  Some major conventional risk factors for CVD 
Classification of factor Examples of risk 
Non-modifiable Sex (♂>♀), Age, Diabetes, Family history, Ethnic 
background, Gestational diabetes. 
Modifiable Smoking, Blood pressure, sedentary lifestyle, adiposity 
(BMI or waist circumference), cholesterol (total or total: 
HDL), salt intake, hypertension, lack of exercise. 
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1.13.1.2 Current cardiovascular risk factors 
All conventional risk factors that are recognized by most lay people and healthcare 
professionals today came from epidemiological work including Framingham Study. 
Some general risk factors include sex, age, family history, lifestyle, smoking, obesity, 
hypertension and hyperlipidemia, which interrelate in several ways both directly and 
indirectly. Age, sex and family history are obviously non-modifiable, so the five main 
risk factors usually considered clinically are smoking, diabetes, hyperlipidaemia, 
adiposity, and blood pressure (Kannel et al, 1961, Hu et al., 2001). 
These major risk factors are currently combined in scores or charts, which predict risk 
of CVD, e.g. the Joint British Societies, chart (See Figure 1.4). This current chart 
utilises the total HDL: cholesterol ratio as a measure of atherogenic blood lipids and 
hence takes into account the fact that not all cholesterol is equal in terms of CHD risk. 
VLDL and LDL cholesterol play direct roles in atherogenesis, but HDL cholesterol, in 
contrast, plays a role in reverse lipid transport (and other anti-atherogenic processes) 
and hence reduces risk of coronary heart disease (Barter et al., 2004). So although in 
general hyperlipidaemia is a risk factor for CHD, this can be tempered if a high part of 
the total circulating cholesterol is HDL (Haffner and Ashraf, 2000). 
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Figure 1.4: Charts showing Clinical Joint British Societies risk assessment for CHD in 
diabetic patients. (Adapted from: BMJ, 2000). 
 
1.13.1.3 Emerging CVD risk markers 
Recently, considerable interest has been shown in novel metabolic and dietary markers. 
The metabolic syndrome (The WHO criteria, 1999; defined as presence of diabetes 
mellitus, impaired glucose tolerance, impaired fasting glucose or insulin resistance, plus 
any two of hypertension, dyslipidaemia, obesity, and microalbuminuria – although there 
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are several proposed clinical definitions) has attracted considerable attention as a 
predictor of T2DM as well as cardiovascular disease. 
Recent meta-analysis shows T2DM as a predictor of CVD (Galassi et al., 2006), 
although the clinical utility in diagnosing the syndrome as a CHD risk marker over and 
above the Framingham risk assessment is extremely uncertain despite enthusiasm for its 
use particularly in the USA (Wannamethee et al., 2005). In other examples, of 
individual dietary hormones, lipids and triglycerides have recently been confirmed to be 
moderately associated with the incidence of CHD during meta-analysis (Sarwar et al., 
2007). This is believed to have lipoprotein (a)  (Danesh et al., 2000) and apolipoprotein 
B:A ratios (Thompson and Danesh, 2006). In contrast, the hormone adiponectin is often 
reported to be inversely associated with CHD, but any association was recently shown 
to be weak on meta-analysis (Sattar et al., 2006). Some haemostatic markers have also 
been shown to be associated with the incidence of CVD, perhaps due to their roles in 
thrombus formation, longevity and degradation (Lowe, 2004).  
In addition to these, measurements of subclinical plaque progression and stenosis have 
also been shown to have associations with incident CVD. The simplest measure of 
peripheral arterial resistance is the ankle brachial index (ABI), which shows a low 
sensitivity, but high specificity association with CVD and CHD risk. More recent 
computer imaging shows both non-invasive, and invasive procedures can predict CHD 
risk (Ottolini et al., 2005). Typically, all of these markers have risk associations with 
CVD and CHD that can be described as moderate, but are clearly not as useful as the 
Framingham-based tests in clinical practice. 
1.14 Inflammatory risk markers 
As mentioned above, the role of inflammation in atherogenesis would suggest, a great 
deal of work has been done looking for inflammatory markers that are risk factors for 
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CHD (Libby et al., 2002). The most widely examined markers are fibrinogen, C-
reactive protein (CRP), white cell count (WCC) and IL-6. All of these markers are 
associated with acute phase response and hence circulating levels reflecting the current 
inflammatory state of the individual with WCC and CRP being the routine clinical 
measures of inflammation. 
These have been used in epidemiological studies to examine the hypothesis ―elevated 
baseline inflammation predicts risk of CVD.‖ Meta-analysis of prospective studies in 
generally healthy populations has shown that WCC (Wheeler et al., 2004), CRP 
(Danesh et al., 2004), and fibrinogen (FSC, 2005) are risk predictors for CHD. CRP has 
been promoted as a risk marker in cardiovascular disease, and much publication space 
has been dedicated to this, particularly from the USA (Verma et al., 2005). Publication 
bias is an important confounding factor in the epidemiological study of newer risk 
markers. 
In the USA, the measurement of CRP level has been suggested to add to established risk 
factors for individual risk prediction for cardiovascular prevention (Pearson et al., 
2003), but not in Europe. Several other markers were considered potential candidates as 
inflammatory risk markers in this debate (including WCC, fibrinogen and IL-6), but it 
was decided that CRP best fitted the above criteria, and was generally the most 
comprehensively studied of the markers (Pearson et al., 2003). 
1.14.1 Inflammation and T2DM 
T2DM is a progressive disorder emerging as a global epidemic and imposes a 
tremendous burden on the health economy of many countries due to its fatal micro and 
macrovasular complications (Zimmet et al., 2003). T2DM patients have an increased 
risk for CVD due to many conventional risk factors which cannot fully account for the 
disease. There is increasing evidence that atherosclerosis is accompanied by 
 Page 38 
 
inflammation in several research studies. Full blood cell count including RBC, WBC 
cell counts, C- reactive protein (CRP), HbA1c, lipid profile including HDL, LDL, 
triglycerides are all positively associated with increasing CVD risk in T2DM (Kumar 
and Clark, 2007).  
1.14.2 Inflammation 
Inflammation is the local protective response to tissue injury. The word inflammation 
means ―setting on fire‖ (16th century), and the process has been known since Egyptian 
times (c. 2500 B.C.). The cardinal signs of redness, swelling, heat, and pain were 
described by Celsus (first century A.D.), and loss of function was added by Galen (130–
200 A.D.) (Rather, 1971). Microscopically, these features are due to vasodilation, 
accumulation of leukocytes, increased capillary permeability and interstitial fluid, and 
stimulation of nerve endings by mediators such as substance P. 
Cells such as monocytes, macrophages, T-cells, endothelial cells, vascular smooth 
muscle cells, release inflammatory mediators including cytokines and chemokines 
during the process of plaque development, which develop an inflammatory response in 
the vessel (Ross, 1999). Potential epidemiological studies have found increased 
cardiovascular risk with elevated basal levels of some of these same mediators 
particularly, cytokines such as interleukin (IL)-6 or tumor necrosis factor-α (TNF-α), 
soluble adhesion molecules, and downstream acute phase reactants such as C- reactive 
protein (CRP), fibrinogen, and serum amyloid A (SAA) which have shown to predict 
the risk of cardiovascular events (Libby et al., 2002). 
It has been proposed that inflammatory cytokines secreted by the adipose tissue exert an 
endocrine effect which is responsible for insulin resistance in liver, skeletal muscle and 
vascular endothelial tissue and ultimately results in clinical expression of both T2DM 
and CVD (Yudkin et al., 1999; Hu and Stampfer, 2003). An elevated production of 
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adipocyte cytokines particularly,  tumor necrosis factor (TNF-α) and interleukin-6 (IL-
6) produces an acute phase response that leads to an increased production of C-reactive 
protein (CRP), a sensitive marker of low-grade systemic inflammation (Hotamisligil & 
Spiegelman, 1994; Caballero et al., 1999). Apart from promoting insulin resistance, 
TNF-α, IL-6 and CRP also stimulate endothelial production of adhesion molecules 
including E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion 
molecule-1 (VCAM-1) which are crucial mediators of endothelial dysfunction in 
capillary and arteriolar endothelium (Gabay and Kushner, 1999; Targher et al., 2005).  
Interleukine 6 is a major proinflammatory cytokine produced in tissues including 
activated leukocytes, adipocytes and endothelial cells. C- reactive protein is the main 
downstream mediator of acute phase response and is primarily derived from IL-6-
dependent haepatic biosynthesis (Sattar et al., 2007). IL-6 has been shown to induce 
gluconeogenesis, subsequent hyperglycemia, and compensatory insulinemia in rodent 
models of glucose metabolism. Similar metabolic responses have been observed in 
humans after subcutaneous administration of recombinant IL-6 (Tsigos et al., 1997). 
Cross–sectional studies have shown that inflammation plays a major role in the 
aetiology of T2DM and also demonstrated that elevated levels of IL-6 and CRP have 
been observed in individuals with T2DM (Sattar et al., 2004).  
Markers of inflammation are associated with T2DM and features of the metabolic 
syndrome in cross-sectional studies (Thorand et al., 2007). Several cross-sectional 
studies in non-T2DM subjects, the general population or in individuals with impaired 
glucose tolerance (IGT)/impaired fasting glucose (IFG) have confirmed that acute-phase 
reactants such as CRP (and sometimes the cytokines IL-6 and TNF-α) are positively 
correlated with measures of insulin resistance/plasma insulin concentration, BMI/waist 
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circumference, and circulating triglycerides and negatively correlated with HDL 
cholesterol concentration.  
In general, increasing components of the metabolic syndrome in individuals are 
associated with higher levels of inflammatory markers. In subjects with IGT or IFG, IL-
6 but not TNF-α appears to be elevated compared with individuals with normal glucose 
tolerance and in one study, inflammatory markers were related to insulin resistance but 
not to insulin secretion. 
Additional cross-sectional studies in newly diagnosed or established T2DM patients 
have confirmed that acute-phase markers such as CRP and IL-6 are elevated in these 
subjects compared with non-diabetic control subjects. In the study by Leinonen et al., 
2003, all markers of inflammation, including CRP, serum amyloid A, secretory 
phospholipase A2, and IL-6, and endothelial dysfunction (soluble cell adhesion 
molecules) correlated with the homeostasis model–measured insulin resistance.  
1.15 Cations in T2DM  
Several studies were published during the last century evaluating the various cations 
and trace elements in T2DM. However, significant changes were observed within 
similar reports and these differences were shown to be a result of various factors 
including age, genetic factors, dietary habits, medication and glycaemic control of 
patients. Alterations in the levels of various cations could also result due to chronic 
hyperglycaemia and possibly modulation of glucose homeostasis by micronutrients 
themselves. Blood plasma is considered to be a tissue pool for various cations and 
single trace elements. However, recently, it became evident that micronutrient level of 
plasma is a reflection of cations and trace elements only in cases of severe deficiency or 
in excess. Several underlying factors for excess and deficiency of these various cations 
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in plasma include infection, regulation of hormones, stress, circadian rhythm, impaired 
homeostatic regulation.  
1.15.1 Sodium (Na
+
) 
Hyperglycaemia in patients with T2DM is a common clinical problem in which variable 
changes in plasma sodium (Na
+
) concentration can occur.  Acute studies suggest that 
hyperinsulinemia may cause sodium retention and increased sympathetic activity, which 
will be an important cause of hypertension (Reaven & Hoffman, 1987). Much evidence 
from epidemiological, migration, intervention, animal and genetic studies suggest that 
salt intake plays an vital role in regulation of blood pressure (He and MacGregor, 2003). 
Several other studies have described significant effects of dietary salt intake on blood 
pressure in normotensive and hypertensive patients (Morgan et al., 1978).  
Recently, it has been predicted that through its effects on blood pressure, the 
cardiovascular benefits of reduced salt intake are comparable with the benefits of 
population-wide reductions in tobacco use, obesity and cholesterol levels (Bibbins-
Domingo et al., 2010). However, dietary salt intake may play a more important role in 
diabetes than in the community at large, as it has been shown that patients with diabetes 
have an increased total body exchangeable sodium (Beretta-Piccoli & Weidmann, 1982) 
and moreover, they have higher blood pressure levels and higher aggregate 
cardiovascular risk than the general population (Sowers et al., 2001).  
1.15.2 Potassium (K
+
) 
The results from the Atherosclerosis Risk in Communities (ARIC) Study, suggest that 
serum potassium is an independent predictor of incident T2DM. Essentially, 
maintenance of normal potassium homeostasis is important limiting factor in the 
therapy of cardiovascular disease.  
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A diet deficient in potassium intake has a critical role in regulating blood pressure in 
primary hypertension (Horacio and Nicolaos, 2007) and may potentially increase the 
risk of stroke (Green et al., 2002). Several studies have shown that hypokalemia could 
be a possible risk factor for T2DM. Serum potassium levels affect insulin secretion by 
pancreatic β-cells. Serum potassium in randomized controlled trials of thiazide diuretics 
was found to be inversely associated to glucose which might possibly be a result of oral 
potassium supplementation (Zillich et al., 2006). Experimental evidence also suggests 
that thiazide-induced hypokalemia can lead to reduced insulin secretion (Rowe et al., 
1980, Adrogue and Madias, 2007).  
1.15.3 Calcium (Ca
2+
) 
Calcium is the most important physiological cation in the body (Berridge et al., 2000). 
It is the mediator and promoter of several physiological processes. Calcium is an 
essential component for insulin secretion as it is a calcium-dependent process (Hellman 
et al., 1994). Therefore, fluctuations in calcium levels might intervene and effect β-cell 
secretory function. Inadequate calcium intake might alter the balance between 
extracellular and intracellular cell calcium pools which interfere with normal insulin 
release, particularly when there is glucose overload (Berridge, 1994). In insulin-
responsive tissues such as skeletal muscle and adipose tissue calcium are essential for 
insulin-mediated intracellular processes (Ojuka, 2004; Wright et al., 2004). A very 
narrow range of [Ca
2+
]i is needed for optimal insulin-mediated functions (Draznin et al., 
1987). Changes in [Ca
2+
]i in primary insulin target tissues possibly contribute to 
peripheral insulin resistance via impaired insulin signal transduction, resulting in a 
decreased glucose transporter-activity (Draznin et al., 1989). 
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1.15.4 Magnesium (Mg
2+
) 
Magnesium (Mg
2+
) is the fourth most abundant cation in the human body and the 
second most abundant intracellular cation, which is an important cofactor for many 
enzymes, particularly those involved in phosphate transfer reactions (Wacker, 1969). 
Mg
2+
 is therefore essential in the regulation of metabolism of other ions and cell 
functions. Recently, interest has been focused on the clinical importance of altered Mg
2+
 
status (Whang, 1987). It has been shown that Mg
2+
 deficiency is associated with serious 
cardiovascular diseases, such as cardiac arrhythmia and coronary heart disease, as well 
as with risk factors including hypertension, hypercholesterolemia and diabetes mellitus 
and moreover, a deficiency of serum magnesium has been reported in T2DM (Altura 
and Altura, 1991). 
1.15.5 Zinc (Zn
2+
) 
Zinc (Zn
2+
) forms part of many protein domains, such as zinc metaloenzymes, and are 
involved in the synthesis, storage and secretion of insulin monomers (Maret & 
Sandstead, 2006; Kazi et al., 2008). It is considered to be deficient if serum zinc is less 
than 60 μg/dl. Diabetes is usually accompanied by zincuria and consumption of 
nutritional supplements can substantially increase zinc absorption by the gastrointestinal 
tract (Cunningham et al., 1994). Nevertheless, the effects of zinc supplement, if dietary 
intake is adequate, are incompletely understood. More clinical data on diabetic patients 
who are at increased risk of zinc deficiency would be helpful as zinc has an 
insulinomimetic effect and moreover, it also protects against the oxidative damage 
associated with the disease (Chen et al., 1998). Additionally, oxidative damage in 
diabetic patients may result in lower antioxidant micronutrient status, especially trace 
elements (Wolff et al., 1991). 
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Therefore, abnormal serum Zn
2+
 status, can promote the progression of diabetes (Ding 
et al., 1998). Microalbuminuria is a major factor which predicts the onset of overt renal 
disease and reflects glomerular dysfunction in diabetic patients (O'Brien et al., 1997). 
Zinc supplementation has beneficial effects on microalbuminuria and serum lipid profile 
in T2DM with microalbuminuria (Mahmoud et al., 2008). 
1.15.6 Copper (Cu
2+
) 
Copper is one of the essential trace elements and it plays an important role in 
cytochrome oxidase function at the terminal end of the mitochondrial electron transport 
chain. Loss of this activity might contribute to the characteristic swelling and distortion 
of mitochondria which can be observed in copper deficiency, particularly in 
metabolically active tissues such as pancreatic acinar cells, enterocytes, and hepatocytes 
(Aggett, 1985). In subjects with insulin dependent diabetes mellitus (IDDM), zinc 
concentrations have been demonstrated to be lower in leucocytes and erythrocytes than 
in serum, while no such alteration has been found with copper (Razz & Haivivi, 1989). 
No definite association has been explained between copper concentrations and the 
clinical status of patients with diabetes mellitus (Fujimoto, 1987).   
1.15.7 Iron (Fe
2+
) 
Iron is the most abundant transitional metal in the body and it has been recognized that 
an increase of total body iron stores is associated with an increased risk for the 
development of T2DM (Fernández-Real et al., 2002). T2DM is a common 
manifestation of haemochromatosis, a disease of iron overload. Iron is a catalyst 
involved in the formation of hydroxyl radicals, which are powerful pro-oxidants that 
attack cellular membrane lipids, proteins, and nucleic acids (Beard, 2001; Andrews, 
1999). Formation of hydroxyl radicals catalyzed by iron contributes initially to insulin 
resistance and subsequently to decreased insulin secretion which leads to the 
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development of T2DM (Larry, 1988). Thus, iron plays a major role in several steps of 
insulin action and glucose metabolism.   
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1.16 Biochemical markers  
1.16.1 Glucose  
T2DM is a disease associated with abnormal carbohydrate metabolism which arises due 
to insulin deficiency as insulin is the key hormone responsible for glucose homeostasis 
in blood (Kumar et al., 2005). Consequently, elevation of blood glucose predominantly 
affects RBC‘s, vascular endothelial cells and walls of capillaries which often leads to 
microvascular complications in T2DM including retinopathy, nephropathy and 
neuropathy (Pirat, 1978). Hyperglycaemia can lead to vascular complications through 
various mechanisms (DSouza et al, 2009). High blood glucose concentration or 
hyperglycaemia can activate several factors including nuclear factor kB, which in turn 
increases the expression of various genes in endothelial cells, monocyte-derived 
macrophages and vascular smooth-muscle cells (DSouza et al., 2009). Various 
mechanisms have been proposed to explain how hyperglycaemia causes vascular 
complications in T2DM. An increase in glucose can lead to an increase  in the 
fluctuation of glucose to sorbitol through the polyol pathway as well as an increase in 
glucosamine -6-phosphate via the hexosamine pathway, activation of PKC (protein 
kinase C) via de novo synthesis of diacylglycerol DAG (Ahmed, 2010). The first study 
which reported glucose as a risk factor in the UK was the Bedford Study in 1965 and 
the Tecumseh Study in the U.S which suggested that elevation of glucose could be 
associated with CHD mortality and verified this hypothesis. 
The results from several clinical trials have proven that intensive glucose control can 
reduce the risk of microvascular complications among T2DM patients although its 
effect on CVD is uncertain. One of the most crucial features of T2DM is 
hyperglycaemia that affects haemoglobin and membrane proteins of RBC as a result of 
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abnormal glycation which is shown to be positively correlated with reduced membrane 
fluidity.  
1.16.2 Liver function tests (LFT’s) 
Human liver plays an important role in maintaining blood glucose concentration during 
both fasting and postprandial states. An increase in haepatic glucose production 
following glycogenolysis is due to loss of insulin effect on the liver. Early 
manifestations of conditions that are characterized by insulin resistance and detected 
earlier than fasting hyperglycaemia include abnormalities of triglyceride storage and 
lipolysis in insulin-sensitive tissues such as liver. The sequence of various events and 
factors leading to underlying insulin resistance include genetic, environmental and 
metabolic factors. However, the mechanism how these factors induce insulin resistance 
is not clearly understood. Individuals with T2DM have a higher incidence of liver 
function test abnormalities when compared with healthy age-matched controls (Lewis et 
al., 2002; Harris, 2005).  
Serum aminotransferases, alkaline phosphatase, bilirubin, albumin are the most 
common LFT. Aminotransferases including alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) serve as markers of hepatocyte injury by measuring 
the concentration of intracellular hepatic enzymes that leaked into the circulation. 
Albumin and prothrombin reflect liver synthetic function while alkaline phosphatase 
(AP) and γ-glutamyl transpeptidase (GGT) act as markers of biliary function and 
cholestasis.  
1.16.3 HbA1c 
Haemoglobin A1c is a marker of cumulative glycaemic exposure over the preceding two 
to three months in diabetic patients. Measurement of glycated haemoglobin was the first 
clinically used method around 30 years ago to assess the levels of hyperglycaemia in 
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T2DM patients (Koenig et al., 1976). The values of HbA1c in patients are a reflection 
of weighted mean glucose levels over the past 3-month period (Tahara and Shima, 
1995). Elevated HbA1c is strongly associated with long-term microvascular 
complications and assessment of HbA1c is used for monitoring effective glycaemic 
levels.  
In recent years, several research studies have made an effort to expand the role of 
HbA1c as an index of cumulative glycaemic exposure in both diabetes and 
cardiovascular risk assessment (Ko et al., 2000). Several studies have also tried to 
evaluate the function of HbA1c in predicting future T2DM in patients with high risk 
pre-diabetes. Recent studies also have suggested that HbA1c can be used to predict 
cardiovascular risk in T2DM patients. During the past three decades, elevated HbA1c 
has been associated with long-term risk of microvascular complications and currently, 
HbA1c assessment is being used ubiquitously for monitoring effective glycaemic 
control as a keystone of diabetes care (Little, 2003). In one of a recent case-control 
study, it has been shown that elevated levels of HbA1c could predict the incidence of 
cardiovascular events. However, this similar effect was not observed when some of the 
other cardiovascular risk factors were adjusted (Blake, 2004).  
1.16.4 Full blood count 
A number of studies have reported significant associations of routine haematological 
parameters with T2DM and CVD. Results suggest that these abnormalities might form 
the common soil for both T2DM and CVD. In this study, the levels of various 
haematological parameters including haemoglobin, RBC, WBC, glucose concentration 
were evaluated and compared with non-diabetics. A strong association between insulin 
resistance syndrome and cardiovascular diseases has been demonstrated. High RBC 
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count is a strong independent predictor of acute cardiovascular events including stroke 
and myocardial infarction.  
Haemorheological parameters including haematocrit, plasma proteins, erythrocyte 
aggregation, and erythrocyte deformability in T2DM patients are often disturbed. These 
abnormalities lead to an increase of both plasma and whole blood viscosity (WBV). 
Deformability of RBC‘s is one of the haemorheological parameters which is altered in 
T2DM patients. RBCs of T2DM patients tend to aggregate more easily when compared 
with healthy subjects. Excessive aggregation of RBC is one of the most important 
features in T2DM patients with poor glycaemic control.  This has a direct effect on the 
WBV (Grigoleit et al., 1973).  
1.16.5 Lipid profiles 
A significant percentage of T2DM patients have abnormal serum lipid. Recent studies 
have revealed that insulin resistance is not only associated with hyperglycaemia alone, 
but also with several other disorders which are associated with the concentrations of 
lipoproteins (Grundy, 1997). In T2DM patients, typical abnormalities frequently 
observed in lipid profile are elevated total and VLDL cholesterol, triglyceride, low 
levels of HDL, and a large number of dense LDL particles (Lamarche et al., 1997). It is 
well understood that diabetic dyslipidemia is a major hallmark of metabolic syndrome 
and found to play an extensive role in the pathogenesis of CVD (Wannamethee et al., 
2007). Moreover, it has become the main reason responsible for cardiovascular 
morbidity and mortality in T2DM patients. An increased risk of coronary heart disease 
has been observed in both T2DM patients and non-T2DM subjects having 
triglyceridemia (Fontbonne, 1989). The central characteristic of dyslipidemia in T2DM 
patients is an elevated triglyceride level, particularly triglyceride-rich VLDL and 
decreased HDL cholesterol levels, though concentration of LDL cholesterol does not 
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significantly differ from non-diabetic subjects. This characteristic lipid triad is often 
referred to as atherogenic dyslipidemia which is commonly observed in people having 
premature CAD and considered as diabetic dyslipidemia when observed in T2DM 
patients and which leads to CVD risk. According to American Diabetes Association 
(ADA), increased levels of triglyceride and decreased levels of HDL is the best 
predictor of CVD in T2DM patients.  
1.16.6 C- reactive protein (CRP) 
Multiple organs and organ systems as the heart, brain, kidneys and peripheral arteries 
are typically affected by the risk factors for CVD. T2DM and hypertension are two 
major candidates which are associated with CVD risk and other organ damage. 
Recently, novel CV risk markers have been introduced as predictors of cardiovascular 
morbidity and mortality. One such factor is C-reactive protein (CRP). CRP is the 
prototypic acute-phase protein which can predict cardiovascular (CV) morbidity and 
mortality in high-risk patient groups such as T2DM and the general population. CRP is 
a sensitive marker of inflammation (King et al., 2003; Lloyd et al., 2006). 
Inflammation, either systemically or at local sites may underlie the atherosclerotic 
process resulting in vascular end-organ damage or applies to multiple vascular beds. 
Indeed, slight increases in serum CRP levels are associated with an increased risk for 
damage in different vascular beds (Ridker et al., 1997) including the heart, brain, 
kidneys and lower extremities. However, CRP is not an independent risk marker for CV 
disease in some reports.  
CRP, an acute phase biomarker in systemic inflammation plays an important role in the 
patho-physiology of T2DM (Dehghan et al., 2007). It is also one of the emerging 
independent risk factors for cardiovascular disease and it can be used as a predictor in 
some healthy populations (King et al., 2002). CRP is an oligomeric protein belonging to 
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the family of pentraxin and is known to engage in innate immunity in recognition of 
patterns (see Table 1.4).  
CRP actively participates in complement fixation, modulation of platelet activation, in 
enhancement of activity of leukocytes and in the elimination of cellular debris from the 
sites of active inflammation (King, 2003). 
CRP is produced by the liver through the stimulation of other cytokines like Interleukin 
1 and 6 and tumour necrosis factor. Many prospective recent studies have suggested that 
CRP carries a higher risk for the development of T2DM (Doi et al., 2005). Numerous 
cross sectional studies stated that high levels of CRP in serum are linked with obesity, 
insulin resistance and glucose intolerance (Ford, 1999). A high level of C-reactive 
protein is associated with an increase in the risk of thrombotic events and later 
development of diabetes (Ridker et al., 1997). There is an established relation between 
CRP and insulin resistance (Festa et al., 2003). It is widely assumed that CRP represents 
the inflammatory component of the process of atherosclerosis in the arterial vessel wall 
(Table 1.4).     
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Table 1.4: Direct role of C-reactive protein in atherogenesis 
Localisation 
Localises in shoulder regions of (vulnerable) plaques 
Depositions with inflammatory cells and lipid-rich areas 
Co-localisation with complement in infarcted tissue 
CRP ligand binding 
Binds selectively to LDL, especially oxLDL 
Aggregated and/or ligand-complexed CRP activates complement  
Phagocytic function 
Enhances LDL uptake by macrophages 
Vascular function 
Decreases NO synthase expression in endothelial cells 
Decreases prostacyclin release from human aortic cells 
Relaxes human vessels  
Leukocyte adhesion 
Induces expression of leukocyte adhesion molecules  
Induces secretion of MCP-1 
Thrombosis 
Increased rate of thrombosis in CRP-transgenic mice  
Tissue factor production by macrophages  
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1.16.7 Interleukin-6 (IL-6) 
Interleukin-6 is a pleiotropic cytokine belonging to the IL-6 family which include IL-11, 
oncostatin M, ciliary neurotrophic factor, cardiotrophin-1, cardiotrophin like cytokine 
and leukemia inhibitory factor (Giraud et al., 2007). It is a 26 kDa pleiotropic cytokine 
mainly produced by endothelial cells, macrophages, adipocytes and lymphocytes (Kerr 
et al., 2001). As mentioned previously, IL-6 is implicated as a pivotal acute phase 
response (APR)-inducing cytokine in IL-6 knock out (KO) mice, although there is 
evidence that it is not exclusively responsible for this. In addition to its role in the APR, 
it is thought to stimulate haemostasis and influence T- and B-cell differentiation (Kerr et 
al., 2001) as well as stimulating endothelial cells to produce chemokines (in complex 
with soluble IL-6 receptor [sIL-6R]). Moreover, it also plays a major role in the 
transition between acute and chronic inflammatory responses (Gabay, 2006). Mouse 
models indicate that exogenous addition of IL-6 exacerbates atherogenesis, indicating a 
role for IL-6 (Huber et al., 1999) through the mechanisms described above. Despite this, 
IL-6 KO models indicate that basal physiological levels of IL-6 may be required to 
maintain plaque integrity. This observation may be consistent with some of the 
condition-specific pro- versus anti-inflammatory actions of IL-6 (Kerr et al., 2001; 
Gabay, 2006). 
In epidemiology, major correlates of IL-6 are age, smoking and acute phase response 
markers. A recent meta-analysis of 10 available prospective studies (Ridker et al., 1997) 
including 2089 cases of non-fatal MI or CHD deaths, demonstrated that men in the top 
third of the population for IL-6 expression had an OR 1.67 (95% confidence intervals 
[CI] 1.35 –2.05) independent of conventional risk markers. This does not include more 
recent data, such as that from the Edinburgh Artery Study (Tzoulaki et al., 2007).  
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Although the data are again in broad agreement with the meta-analysis; OR 1.85 (1.33 
to 2.58) in the top versus bottom tertile in a fully adjusted model. 
In the same study (Mann et al., 2011) a meta-analysis of the well-studied IL-6 promoter 
polymorphism -174 G/C was performed, since this allele is generally thought to be 
associated with elevated circulating concentrations of IL-6. In this analysis, and in 
contrast with some published literature, no association between the   single nucleotide 
polymorphism (SNP) and circulating levels of IL-6 was observed (in 9 studies with 
5871 participants) and unsurprisingly nor was there any association with CHD risk. 
Hence, IL-6, like fibrinogen and CRP, is associated with atherogenesis in some 
molecular and animal models, and moreover, it is associated with CHD risk in 
epidemiological studies to a similar extent.  
IL-6 impinges on the immunoregulation and non-immune processes in various cells of 
the body. Several studies have revealed the relation between IL-6 and pathogenesis of 
type 2 diabetes (Yudkin et al., 2000; Kristiansen and Mandrup, 2005). IL-6 is produced 
by many types of cells counting endothelial cells, skeletal and smooth muscle cells, 
islet-cells, microglial cells, hepatocytes, astrocytes, adipocytes and most of the cells of 
immune system.  
1.16.8 Fatty acid binding protein (FABP) 
H-FABP is a protein of low -molecular weight concerning the uptake of free fatty acids 
in the myocardium (de Windt et al., 2002). It is abundantly found to be in the cytoplasm 
of cardiomyocytes and it gets elevated when there is myocardial injury. FABP assists in 
the transportation of fatty acids in cardiomyocytes and moreover, it holds a key role in 
the mitochondrial beta oxidative system.  
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Heart type fatty acid binding protein (HFABP) is known to play a major role in 
myocardial infarction (Naraoka et al., 2005). FABP is found to be a new biomarker 
predicting the development of T2DM. It has been recognized that there is an augmented 
level of circulating FABP in people with glucose dysregulation. 
It has been shown earlier that FABP levels are associated with metabolic syndrome 
leading to an increased risk of T2DM (Tso et al., 2007). FABP alters the production of 
inflammatory cytokines and the accretion of cholesterol esters in the macrophages 
which are quite similar to adipocytes (Xu et al., 2006). 
1.16.9 Homocysteine  
Homocysteine is recognized as a possible independent risk factor for atherosclerotic 
disease (Selhub et al., 1995). It a sulphur containing amino acid produced by the 
metabolism of amino acid methionine (Cronin et al., 1998) which is reversibly 
converted into homocysteine by the transmethylation process. It is identified as an 
independent cardiovascular risk factor among diabetic patients and is quite often linked 
to insulin resistance syndrome (Tessari et al., 2005) by numerous potential clinical 
studies. Prospective studies have also suggested a possible association between an 
increased level of plasma homocysteine and insulin resistance (Malinow et al., 1995, 
Cornelius et al., 1998).  
An array of risk factors for cardiovascular disease such as obesity, hypertension, and 
hyperlipidemia are related to insulin resistance which consequently can result in 
atherosclerotic events in diabetic population (Anan et al., 2007). One of the possible 
means by which elevated levels of plasma homocysteine can lead to atherosclerosis is 
through inflammatory processes (Zhang et al., 2004). 
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1.16.10 Tumour Necrosis Factor- α (TNF- α) 
TNFα is now acknowledged as being a pluripotent cytokine, and the mechanisms of 
many of its biological activities are still not clearly understood. It seems to be capable 
of inducing diverse, and at times, contradictory physiological effects depending on the 
experimental setting. It is known that TNFα can cause apoptosis, septic shock, 
inflammation and cachexia systemically (Beutler and Ceramic, 1988). Yet, in contrast, 
it can induce growth through mitosis, it immunologically protects the host, and may also 
help to induce obesity by metabolic mechanisms (Ferrari, 1999). 
TNFα has a long scientific history associated with CVD. For more than 2.5 millennia, it 
has been recognised that patients with end-stage chronic heart failure (CHF) share 
clinical features with individuals with neoplasia or inflammatory disorders (Ferrari, 
1999). 
1.17 Cellular Calcium (Ca
2+
) homeostasis and Type 2 diabetes (T2DM)  
Moreover, complications of T2DM can also affect vascular endothelium, vascular 
smooth muscle cells, platelets, monocytes and several other cells and tissues. Ca
2+
 
homeostasis and Ca
2+
 signalling play a very crucial role in the regular functioning of 
these cells as they are actively involved in cell-proliferation, cell-death and secretion in 
many cells (Kumar and Clark, 2007). Numerous studies have investigated the diverse 
aspects of Ca
2+ signalling in β-cells and homeostasis in T2DM. It is well known that 
Ca
2+
 plays a very active physiological role in insulin secretion and there is also evidence 
that Ca
2+
 is involved in mediating actions of insulin contributing to the pathogenesis of 
insulin resistance in T2DM. It is observed that basal Ca
2+ 
is elevated and Ca
2+ 
signalling 
is impaired in many cells including platelets, endothelial cells and vascular smooth 
muscle cells in diabetes and hypertension (Resnick et al., 1983). Insulin decreases 
vascular resistance by stimulating nitric oxide production in endothelial cells and 
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reduces Ca
2+
 in vascular smooth muscle cells. High concentration of Ca
2+ 
in endothelial 
cells increases secretion of basement membrane proteins and contributes to thickening 
of basement membrane which leads to narrowing of blood vessels.  
There is increasing evidence which reveals that T2DM is a state in which calcium 
homeostasis is impaired (Marhoffer et al., 1992; Levy et al., 1994b). Dysfunctioning of 
calcium regulation is found in various body cells including erythrocytes, platelets, 
lymphocytes and neutrophils which confirm the basic pathology associated with 
diabetic condition. An increase in the calcium level is the most common finding which 
was described in diabetes among the various other problems associated with the 
dysregulation of calcium homeostasis.  
The primary defect of these multiple functions involved in Ca
2+
 regulation is still 
unknown. Ca
2+
 metabolism plays a very important role in the vascular complications 
associated with T2DM such as atherosclerosis, hypertension and angiopathy and also in 
the pathogenesis of some of the microvascular complications. Therefore, Ca
2+
 
homeostasis could be a common pathway which links most of features of T2DM.  
1.17.1 Cell Ca
2+
 regulation  
Even though there underlies tissue specificity, most of the mechanisms for the 
maintenance of Ca
2+ 
homeostasis are shared by tissues (Howard, 1989; Okamoto et al., 
1992; Antony, 1994; Levy et al., 1994a). Intracellular free Ca
2+ 
concentration [Ca
2+
]i is 
10
4
 times lower than extracellular Ca
2+
 levels which is maintained by a complex 
interplay of various Ca
2+ 
transporters responsible for the influx, extrusion and release of 
Ca
2+ 
in different cells. These include the Na
+
/Ca
2+ 
exchanger, the calmodulin- (CaM) 
dependent Ca
2+
- ATPase, the sarcoplasmic endoplasmic ATPase pump (SERCA) which 
induces calcium release from the ER or SR and the different Ca
2+ 
channels that regulate 
Ca
2+ 
entry into the cell (Rasmussen, 1986; Petersen et al., 1994).  
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Ca
2+
 is mainly stored in cell organelles such as the endoplasmic sarcoplasmic reticulum 
(ER/SR), and the mitochondria within the cell (Ann, 1993). Regulation of [Ca
2+
]i  is 
more active in the ER than the mitochondria. Release of Ca
2+
 from the ER has several 
mediators which include inositol triphosphate (Ip3), Ca
2+
 via ryanodine receptors and 
also cyclic adenosine triphosphateribose (cADP-ribose) (Takasawa et al., 1993). The 
entry of Ca
2+
 into the ER is mediated by a CaM-independent Ca
2+
-ATPase. 
Flooding of excess Ca
2+ 
into the cytoplasm after its release from the cellular stores is 
mediated by several cellular responses (Clapham, 1993). Excess Ca
2+ 
is pumped out of 
the cell and back to the ER which is mediated by Ca
2+
-ATPase pumps. To prevent 
depletion of Ca
2+
 stores due to the repetition of such cycles, there are Ca
2+
 specific Ca
2+ 
channels in the plasma membrane which allow a small amount of Ca
2+
 into the cell and 
pumped into the Ca
2+ 
stores to replenish the ER. The rate of this Ca
2+ 
entry is 
determined by Ca
2+ 
influx factor and cytoplasmic Ca
2+ 
levels. (Na
+
 + K
+
)-ATPase and 
the Na
+
/H
+
 and Na
+
/ Ca
2+
 exchanger are some of the other mechanisms that regulate 
[Ca
2+
]i which affect [Na
+
]i. The stimulation or inhibition of Na
+
/Ca
2+
 exchanger might 
result in the increase or decrease of Ca
2+
 levels which ultimately leads to the disruption 
of [Ca
2+
]i homeostasis and damage Ca
2+
-regulated ligand functions (Levy et al., 1994a). 
However, it is important to emphasize that the calcium signal is very specific to the 
particular stimuli involved. This specificity of calcium signal is accomplished since two 
factors determine the ―calcium language‖: the amplitude of the change in [Ca2+]i level, 
and the distance that this change spreads. A specific pattern of change is created by 
these two determinants in the level and distribution of the cation in the cell, and make 
each Ca
2+
 signal unique to the specific stimuli (Allbritton et al., 1992; Petersen et al., 
1994). 
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1.17.1.1 Abnormal-cell Ca
2+
 regulation in diabetes 
Although [Ca
2+
]i is important for vital functions in all cells, some of its effects such as 
contraction in muscle and secretion in glands are tissue-specific (Boris, 1988; Levy et 
al., 1989; Levy et al., 1994a).Therefore, defects in [Ca
2+
]i homeostasis might be 
expressed differently in the different tissues involved. Further, since the mechanisms 
that regulate [Ca
2+
]i are tightly interrelated, a defect in one mechanism may impair the 
function of the other mechanisms, making the identification of the primary defect a 
complicated task. Various abnormalities in [Ca
2+
]i regulation were described in animal 
models of diabetes and obesity and in obese and diabetic patients (Kato et al., 1994; 
Levy et al., 1994b). These include pathologies of function of the plasma membrane and 
the ER/SR Ca
2+
-ATPase, (Na
+ 
+ K
+
)-ATPase, Na
+
- Ca
2+
 exchanger, Ca
2+
-induced Ca
2+
 
release from the ER, the tissue total calcium content, and the actual [Ca
2+
]i levels (Juntti 
et al, 1993; Roe et al., 1994).  
Defects in cell Ca
2+
 homeostasis were described in erythrocytes, cardiac muscle, 
platelets, skeletal muscle, kidney, aorta, adipocytes, liver, osteoblasts, arteries, lens, 
peripheral nerves, brain synaptosomes, retinal tissue, and in pancreatic β cells 
(Tomizawa et al., 1993; Roe et al., 1994; Janicki et al., 1994; Levy et al., 1998).  
However, there is noticeable variation with regard to the described specific defect in 
each of the [Ca
2+
]i regulatory functions. For example, basal [Ca
2+
]i levels have been 
described to be either high, low, or normal in cardiomyocytes in diabetes ( Schaffer & 
Mozaffari, 1996; Hayashi & Noda, 1997; Yu et al., 1997). Similarly, basal activity of 
the plasma membrane Ca
2+
-ATPase was described to be either high, low, or normal 
(Levy et al., 1994b). However, even when basal functions were normal, dynamic 
studies that tested responses of the [Ca
2+
]i regulatory function to an agonist were 
abnormal, suggesting that dynamic studies might be more sensitive in identifying early 
defects in cell Ca
2+
 homeostasis in diabetes and obesity. Since the functional state of the 
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[Ca
2+
]i regulatory mechanisms, such as the ATPase‘s, depends on many factors 
including membrane phospholipid content, level of Mg
2+
, free fatty acids, cholesterol, 
and glucose and these conditions were not standardized in the different studies, it is 
expected to observe contradictory results obtained in the different reports. However, an 
increase in the level of [Ca
2+
]i has been described most frequently as a defect in cell 
[Ca
2+
]i homeostasis in diabetes and obesity (Levy et al., 1988; Gonzalez Flecha et al., 
1990; Mene et al., 1993; Williams & Schrier, 1993, Espino et al., 2010).  
1.17.1.2 Impaired-Cell Ca
2+
 Homeostasis and Insulin Secretion 
So far, defects in β-cell [Ca2+]i homeostasis have been described only in animal models 
of diabetes and in islet cells exposed to high glucose for a long time, but it is expected 
that similar defects will appear in human diabetes (Roe et al., 1994). Islets from db/db 
mice lack the initial reduction of [Ca
2+
]i and the subsequent Ca
2+
 oscillations in 
response to glucose, and islets from neonatal induced T2DM rats lacking insulin 
response to glucose, but respond to amino acid stimulation have selective defect in the 
increase of [Ca
2+
]i in response to glucose (Giroix et al., 1983; Tsuji et al., 1993). L-type 
voltage-dependent Ca
2+
 channel activities are increased in β cells from these T2DM rats 
and their Ca
2+
-ATPase activity is decreased. Since oscillations of [Ca
2+
]i are essential 
for the pulsatile insulin secretion, loss of these oscillations may play a significant role in 
the loss of pulsatile insulin secretion observed early in T2DM (Leahy, 1990). Finally, 
there is evidence that the ―glucose toxicity,‖ which selectively impairs insulin secretion 
in response to glucose (and may play a significant role in the β-cell dysfunction in 
diabetes) may be mediated in part by a glucose-induced impairment in the β cells‘ 
[Ca
2+
]i homeostasis (Dunbar et al., 1989; Okamoto et al., 1992). Culture of rat islet cells 
in media that contain high glucose concentration cause a progressive, dose- and time-
dependent decrease in the membrane Ca
2+
-ATPase activity of the islet cells (Levy et al., 
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1998). In turn, the significance of the Ca
2+
 ATPase for normal insulin secretion has 
recently been considered (Gagliardino & Rossi, 1994). 
1.17.2 Calcium and cardiovascular disease 
T2DM is a well-established and independent risk factor for the development and 
progression of atherosclerosis. The mechanisms that predispose T2DM subjects to 
organ injury and atherosclerosis are multifactorial. Abnormalities of endothelium 
function and morphology appear to play a central role in the pathogenesis of T2DM-
related atherosclerosis. Among the mechanisms causing endothelial dysfunction that 
have been recently implicated in essential T2DM are insulin resistance and its 
accompanying compensatory hyperinsulinemia, oxidative stress (OS), and 
inflammation. Recent evidence from various studies suggests that Ca
2+
 might play a 
major role in hypertension, atherosclerosis and cardiomyopathy (Levy et al., 1994a; 
Schaffer & Mozaffari, 1996).  
It has been suggested that diabetes and cardiovascular disease are associated with a 
common defect of divalent cation metabolism, which also includes calcium (Lawrence, 
1989). [Ca
2+
]i has a role as a key mediator in the production of oxidants by PMN and in 
their degranulation, resulting in OS, inflammation, and damage to endothelial cells, 
vasoconstriction, and hypertension. Elevated [Ca
2+
]i has been described in various cells 
in insulin-resistant states such as uremia, diabetes, and hypertension. An elevation in 
[Ca
2+
]i in PMN from hemodialysis patients, diabetic patients, and diabetic rats has been 
previously described as playing an important role in the pathogenesis of their impaired 
phagocytosis (Espino et al., 2011). 
1.18 Structure of red blood cell (RBC) or Erythrocyte membrane 
Structure of RBC membrane is studied comprehensively as a model for the membrane 
of many other complex cells. Due to their availability in large numbers and relatively 
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simple membranes which can be purified easily, erythrocytes have attracted such 
investigations for many years including medical conditions like haemolytic anaemia, 
transfusion reactions and so on. Erythrocyte skeleton plays a major role in determining 
the shape and the deformability of the cell. Disruption of the interaction between the 
various components of the red cell membrane skeleton may cause loss of structural and 
functional integrity of the membrane.  
The erythrocyte holds a unique, biconcave shape which allows an excess of about 40% 
membrane surface to cell volume (Mayhew et al., 1994). This shape provides plasticity 
to the cell and contributes to its deformation, which is an essential component to 
traverse capillary beds containing vessels smaller than a diameter of 8 μm. A dynamic 
interaction between the cytoskeleton and the membrane enables these morphological 
changes to take place in the RBC (Sivilotti, 2004). The membrane skeleton is made of a 
protein network which consists of structural proteins on the inner surface of the 
erythrocyte membrane and is bound, through linking proteins, to integral proteins of the 
erythrocyte membrane (Delaunay, 2007). Hence, the membrane is considered as a 
structure that extends into the cytoplasm as well as the extracellular space (Bruce et al., 
2003). 
Erythrocyte membrane belongs to the bilayer membrane composed of various proteins 
and lipids. The nomenclatures and ordinal numbers of the erythrocyte membrane 
proteins are assigned according to the mobility of their bands during separation by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Petropoulos 
et al., 2007). In general, erythrocyte membrane proteins can be divided into two groups. 
One group includes peripheral proteins such as spectrin, ankyrin, protein 4.1, actin, 
protein 4.2 and the other group includes integral proteins such as band 3 and 
glycophorin (Figure. 4.1).  
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1.18.1 RBC membrane proteins 
1.18.1.1 Spectrin  
Spectrin is the major components of the RBC membrane skeleton and it comprises of 
25%–30% of total membrane proteins. It is a heterodimer consisting of alpha- and beta-
subunits that are encoded by different genes and associate head-to-head to form 
tetramers. The molecular weight of α-spectrin is 240 kDa, which contains 20 
homologous 106 amino acid repeat segments and two non-homologous segments. The 
molecular weight of β-spectrin is 220 kDa, which contains 17 homologous 106 amino 
acid repeat segments, non-homologous amino terminal anti-parallel segments, 
connected by short non-helical segments. Spectrin heterodimer is a rod-like flexible 
filament, measuring approximately 100 nm in length (Gallagher and Forget, 1993). 
Each erythrocyte contains about 200,000 copies of α and β Spectrin and these chains 
interlink in an anti-parallel fashion, forming the heterodimer. Spectrin tetramers link 
together in a hexagonal array which is connected to the plasma membrane at junctional 
complexes by interacting with actin, protein 4.1 and GPC. Self-association of spectrin 
dimers into tetramers is possibly the best-characterised interaction of membrane 
proteins, allowing the erythrocyte to acquire its mechanical properties (Van Zwieten et 
al., 1995).   
The functions of spectrin include maintenance of erythrocyte shape, regulation of lateral 
motion of integral proteins and to provide structural support to the lipid bilayer and are 
dependent on its interaction with membrane proteins. Spectrin also plays an essential 
role in maintaining local concentration of plasma membrane proteins. It is also involved 
in early stages of cell junction formation and regulation of entrance of secretory vesicles 
into the plasma membrane in non-erythroid cells (Schwartz et al., 1991). 
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1.18.1.2 Ankyrin  
Human ankyrin is an asymmetrical polar protein composed of 1881 amino acid 
residues, with a molecular weight of 206 kDa. It is a mixture of proteins with different 
sizes and contains three functional domains defined by chymotrypsin cleavage. These 
include the 89 kDa N-terminal domain extending from Pro-2 to Phe-827 containing the 
binding site for band 3 and tubulin, the central 62 kDa domain which starts at Lys-828 
and ends at either Leu-1382 or Tyr-1386 or both. It contains the binding sites for β-
Spectrin and the intermediate filament proteins vimentin and desmin. Spectrin is 
anchored on the cell membrane using a functional 55 kDa domain formed from the 
remaining 495 th−499 th C-terminal amino acids. It participates in the widely selective 
processing of mRNA and modulates the interaction of ankyrin with Sp and band 3. This 
domain can affect the hydrodynamic properties of ankyrin and is extremely sensitive to 
proteases, suggesting that it may be more loosely assembled and its last 20 kDa segment 
possibly extends from the ankyrin molecule like a tail. 
The binding protein, ankyrin, creates a second linkage by linking of spectrin to the 
erythrocyte anion exchanger, band 3 through high affinity (Bruce et al., 2003).  
Recently, two erythrocyte membrane multiprotein complexes namely band 3 complex, 
positioned close to the center of the spectrin tetramer, and protein 4.1 located at the 
membrane skeletal junctions have been described elaborately (Salomao et al., 2008).   
1.18.1.3 Protein 4.1 
Protein 4.1 accounts for about 6% of the total membrane proteins and can be separated 
by PAGE into two isoforms (4.1a and 4.1b) with molecular weights of 80 kDa and 78 
kDa, respectively. Protein 4.1 gene is located on chromosome 1 adjacent to Rh protein 
locus, and usually encounters alternative mRNA processing that shows cell 
differentiation and tissue-specific nature. Protein 4.1 possesses two important functions 
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which include interaction of its 10 kDa Spectrin-binding domain with the N-terminal of 
β-Sp which promotes the binding of spectrin with actin and binding of its N-terminal 
domain with GPC. These negatively charged lipids which are present on the inner hemi-
leaflets of lipid bilayer allow the distal ends of spectrin tetramer to bind to erythrocyte 
membrane.  
1.18.1.4 Actin  
Actin is one of the important proteins which is required for muscular contraction and 
motion of the cell. Each erythrocyte consists of appropriately 40~50 x10
4
 actin 
monomers, arranged into short protofilaments of F-actin composing of 12–14 
monomers within erythrocyte membrane, 30–40 nm in length. β-actin participates in the 
formation of junctional complex (JC). Protein 4.2 is present in almost same number of 
copies as Spectrin or ankyrin. It is associated with the cytoplasmic domain of band 3, 
ankyrin, and protein 4.1, but its function is unknown. A complete deficiency of protein 
4.2 may cause spheroovalocytosis and hemolytic anemia, suggesting that it plays a 
certain role in the maintenance of erythrocyte membrane integrity. 
1.18.1.5 Band 3  
Band 3 is the major trans-membrane protein of erythrocytes, comprising of about 25% 
of the total membrane proteins. Each erythrocyte contains 106 copies of band 3 
protomer with a molecular weight of 95 kDa. Various forms of band 3 exist in 
erythrocyte membrane including homodimer, tetramer or oligomer; and its 
polymorphism appears approximately in 6% of population. This is a multifunctional 
protein consisting of 3 domains, a membrane-spanning domain that carries out 
chloride/bicarbonate exchange, a short C-terminal cytoplasmic domain, and a large N-
terminal cytoplasmic domain (Tanner, 1997). The C-terminal cytoplasmic domain of 
band 3 binds carbonic anhydrase II (CAII), forming a metabolon that channels HCO
-
3 at 
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the cytoplasmic face of band 3 and facilitates its interaction with CAII and band 3.3. 
The N-terminal cytoplasmic domain of band 3 binds glycolytic enzymes, haemoglobin 
(Hb), and hemichromes that may induce the aggregation of band 3 and cell turnover. 
However, a major function of the N-terminal domain of band 3 is to anchor the RBC 
membrane to the underlying cytoskeleton. About 60% of Band 3 exists as dimers and 
40% as tetramers in the RBC membrane. The tetrameric form binds ankyrin and protein 
4.2 (Michaely and Bennett, 1995), and it is the major attachment site of the RBC 
membrane to the cytoskeleton. The 40 kDa N-terminal ankyrin-binding domain is 
located within the cytoplasm, whereas the C-terminal 55 kDa anion transport portion 
spans across the erythrocyte membrane for 13 to 14 times (Figure 4. 1). The N-terminus 
of band 3 is embedded deeply inside the cytoplasm, with its C-terminus extended 
outside the membrane. Band 3 is glycosylated at a single external site (Asn-642).   
 
 
Figure 1.5: Diagram showing the structure of erythrocyte membrane; The model 
depicting the interactions and associations of the major human erythrocyte membrane 
proteins which include α and ß spectrin, ankyrin, band 3, 4.1 (protein 4.1), 4.2 (protein 
4.2), actin, and GP (glycophorin) (Adapted from Tse and Lux, 1999).  
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1.18.1.6 Glycophorin  
Glycophorin (GP) molecules consist of about 60% saccharides. The N-terminus of its 
polypeptide chain extends beyond the erythrocyte membrane. The majority of 16 
scattered oligosaccharides hold trioses and tetroses on their side chains, with sialic acid 
as end sugar residues. Erythrocyte membrane of healthy subjects display 4-5 GP bands 
after electrophoretic separation using periodic acid-Schiff (PAS) staining Human GPs 
belong to transmembrane sialoglycoprotein families, including GPs A, B, C, D (α, δ, β, 
γ GPs), and GP E. GPs A, B, and E carry the MNSs blood group antigens: while GPs C 
and D carry the Gerbich (Ge) blood group antigens. The structures of all five GPs and 
their encoding genes are clearly explained, with molecular weights ranging in between 
17–36 kDa. High degree of homology is found in the amino acid sequences of primary 
structures among GPs A, B, and E. The α, δ and ε genes encoding GPs A, B, and E are 
located on q31-34 of chromosome 4. They relate to the autosomes of codominant 
heredity, which are organized in clusters, with spanning sequence of approximate 330 
kb in order of 5p−GP A−GP B−GP E−3p. Previous research studies provided 
information that about 25 variants were detected in GP families, most of them which 
originated as a result of unequal homologous recombination or micro-conversion 
between α GP genes and δ GP genes. Five types of GP variants were also identified in 
Southern China (Lu and Liu, 1999).  
1.19 Osmotic fragility 
Osmotic fragility of Red blood corpuscles (RBCs) can be defined as the rate at which 
the cells burst in hypotonic solutions. Several factors including disease, age, and drugs 
can alter the fragility of red blood cell membrane which plays a major role in the 
survival and function of the RBCs. Cell membranes are semi- permeable barriers and 
there are certain established osmotic gradients between intracellular and extracellular 
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fluids which allow water to flow in and out of these membranes. The concentration of 
non-diffused ions on either side of the cell membrane determines the amount of osmotic 
pressure.  
Prolonged exposure of RBC membrane to elevated concentrations of oxygen and iron in 
haemoglobin (Hb), and its high polyunsaturated fatty acid contents are some of the 
factors which make RBCs a very sensitive model to study injury caused by oxidative 
stress (Kusmic et al., 2000). Elevated levels of glucose (hyperglycaemia) in blood is 
known to cause damage to cell membrane and cell death in various cells including 
cultured pericytes, endothelial cells, kidney cells, retinal cells and RBC‘s (Li et al., 
1984).  
Anaemia is a highly prevalent condition in T2DM patients. According to World Health 
Organisation (WHO), nearly 30% of T2DM patients have anaemia, especially those 
having kidney problems (Almoznino-Sarafian et al., 2010). People with T2DM have 
anaemia with a complex and multifactorial etiopathogenesis and is associated with an 
increased risk of cardiovascular mortality (Zoppini et al., 2010). Recent epidemiological 
studies predominantly performed on Asian and African populations reported that 
patients with T2DM are characterised by increased erythrocyte osmotic fragility 
(Ramana Devi et al., 1997; Ibanga et al., 2005; Osuntokl et al., 2007; Kung et al., 
2009).   
1.20 Advanced Glycation End-products (AGEs) 
T2DM is greatly associated with an increased risk of CVD which cannot be explained 
by known risk factors. Diabetes is regarded as a CHD risk equivalent by the adult 
Treatment Panel III. Some of the factors involved in determining atherosclerotic disease 
are formation of advanced glycation end-products (AGEs). There is increasing evidence 
that AGEs play a major role in atherosclerosis in diabetics. Accumulation of AGEs is 
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considered as a measure of hyperglycaemia and also represents the increasing metabolic 
burden, oxidative stress and inflammation (Baynes and Thorpe, 2000). Inflammatory 
reactions and endothelial dysfunction occur as a result of interactions between AGEs 
and AGE-specific receptors (Ahmed, 2005). AGEs cause damage through the formation 
of unusual cross-links in collagen which might contribute to vascular stiffening 
(Vlassara and Palace, 2002). Recent studies have reported that there is an increased 
serum level of AGEs in T2DM patients with Coronary Heart Disease (CHD). It has also 
been shown that AGEs tend to accumulate in coronary atherosclerotic plaques and 
cardiac tissue of T2DM patients in several immune-histochemical studies (Nakamura et 
al., 1993, Grillo and Colombatto, 2008).  
1.20.1 Formation of AGEs  
Glucose reacts non-enzymatically and chemically with proteins in vivo, to form 
covalently attached glucose-addition products and cross-links between proteins. 
Advanced glycation end-products are a class of complex products formed as a result of 
Maillard‘s reaction which occurs between carbohydrates and free amino group of 
proteins. Intermediate products during this reaction are a result of dehydration, 
molecular rearrangement which leads to carboxyl residue as 3-deoxyglucosone  which 
in turn reacts with free amino groups and form cross linked proteins. Maillard‘s reaction 
is a succession of chemical reactions linked in a complicated network. The first step 
results in the formation of a Schiff base after a condensation reaction between amino 
group and a carboxyl group. The second step includes a molecular rearrangement that 
results in the formation of N-substituted glycosylamine which leads to Amadori‘s 
products. Finally, Amadori‘s products undergo further rearrangements to form AGEs 
(Ahmed, 2005; Diamanti et al., 2007; DSouza et al., 2009). 
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AGEs are very unstable, reactive compounds and their end products are often 
complicated to be completely analysed. Pentosidine and carboxymethylysine (CML) are 
the best chemically characterised AGEs in humans. Excessive accumulation of these 
products is believed to contribute to chronic complications of DM. Chemical 
modification of proteins by reducing sugars in diabetes alters the structure and function 
of tissue proteins leading to further diabetic complications (Monnier, 1990). Glycation 
involves formation of chemically reversible early glycosylation products with proteins 
namely Schiff bases and Amadori‘s products. These products undergo slow and 
complex rearrangements and form AGEs.  
The significance of oxidizing conditions and reactive oxygen species involved in the 
formation of glycoxidation products which are a major class of AGEs that accumulate 
in diabetic tissues was studies by Baynes and colleagues (Baynes and Thorpe, 2000). 
Some of the other pathways which lead to the formation of AGEs are autoxidation of 
glucose by reactive oxygen species and through carbonyl compounds (Kilhovd et al., 
2003). Predominantly, methylglyoxal which is a reactive dicarbonyl metabolite of 
glucose has received substantial consideration as the most reactive AGE precursor in 
endothelial cells (Ahmed, 2010). Curcumin diminishes the impact of hyperglycemia. 
This is affected through abrogating GLUT2 gene expression. It also induces expression 
of PPARγ to reduce oxidative stress (Lin and Chen, 2011). Curcumin also eliminates 
oxidised LDL by suppressing Lectin like oxidised LDL receptor-1 (LOX-1) (Kang and 
Chen, 2009).  
1.20.2 AGEs in Diabetes  
Some of the most common features of diabetic microvascular complications are 
capillary basement membrane thickening and hypertrophy of extracellular matrix. High 
plasma levels of glucose lead to an accumulation of AGEs in tissues which further 
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cause tissue damage and moreover,  several studies showed a significant correlation 
between AGE deposits and diabetic complications (Hammes et al., 1999, Kaji et al., 
2006; Meerwaldt et al., 2008). 
A state of exaggerated oxidative stress in diabetic patients is because of excessive 
production of free radicals including free oxygen species, increased oxidation of 
substrates and auto-oxidation of glucose. In several animal studies, it has been 
demonstrated that excess production of free radicals via a decrease in production of 
nitric oxide (NO) leads to endothelial dysfunction which further restricts vaso-
relaxation of smooth muscle cells (Testafamarian, 1994).  
1.20.3 AGE’s in cardiovascular disease  
There is an increased risk of cardiovascular morbidity and mortality in patients with 
T2DM. AGEs play a significant role in the development and progression of CVD in 
diabetic patients (Jakus and Rietbrock, 2003). Serum level of AGEs are higher in 
diabetic patients with CHD when compared with those without CHD (Kiuchi et al., 
2001).  Serum AGE levels are found to be significantly associated with CHD even after 
other CVD risk factors have been adjusted and several studies have demonstrated 
deposits of AGEs in atherosclerotic plaques and also in myocardium fibres (Sakata et 
al., 1995; Schalkwijk et al., 2004).  
AGEs also increase the level of NF-Kappa B, a transcription factor which is considered 
to be involved in the development of atherosclerosis and also in apoptosis (Bierhaus et 
al., 1997). AGEs promote atherogenesis by oxidizing low density lipoproteins and 
cause changes in the intimal collagen. Some studies have led to isolation of a receptor 
for AGEs on cell surface which is termed as RAGE. This functions as a signal 
transduction receptor and in binding non-AGE-related pro-inflammatory molecules 
such as S100/calgranulins and amphoterins. Elevated levels of AGEs and CML have 
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been reported in T2DM patients with CHD (Kilhovd et al., 1999). Analyses of human 
atherosclerotic lesions have demonstrated extracellular as well as intracellular 
deposition of AGEs in macrophages and vascular smooth muscle cells (Nakamura et al., 
1993; Vlassara et al., 1996). Concentration of AGEs in tissues is associated with the 
severity of atherosclerotic lesions and accumulation of plasma proteins, lipids and 
lipoproteins in the vessel wall (Sims et al., 1996). AGEs can highly affect the integrity 
and function of blood vessel wall through various mechanisms. The first method to 
promote atherogenesis includes formation of AGE cross bridges within the vessel wall 
macromolecules causing mechanical dysfunction and the second is adherence of 
circulating blood cells to the vessel wall due to excessive accumulation of AGEs (Sell 
and Monnier, 1989).  
The final mechanism is through alterations of cellular function of various cells 
including macrophages, endothelial cells, smooth muscle cells, renal and neuronal cells 
by binding to a variety of receptors (Hori et al., 1995; Miyata et al., 1996;Yan et al., 
1996). Formation of AGEs alters functional properties of several important matrix 
molecules. Collagen within the blood vessel has a comparatively long biological half-
life and undergoes non-enzymatic glycation to play a significant role in atherosclerosis 
(Brownlee et al., 1986).  AGEs also entrap soluble plasma proteins like LDL and 
immunoglobulin (IgG) and form covalent cross links (Meng et al., 1998). Furthermore, 
the mechanism through which AGEs could lead to the development of CVD is unclear. 
Some of these mechanisms including endothelial and renal dysfunction, low-grade 
inflammation and arterial stiffness could contribute to the progression of CVD in T2DM 
patients (Suliman et al., 2003; Goldin et al., 2006; Semba et al., 2009).  
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1.21 Total Antioxidant Status 
In recent years, several studies have investigated the possible role of reactive oxygen 
species (ROS) in the pathogenesis of T2DM (Galli et al., 2005). In disease mechanisms, 
where increased oxidative stress might play a major role, ROS are considered to be 
actively involved in a large variety of physiological and patho-physiological processes. 
Oxidative stress can be defined as excessive formation of highly reactive molecules 
(free radicals) including ROS and reactive nitrogen species. Oxidation reactions 
produce free radicals which start chains of reactions that damage cells (DSouza et a.l, 
2009; Ahmed, 2010).  
Antioxidants serve as reducing agents by terminating these chain reactions through 
removal of free radical intermediates and inhibition of other oxidation reactions (Sies, 
1997). There are several other potential sources of free radical production in diabetes 
which include autooxidation of glucose, activation of leukocytes and increased 
bioavailability of transition metal which could perturb the natural antioxidant defence in 
the body (Wolff et al., 1991). These highly reactive molecules quench nitric oxide 
(NO), which is the main endothelial vasodilatation factor and impairs NO-mediated 
vasodilation by reducing its bioavailability (Honing et al., 1998). Serum of diabetic 
patients is found to contain increased levels of lipid peroxides produced due to oxidative 
damage caused to lipids and proteins which shows an association with the development 
of diabetic complications (Nishigaki et al., 1981; Jones et al., 1988; Stringer et al., 
1989). Research has exposed that free radicals have an important role to play in 
aetiology of T2DM and a strong association exists between oxidative stress and 
secondary complications of diabetes (Singal et al., 2001; Rolo and Palmeira, 2006).  
Patients with T2DM have chronic oxidative stress (Ghiselli et al., 1995). It has been 
demonstrated that increased levels of intracellular ROS play a significant role in chronic 
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inflammatory responses to atherosclerosis (Berliner et al., 1995; Kojda & Harrison, 
1999; Chisolm & Steinberg, 2000). In T2DM patients, LDL oxidation contributes to 
LDL accumulation and therefore leads to an accelerated development of atherosclerosis 
(Panasenko et al., 1991). Recently, much attention has been given to the possibility that 
T2DM patients might be subjected to severe oxidative stresses. Oxidative modification 
of LDL particles is presently recognized as a vital step in the atherogenic process 
(Steinberg et al., 1989).  
Higher levels of oxidative stress in T2DM patients might be a result of prolonged 
periods of hyperglycaemia which cause non-enzymatic glycation of plasma proteins 
including LDL (Tames et al., 1992). Persistent hyperglycaemia increases the production 
of ROS within the aortic endothelial cells. Some of the recognized biochemical 
mechanisms of hyperglycaemia induced cell and tissue damage are ROS-induced 
activation of protein kinase-C isoforms, increased formation of glucose–derived AGEs, 
increased glucose flux via aldose reductase pathways and activation of cytokines 
(Brownlee, 1995).  Reaction of ROS on cell membranes leads to the formation of lipid 
peroxidation products such as malondialdehyde (MDA). 
Patients with T2DM suffer from an increased risk of vascular disease when compared 
with those without T2DM (Deckert et al., 1978). Vascular complications take the form 
of premature and accelerated atherosclerosis of large arteries or cause increased 
permeability of capillaries which is associated with thickening of the basement 
membrane. Increased prevalence of dyslipidemia and hypertension are the most 
important predisposing factors for the development of vascular disease in diabetes 
(Bierman, 1992).  
Several low molecular weight antioxidant molecules such as vitamin C, vitamin E, 
urate, thiols and bilirubin act as primary defence against oxidative stress in extracellular 
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fluids (Frei et al., 1988). A wide range of natural antioxidants including superoxide 
dismutase, glutathione-glutathione peroxidase system are present to scavenge free 
radicals in order to prevent oxidative damage. Superoxide dismutase becomes inactive 
due to prolonged hyperglycaemia in diabetic patients (Arai et al., 1987).  
Antioxidant therapy may be useful to relieve symptoms and complications in T2DM 
patients. Many traditional medicinal plants are found to possess substantial amount of 
anti-oxidant properties that were effective against diabetes and its related complications 
(Bailey and Day, 1989).  Correspondingly, it has been proven  that anti-oxidants 
including vitamin C and E improve endothelium-dependent vasodilation in DM 
(Keegan et al., 1995; Ting et al., 1996; Timimi et al., 1998).  
1.22 Working hypothesis  
Endogenous inflammatory markers and mediators can predict the risk for cardiovascular 
diseases in T2DM patients.  
1.22.1 Main Aim 
The main aim of this study was to investigate the relationship between endogenous 
inflammatory markers and mediators and the risk of CVD in T2DM patients.  
1.22.2 Objectives  
The objectives of this study are the following  
 To carry out an epidemiological study of some risk factors among T2DM 
patients.  
 To measure intracellular free calcium concentrations in lymphocytes and 
neutrophils of T2DM patients compared to healthy age-matched controls. 
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 To measure cations, inflammatory markers and mediators in blood of T2DM 
compared to healthy age-matched controls. 
 To investigate the osmotic fragility and different membrane proteins in RBC of 
T2DM patients compared to healthy age-matched control. 
 To measure low molecular weight advanced glycation end products, anti-oxidant 
status in the blood of T2DM patients compared to healthy age-matched controls. 
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Chapter 2 
Materials and Methods
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2.1 Subjects and samples 
2.1.1 Recruitment of subjects  
This project recruited both male and female T2DM patients and healthy age-matched 
control subjects from Royal Preston Hospital, Chorley General Hospital, and Christina 
Infant hospital in Badajoz, Spain, University of Central Lancashire. Type 2 diabetic 
patients who attended the Diabetic Clinics at Royal Preston Hospital, Chorley General 
Hospital were recruited for this study. The project had relevant ethical clearance from 
LREC (LTHTR Ethics Committee), UCLan Ethics Committee and the University of 
Extremadura in Spain.  
Since each chapter of this thesis comprised of different cohort of patients, the 
recruitment process including venipuncture techniques, handling of the samples, and 
patient follow up were discussed individually in each chapter. 
2.2 Blood collection 
Samples of blood were collected by venipuncture technique from both T2DM patients 
and healthy controls following consent. The patients were also given a questionnaire to 
fill in which contained several questions regarding their lifestyle habits and medical 
history for epidemiological study. 
2.3 Sample handling and storage  
The collection, handling and storage of blood samples were considered a vital 
component in order to minimise any inter-sample differences. The results obtained from 
these studies were definitely a reflection of the care taken during these procedures. 
Therefore, blood samples were only collected from patients who were diagnosed with 
T2DM and healthy age-matched controls. 
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2.3.1 Blood handling and preservation  
Universal precautions were followed while handling the blood samples. Plasma and 
serum tubes were labelled properly with an ID number and collection date. The samples 
were centrifuged depending on the requirements followed by storage at appropriate 
temperatures. 
2.3.2 Blood storage 
The blood (5 ml) was collected by the candidate in EDTA tubes, centrifuged at 3500 
rpm for 10 minutes to separate the red blood cells from the plasma, buffy coat and was 
stored at -80 ºC for later analysis. The candidate has obtained relevant training at Royal 
Preston Hospital, Preston to collect blood from patients and age matched control 
subjects by venipuncture technique.  
2.4 Comparison and analysis of various biochemical parameters and 
inflammatory mediators in plasma of T2DM and healthy controls 
2.4.1 Measurement of various cations in plasma 
Measurement of various cations including sodium, potassium, calcium, magnesium, 
zinc, copper, iron and selenium was performed using inductively coupled plasma mass 
spectrometry, (ICP-MS) technique with plasma of both T2DM and healthy controls. 
Blood was collected in an EDTA tube by venipuncture technique and it was centrifuged 
at 3500 rpm for 10 min to separate plasma from the red blood cells. A volume of 0.2 ml 
of plasma was diluted with 9.8 ml deionised water to make 10 ml solution in each tube. 
A volume of 4 ml of nitric acid was added to 1 ml of the above solution in each tube 
and 10 µl of internal standard was added to each tube. The HNO3 was used to denature 
any proteins in the plasma in order to facilitate the measurement of the ions. Cations 
were measured using ICP-MS according to standard protocol of the instrument. Values 
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were expressed as parts per billion which were subsequently converted into mM/L 
values. 
2.4.2 Measurement of various biochemical parameters 
Various biochemical parameters in blood including glucose, insulin, full blood count, 
cholesterol, serum lipid profile, HbA1c, U and E, and C - reactive protein were 
measured according to standard protocols in both T2DM and healthy controls using Pre-
modular analytics by Roche/Hitachi in the Biochemistry Laboratory, at the Pathology 
Department at Royal Preston Hospital.  
2.4.3 Measurement of inflammatory mediators 
Inflammatory mediators were measured using microarray kits. Quantitative 
measurement of 10 human cytokines in the serum samples was done using Quantibody
®
 
Human Inflammation Array 1 from Ray Biotech, Inc., USA. The cytokines including 
IL-1α, IL-1β, IL-4, IL-6, IL-8, Il-10, IL-13, MCP-1, IFNγ, and TNFα were detected by 
fluorescence measurement of samples using laser scanner with Cy3 equivalent dye.  
2.4.3.1 Experimental procedure 
The glass chip was removed from the box and air dried by leaving at room temperature 
for 20-30 min inside the sealed plastic bag. Thereafter, the slide was removed from the 
plastic bag, the cover film was peeled off and air dried again for 1-2 hours at room 
temperature as incomplete air drying of the slide would result in the formation of comet 
tails. 
2.4.3.2 Preparation of standard dilutions of cytokines 
The cytokine standard mix was provided in lyophilized form and then was reconstituted 
by adding 500 µl of sample diluents to the tube. The powder was dissolved thoroughly 
by mixing gently and labelled as standard 1. This was done within one hour of usage. A 
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total of 6 clean microcentrifuge tubes were labelled as Std 2 to Std 7 and 200 µl of 
sample diluent was added to each tube. A volume of 100 µl of Std 1 was pipetted into 
Std 2 tube and mixed gently. A serial dilution was performed by carrying on to Standard 
3 up to Standard 7. A volume of 100 µl of sample diluent was added to another tube 
labelled as control. This tube was used as negative control. Either standard cytokines or 
sample was not added to this tube.  
2.4.3.3 Blocking and incubation  
A volume of 100 µl of sample diluent was added into each well and incubated at room 
temperature for 30 min to block slides. The buffer was decanted from each well and 100 
µl of standard of each cytokine and samples were added to each well. The array was 
incubated at room temperature for 2 hours. This step was performed overnight at 4 ºC 
for best results.  
2.4.3.4 Wash  
The samples were decanted from each well and washed 5 times per min for 5 min each 
time with 150 µl of 1 x wash buffer I at room temperature with gentle shaking. The 
wash buffer was completely removed in each wash step. 20 x wash buffer 1 was diluted 
with distilled water. The glass chip with frame was placed in a box with 1x wash buffer 
and washed at room temperature with gentle shaking for 20 min. The 1 x wash buffer 
was decanted from each well and washed with 150 µl of wash buffer II for minimum 
time of 5 min each at room temperature with gentle shaking. The wash buffer was 
completely removed in each wash step. 20 x wash buffer II was diluted with distilled 
water.   
2.4.3.5 Incubation with detection antibody and washing 
The detection antibody was reconstituted by adding 1.4 ml of sample diluent to the tube 
and spinned briefly. A volume of 80 µl of detection antibody cocktail was added to each 
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well and incubated at room temperature. The samples were decanted from each well and 
washed 5 times with 150 µl of 1 x wash buffer I and then 2 times with 150 µl of 1 x 
wash buffer II at room temperature with gentle shaking. The wash buffer was 
completely removed in each wash step. 
2.4.3.6 Incubation with Cytochrome 3 (Cy3) equivalent dye- Streptavidin and wash 
A volume of 1.4 ml of sample diluent was added to Cy3 equivalent dye-conjugated 
streptavidin tube after briefly spinning down and mixed gently. An aliquot or a volume 
of 80 µl of Cy3 equivalent dye- conjugated streptavidin was added to each well. The 
device was covered with aluminium foil to avoid exposure to light and incubated in a 
dark room at room temperature for one hour. The samples were decanted from each 
well and washed 5 times with 150 µl of 1x wash buffer I at room temperature with 
gentle shaking. The wash buffer was removed completely in each wash step. 
2.4.3.7 Detection of fluorescence 
The device was disassembled by pushing the clips outward from the side of the slide 
and the slide was carefully removed from the gasket. The slide was placed in a slide 
washer and enough amount of 1 x wash buffer was added to cover the whole slide and 
gently shaken at room temperature for 15 min. The wash buffer I was decanted and 
washed with about 30 ml of 1 x wash buffer II by gently shaking at room temperature 
for 5 min. The water droplets were completely removed by placing the slide in a washer 
and drying the glass chip by centrifugation at 1000 rpm for 3 min without cap. 
2.4.3.8 Imaging 
The imaging of the signals was visualised using a laser scanner equipped with a Cy3 
wavelength Axon GenePix. Data extraction was done using microarray analysis 
software GenePix and quantitative analysis was done using Quantibody
®
 Q-Analyser 
software. 
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2.5 Analysis of Red blood cell (RBC) membrane proteins using SDS-
PAGE 
In this series of experiments, the analysis of human RBC membrane proteins was done 
using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
Membrane proteins including spectrin, ankyrin, band 3, band 4.1 and glycophorin were 
analysed and compared between T2DM patients and healthy controls. Isolation of 
membrane proteins from human RBC was performed using a kit method from 
Fermentas, UK and native extraction method. 
2.5.1 Extraction of RBC membrane proteins by native method 
2.5.1.1 Purification of RBC from whole blood  
Fresh whole blood was obtained using EDTA tubes and stored at 4 °C. RBC were 
purified within 48 hours of withdrawal from the human donors. Human RBC were 
initially isolated by centrifugation at 600 x g for 20 min at 4 °C. After the careful 
removal of plasma and buffy coat layers by careful suction, the RBC pellet was 
resuspended in cold isotonic buffer (145 mM NaCl, 5 mM KCl, and 5 mM  Hepes, (pH 
7.4) by trituration and then recentrifuged at 2000 x g for 10 min at 4 °C. The RBC were 
washed with the isotonic buffer four times to completely remove the plasma and buffy 
layers. To remove white blood cells from the RBC suspensions, the samples were 
passed through the white blood cell filters (Plasmodipur, Euro-diagnostica B. V.) a total 
of two times. 
At each step in the purification process, the upper RBC layer was removed. The final 
preparation of washed RBC was resuspended in cold isotonic buffer at pH 7.4 to an 
approximate hematocrit 50% and stored at 4 °C. All RBC samples were stored at 4 °C 
and used for analysis within 24 h of purification.  
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2.5.1.2 Purification of human RBC open ghosts 
A volume of 1 ml of packed RBC was lysed by trituration and stirring on ice for 10 min 
in 100 ml of hypotonic lysing solution containing 15 mM KCl, 0.01 mM EDTA, 1 mM 
EGTA, and 5 mM Hepes solution, pH 6.0 at 4 °C to reduce premature, spontaneous 
resealing of the erythrocyte ghosts. The membranes were then centrifuged at 12,000 x g 
for 10 min at 4 °C. After discarding the supernatant, the membranes were then washed 
in 100 ml of hypotonic lysing solution without EGTA by trituration and recentrifuged at 
12,000 x g for 10 min at 4 °C. Once again, after discarding the supernatant, the 
membranes were washed in 100 ml of EGTA –free hypotonic lysing solution containing 
2 mM Mg
2+
 by trituration and re-centrifuged at 12,000 x g for 10 min at 4 °C. After 
removing the supernatant a final time, the erythrocyte ghost membranes were 
concentrated in 4 ml of the EGTA-free lysing solution containing 2 mM Mg
2+
 by 
centrifugation at 12,000 Х g for 10 min at 4°C. This method has been shown to dilute 
most cytosolic components of RBC by 4 million fold. 
2.5.1.3 RBC plasma membrane washes 
Purified RBC open ghost membranes (300 µl) were suspended in 10 mM NaOH (30 ml) 
at 4 °C. The membrane suspensions were then placed on a nutator and were rotated at 
medium speed at 4 °C for 30 min. Washed membrane samples were then pelleted at 
12,000 x g for 10 min and resuspended in fresh 10 mM NaOH (1 ml) at 4 °C. The 
washed membranes were then immediately subjected to proteolytic digestion with 
Proteinase K. 
2.5.1.4 Proteolytic digestion of RBC plasma membrane  
On purifying erythrocyte plasma membranes from human ghosts and washing the 
membrane samples with NaOH, the RBC ghost membranes were shaved by using 
Proteinase K, a serine protease with broad cleavage specificity. In this study, Proteinase 
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K was active over the pH range 7.5-12.0 but was most often used in the pH range 7.5-
9.0. The activity of the enzyme was at a maximum at 37 ºC, but the activity was >80% 
of its maximum between 20 ºC and 60 ºC. Washed RBC ghost membranes were pelleted 
in a microcentrifuge at 12,000 x g at room temperature for 10 min. The supernatant was 
then removed and discarded and the pellet was resuspended in 10 mM NaOH. 
Proteinase K was then added to the membrane suspension at a final concentration of 3.0 
mg/ml per 100 µl of washed membranes for each shaving reaction and the samples were 
left on a nutator at medium speed for varying durations of time (up to 48 h) at room 
temperature. The digestions with Proteinase K were conducted at room temperature 
rather than at 37 °C where protease activity is maximised to reduce the amount of 
resealing of the erythrocyte open ghost membranes that occurred completely within 6 
min at 37 °C.  
At designated time points, PMSF, a protease inhibitor specific for Proteinase K, was 
added at a final concentration of 5 mM and the samples were left on a nutator at 
medium speed for 30 min to be sure that all of the Proteinase K activity was inhibited. 
The membranes were then pelleted in a microcentrifuge at 12,000 x g at room 
temperature for 10 min. The supernatant was then removed and discarded and the pellet 
was resuspended in 10 mM NaOH once again.  
This washing procedure of the fully washed and shaved RBC open ghost membranes 
was repeated 2 more times for a total of four washes. In the final round, the membrane 
samples were resuspended in buffer K (15 mM KCl, 5 mM Hepes, 2 mM Mg
2+
, 0.01 
mM EDTA, pH
 
8.0). To be sure that Proteinase K and PMSF were removed from the 
membrane samples with the series of four wash steps, samples of the supernatants and 
membrane pellets from each wash step were run on 1D SDS/PAGE gels and silver-
stained. By the fourth wash step, all the Proteinase K and PMSF were removed from the 
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membrane pellet. This particular gel system was chosen because it provided a much 
lower pH environment than traditional SDS/PAGE systems. The advantages of the 
lower pH
 
include sharper band resolution and higher accuracy of results. 
2.5.2 Extraction of RBC membrane proteins from suspension cells 
Membrane proteins from human RBC were extracted using ProteoJET
TM
 Membrane 
Protein Extraction Kit (Fermentas Life Sciences, UK). The kit was designed for 
efficient isolation of membrane proteins from mammalian cells. This kit isolated high 
quality membrane and cytoplasmic protein extracts without cross-contamination 
between the two fractions. Both fractions contained pure, non-denatured functional 
proteins. Membrane protein fraction was used directly in SDS-PAGE analysis. Cells 
were first permeabilized with cell permeabilization buffer to release the cytoplasmic 
protein fraction. The cell debris was then treated with the membrane protein extraction 
buffer which selectively solubilized the majority of integral and membrane-associated 
proteins and isolated them as a separate fraction. The extraction procedure was 
performed on ice and ice-cooled buffers were used throughout this process. A protease 
inhibitor cocktail (Fermentas Life Sciences, UK) was added to cell permeabilization and 
membrane protein extraction buffers to minimize proteolysis. The detailed procedure 
included the following: 
2.5.2.1 Cell harvesting and permeabilization 
Approximately, 5 x 10
6
 cells were pelleted by centrifugation for 5 min at 250 × g and 
the supernatant was discarded. The cells were resuspended in 3 ml of ice-cold cell wash 
solution, centrifugation was repeated for 5 min at 250 × g and the supernatant was 
discarded. A volume of 1.5 ml of ice-cold cell wash solution was added and transferred 
into a 2 ml Eppendorf tube. The cells were centrifuged for 7 min at 250 x g and the 
supernatant was discarded. A volume of 1.5 ml of ice-cold cell permeabilization buffer 
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was added to the solution and vortexed briefly to eliminate cell clumps. This solution 
was incubated for 10 min at 4 ºC while shaking continuously in a shaking water bath in 
the cold room. 
2.5.2.2 Extraction of cytoplasmic proteins 
The permeabilized cells were centrifuged at 16000 x g for 15 min at 4 ºC. After 
centrifugation, the supernatant was carefully removed (cytoplasmic protein extract) and 
was transferred into a new tube. This was stored as aliquots at -70 ºC. The cell debris 
pellet which contains membrane proteins was set on ice. All the liquid, which contained 
cytoplasmic proteins, was carefully removed. 
2.5.2.3 Extraction of membrane proteins 
A volume of 1 ml of ice-cold membrane protein extraction buffer was added to the cell 
debris pellet and pipetted thoroughly. This was incubated for 30 min at 4 ºC in the 
thermomixer, shaking at 1400 rpm. Clear membrane protein was extracted by 
centrifugation at 16000 x g for 15 min at 4 ºC. The supernatant (membrane protein 
fraction) was transferred into a new tube. This was used directly or stored as aliquots at 
-70 ºC for later analysis. 
2.6 Protein quantification by Bradford Assay 
Membrane proteins isolated from RBC were quantified using Bradford assay (Bradford, 
1976) kit produced by Fermentas, UK. 
2.6.1 Bovine Serum Albumin (BSA) 
BSA standard set, ready-to-use, (Fermentas, UK), contained seven pre-diluted protein 
concentrations in the following standard solutions 2.0 mg/ml, 1.5 mg/ml, 1.0 mg/ml, 
0.75 mg/ml, 0.50 mg/ml, 0.25 mg/ml and 0.125 mg/ml. The standard assay was 
performed in glass test tubes. The different concentrations of BSA mentioned above 
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were provided in 0.15 M NaCl solution containing 0.05% sodium azide as preservative. 
The Bradford reagent was gently mixed by inverting the bottle a few times before it was 
used, and the amount of reagent needed was aliquoted and equilibrated to room 
temperature. A volume of 20 µl of either each pre-diluted standard or sample was 
pipetted to be assayed into appropriately labelled test tubes. An aliquot of 1 ml of 
Bradford reagent was added to each tube and mixed well. The solution was then 
incubated at room temperature for 5 min and transferred into a cuvette. The 
spectrophotometer was set to 595 nm. The instrument was set to zero with the blank 
sample. The absorbance of either standard or the sample solution was measured. A 
standard curve was created by plotting the absorbance at 595 nm vs protein 
concentration of each protein standard (mg/ml). The protein concentration of unknown 
samples was determined by comparing their absorbance values against the standard 
curve. 
2.6.2 SDS-PAGE Electrophoresis 
Analysis of membrane proteins was performed using SDS-PAGE electrophoresis using 
a mini protean system with 12% Ready gel- Tris HCl gel (Bio-Rad Laboratories, UK). 
10 x Tris- glycine-SDS electrophoresis buffer was used as running buffer (Fermentas, 
UK).   
Protein sample was loaded into SDS-PAGE gels according to manufacturer‘s protocol. 
Dual Color Protein Loading Buffer (Fermentas, UK) was used for the preparation of 
protein samples for SDS-PAGE. Some of the proteins were sensitive to pH changes and 
temperature fluctuations during electrophoresis in Tris buffers. As such, the optimised 
composition of this loading buffer prevented protein degradation during sample heating 
prior to SDS-PAGE and during the electrophoresis run. PageRuler
TM
 Plus Prestained 
Protein Ladder (Fermentas, UK) was used as it was a mixture of 9 recombinant, highly 
 Page 89 
 
purified individually prestained proteins with apparent molecular weights of 10-250 
kDa and contained two coloured reference bands orange and green. This ladder was 
provided in a loading buffer for direct use. The ladder was thawed to room temperature 
or at 37-40 ºC for a few min to dissolve any precipitated solids and mixed gently and 
thoroughly, to ensure that the solution was homogeneous. A volume of 5 µl of the 
ladder was directly loaded on the SDS-PAGE gel (Table 2.1). 
 
Table 2.1:  Step by step procedure for SDS-PAGE. 
Step Procedure 
Thawing 
The reducing agent was thawed at room temperature. Any precipitated 
solids in the loading buffer were dissolved at 37 ºC. 
Mixing 
The components of the pack were vortexed gently to ensure that 
solutions are homogeneous. A volume of 2 µl of 20 x reducing agent 
was placed into a clean micro centrifuge tube and 10 µl of 4 x 
DualColor protein loading buffer was added to it. Each protein sample 
was added and the total volume was made up to 40 µl using nuclease 
free water. 
Denaturing Samples were heated at 100 ºC for 3-5 min 
Loading 
Loading of the samples was done by applying directly to SDS- 
polyacrylamide gel after centrifuging the samples briefly. 
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2.6.3 Silver Staining Method 
PageSilver
TM 
staining kit from Fermentas was used to stain SDS-Page gels after the 
electrophoresis. This kit facilitated rapid and sensitive staining of proteins in 
polyacrylamide gels. This procedure was better than traditional Coomassie Blue 
staining and allowed detection of very low abundance proteins. In this process, the 
protein was bound to silver nitrate at a weakly acidic pH followed by subsequent 
reduction of silver ions to metallic silver by formaldehyde at an alkaline pH. Silver 
staining included the following steps: 
2.6.3.1 Preparation of Fixative Solutions 
Fixative solutions in volumes sufficient to stain one gel were prepared and stored in 
tightly closed bottles at room temperature (Table 2.2). 
 
Table 2.2: Preparation of gel fixing solutions for Silver Staining. 
Reagent 
Gel Fixing Solution 1 Gel Fixing Solution 2 
Volume Final 
Concentration 
Volume 1 Volume 2 Final 
Concentration 
Ethanol 50 ml 50% (v/v) 60 ml 90 ml 30% (v/v) 
Glacial acetic 
acid 
10 ml 10% (v/v) - - - 
Water 
(ultrapure) 
40 ml - 140 ml 210 ml - 
Total 
volume 
100 ml - 200 ml 300 ml - 
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2.6.3.2 Preparation of staining solutions 
The following four staining solutions were prepared using the reagents provided in the 
kit. The staining solutions were prepared on the same day prior to staining. 
Formaldehyde was added only immediately prior to staining. Staining solutions 
sufficient for staining one gel were prepared and stored in marked clean glass bottles 
and indicated volumes of reagents. 
 
Table 2.3: Preparations of reagents/staining solutions for Silver Staining. 
Reagent 
Sensitizing 
Solution 
Staining 
Solution 
Developing 
Solution 
Stop Solution 
Sensitizer 
concentrate 
0.4 ml - 10 µl - 
Staining 
reagent 
- 4 ml - - 
Developing 
reagent 
- - 10 ml - 
Stop reagent - - - 8 ml 
Water 
(ultrapure) 
to 100 ml to 100 ml to 100 ml 92 ml 
Formaldehyde - 54 µl 27 µl - 
Total volume 100 ml 100 ml 100 ml 100 ml 
Staining protocol for maximum sensitivity of protein staining was used which enables 
visualisation of 0.05 ng of protein per band in approximately 2 hour 40 min. This 
protocol did not involve any microwave steps (Table 2.3 and 2.4). 
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Table 2.4: Silver Staining protocol for maximum staining. 
Step Procedure 
1 
Gel fixing 1 
The gel was placed into a staining tray and rinsed briefly with deionised 
water. A volume of 100 ml of gel fixing solution 1 was added and gently 
agitated for 60 min. Gel fixing solution 1 was discarded. 
2 
Gel fixing solution 2 and Washing 
The gel fixing 2 procedure was performed three times for maximum 
sensitivity. A volume of 100 ml of gel fixing solution 2 was added to the 
gel and gently agitated for 20 min. The gel fixing solution 2 was 
discarded after agitation. A volume of 100 ml of deionised water was 
added and gently agitated for 20 seconds. Deionised water was discarded 
and washing procedure was repeated. 
3 
Sensitising and Washing 
A volume of 100 ml of sensitising solution was added to the gel and 
gently agitated for 1 min. The sensitising solution was discarded after 
agitation. A volume of 100 ml of deionised was added and gently 
agitated for 20 seconds. Deionised water was discarded and washing 
procedure was repeated. 
4 
Staining and Washing 
A volume of 100 ml of staining solution was added to the gel and gently 
agitated for 20 min. The staining solution was discarded after agitation. A 
volume of 100 ml of deionised water was added and gently agitated for 
20 seconds. Deionised water was discarded and washing procedure was 
repeated. 
5 
Developing 
A volume of 100 ml of developing solution was added to the gel and 
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gently agitated for approximately 4 min until bands are well-developed 
and the required intensity was reached. The developing solution was 
discarded. 
6 
Terminating 
A volume of 100 ml of stop solution was added to the gel and gently 
agitated for 10 min. The stop solution was discarded and the gel was 
stored in deionised water or dried according to recommendations. 
 
2.6.3.3 Gel imaging 
Gel imaging was performed using ChemiDoc
TM 
XRS (Bio-Rad, UK). Lanes and protein 
bands in each lane were automatically detected and expressed in terms of intensity, 
arbitrary units (AU). The bands were compared between T2DM and healthy controls for 
analysis. 
2.7 Measurement of cytosolic free calcium concentration ([Ca
2+
]i) in 
human lymphocytes and neutrophils of T2DM and healthy controls 
2.7.1 Preparation of cells 
Lymphocytes and neutrophils were prepared from blood samples of both T2DM and 
healthy control blood subjects using the following protocol.  
2.7.2 Preparation of lymphocytes 
Blood was collected in an EDTA tube by venipuncture technique after informed 
consent. Ficoll Histopaque from Sigma Aldrich was used as separating medium. Cells 
were isolated after Density Gradient centrifugation at 600 g for 30 min at room 
temperature. The upper phase of lymphocytes was transferred into polypropylene tubes 
and washed with PBS which was stored in a water bath at 37 ºC. The cells were 
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centrifuged at 480 x g for 10 min at room temperature. The supernatant was discarded 
and each pellet was resuspended in 4 ml of RPMI (Sigma Aldrich, UK).  
A volume of 16 µl of 4 µM Fura-2 AM (fura-2 acetoxymethyl ester) was added to each 
tube and incubated in dark at room temperature. After incubation, the cells were 
centrifuged at 480 x g for 10 min at room temperature and the supernatant was 
discarded. The cells were resuspended by adding 1 ml of Na-HEPES (1 x) per cuvette 
and left for 10-15 min for cleaving. 
2.7.3 Preparation of neutrophils 
Blood was collected in an EDTA tube by venipuncture technique after informed 
consent. Ficoll Histopaque from Sigma Aldrich was used as separating medium. Cells 
were isolated after Density Gradient centrifugation at 600 x g for 30 min at room 
temperature. The lower interphase of neutrophils were transferred into polypropylene 
tubes and washed with PBS which was stored in a water bath at 37 ºC. The cells were 
centrifuged at 480 x g for 10 min at room temperature. After centrifugation, the 
supernatant was discarded and 3-4 ml of cold ammonium chloride was added to each 
tube and stored at 4 ºC for 5 min to lyse the red blood cells in the pellet. The tubes were 
centrifuged at 480 x g for 10 min at room temperature and the supernatant was 
discarded. Each pellet was resuspended in 4 ml of RPMI (Sigma Aldrich). A volume of 
16 µl of 4 µM Fura-2 AM was added to each tube and incubated for 30 min in dark at 
room temperature. After incubation, the cells were centrifuged at 480 x g for 10 min at 
room temperature and the supernatant was discarded. The cells were resuspended by 
adding 1 ml of Na-HEPES (1 x) per cuvette and left for 10-15 min for cleaving. 
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2.7.4 Measurement of intracellular free calcium concentration [Ca
2+
]i in 
lymphocytes  
Fura-2-loaded human lymphocytes from healthy and T2DM patients were stimulated 
with 1 μM thapsigargin (TG) in normal calcium solution (1.2 mM [Ca2+]0). A volume of 
1 ml of suspended lymphocytes was taken in a cuvette and 10 µl thapsigargin was added 
to the cells to measure the level of intracellular Ca
2+ 
release as a result of the 
thapsigargin stimulation. For calibration of the curve, a volume of 6 µl of triton was 
added, left for 50 seconds and then 200 µl of 0.5 M EGTA was added. Fluorescence of 
the sample was measured from the above 1 ml aliquots of magnetically stirred 
lymphocyte suspensions were observed using a Shimadzu spectrofluorophotometer with 
excitation at 340/380 nm and emission at 505 nm and changes in [Ca
2+
]c were calculated 
using the fura-2 340/380 ratio and were calibrated according to the method previously 
described by Espino et al. (2009). 
2.7.5 Measurement of intracellular free calcium concentration [Ca
2+
]i in 
neutrophils  
A volume of 1 ml of suspended neutrophils was taken in a cuvette and 10 µl of fMLP 
Formyl-Methionyl-Leucyl-Phenylalanine (final concentration 10 mM) was added to the 
cells to measure the level of intracellular Ca
2+
 release induced by fMLP. For calibration, 
a volume of 6 µl of triton was added, left for 50 seconds and then a volume of 200 µl of 
0.5 M EGTA was added. Fluorescence of the sample was measured from the above 1 ml 
aliquot of magnetically stirred neutrophil suspensions using a Shimadzu 
spectrofluorophotometer with excitation at 340/380 nm and emission at 505 nm. 
Changes in [Ca
2+
]c were calculated using the fura-2 340/380 ratio and values were 
calculated. Calcium release were estimated using the integral of the rise in [Ca
2+
]c for 
2.5 min after addition of thapsigargin or fMLP. Calcium
 
release were expressed as 
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nanomolar taking a sample every second (nM • s), as previously described by Espino et 
al. (2009).  
2.8 Measurement of low molecular weight AGEs in serum of T2DM 
and healthy control samples  
Low molecular weight AGEs in serum samples of T2DM and healthy controls were 
measured using the following procedure: 
Plasma samples were thawed to room temperature and 0.2 ml of serum sample was 
diluted with 1.8 ml distilled water. Fluorescence of 10 fold diluted serum samples was 
measured in a luminesecence spectrometer at a wavelength of 420 nm after excitation at 
350 nm. The measurement was performed in triplicate. Haemolytic samples were 
excluded. Fluorescence intensity standards were used to calibrate and monitor the 
performance of the instrument and calibrated against quinine sulphate (1 mg/ml) in 
HSO. Deionised water was used as blank to zero the instrument. The fluorescence 
signals of samples were expressed as the relative fluorescence intensity in arbitrary unit 
(A.U) and multiplied by the dilution factor. 
2.9 Antioxidant assay  
Antioxidant assay was performed on plasma samples from both T2DM and healthy 
control samples using Antioxidant assay kit method (Cayman Chemical Company, 
USA). This kit was used to measure the total anti-oxidant capacity of plasma. This kit 
gave the combined anti-oxidant activities of all its constituents including vitamins, 
proteins, lipids, glutathione, uric acid, etc. The assay relied on the ability of anti-
oxidants in the sample to inhibit the oxidation of ABTS
®
 (2, 2
‘
-Azino-di-[3-
ethylbenzthiazoline sulphonate]) to ABTS
®●+
 by metmyoglobin.  The amount of 
ABTS
®●+
 produced was monitored by reading the absorbance at 405 nm. The capacity 
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of the anti-oxidants in the sample to prevent ABTS
® 
oxidation was compared with that 
of Trolox, a water soluble tocopherol analogue, and was quantified as millimolar Trolox 
equivalents. 
2.9.1 Reagent Preparation 
Some of the kit components were provided in lyophilized (under vacuum) or 
concentrated form and were reconstituted prior to use.  
2.9.1.1 Antioxidant Assay Buffer 
A volume of 3 ml of concentrated assay buffer was diluted with 27 ml of HPLC-grade 
water. This diluted assay buffer (5 mM potassium phosphate, pH 7.4, containing 0.9% 
sodium chloride and 0.1% glucose) was used to reconstitute the metmyoglobin. 
2.9.1.2 Antioxidant Assay Chromogen 
Chromogen was supplied as lyophilised powder of ABTS
®
. This was reconstituted by 
adding 6 ml of HPLC-grade water to the vial and vortexed well. The reconstituted 
reagent was stable for 24 h at 4 ºC. 
2.9.1.3 Antioxidant Assay Metmyoglobin 
This was provided in lyophilised powder of metmyoglobin. The content was 
reconstituted by adding 600 µl of assay buffer and vortexed well. The reconstituted 
reagent was stable for at least one month at -20 ºC. 
2.9.1.4 Antioxidant Assay Trolox 
Lyophilized powder of Trolox (6-Hydroxy-2,5,7,8-tetramethylchouroman-2-carboxylic 
acid) was reconstituted by adding 1 ml of HPLC-grade water and was vortexed well. 
The reconstituted reagent was used to prepare the Trolox standard curve. The 
reconstituted reagent was stable for 24 h at 4 ºC. 
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2.9.1.5 Antioxidant Assay Hydrogen Peroxide 
Hydrogen peroxide was supplied as a stock solution of 8.82 M. A volume of 10 µl of 
this solution was diluted with 990 µl of HPLC-grade water. It was further diluted by 
removing 20 µl and added to 3.98 ml of HPLC-grade water to yield a 441 µM working 
solution. The hydrogen peroxide working solution was stable for 4 hours at room 
temperature. 
2.9.2 Sample Preparation (Serum) 
Blood sample was collected without using an anticoagulant and then allowed to clot for 
30 min at 25 ºC. Blood was then centrifuged at 2000 x g for 15 min at 4 ºC. After 
centrifugation, the top yellow serum layer was pipetted off without disturbing the white 
buffy layer. Serum was then stored on ice. Before assaying serum was diluted to 1:20 
and 1:30. 
2.9.3 Performing the Assay 
The assay was performed using 96 well microtitre plate. Trolox standards were prepared 
in seven clean glass tubes. Amount of reconstituted Trolox and assay buffer was added 
to each tube as described in table 2.5. 
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Table 2.5: Preparation of Trolox standard for making standard curve. 
Tubes 
Reconstituted Trolox 
(µl) 
Assay 
Buffer (µl) 
Final Concentration (mM 
Trolox) 
A 0 10000 0 
B 30 970 0.045 
C 60 940 0.090 
D 90 910 0.135 
E 120 880 0.18 
F 150 850 0.225 
G 220 780 0.330 
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Master mix was prepared for Trolox standard wells using 10 µl of Trolox standard 
(tubes A-G), 10 µl of metmyoglobin and 150 µl of chromogen per well. For each 
sample well, 10 µl of sample was added in instead of Trolox standards along with 10 µl 
of metmyoglobin and 150 µl of chromogen per well. The reaction was then initiated by 
adding 40 µl of hydrogen peroxide working solution to all the wells that were used. 
Hydrogen peroxide was added as quickly as possible according to the protocol. After 
adding all the reagents, the 96 well plate was covered with a plate cover and incubated 
on a shaker for 5 min at room temperature. Absorbance of the samples in each well was 
measured in a Tecan plate reader at 405 nm. 
2.9.4 Analysis of results 
Average absorbance of each standard and sample was calculated and the standard graph 
was plotted as a function of the final Trolox concentration (mM) from the table 2.5. 
Antioxidant concentration of the samples was then calculated using the equation 
obtained from the linear regression of the standard curve by substituting the average 
absorbance values for each sample into the equation:  
            (  )  
                                     
     
           
2.10 Comparison of osmotic fragility of RBC’s of T2DM and healthy 
controls. 
Erythrocytes placed in hypotonic solutions, absorbed water osmotically to reach a 
critical volume which resulted in their lysis due to the fragility of their membranes. This 
phenomenon of osmotic fragility was originally described by Parpart et. al., in 1946 
(Parpart et al., 1946). In this study, the osmotic fragility of RBC was compared between 
T2DM patients and healthy controls. Blood was collected in EDTA tubes by a 
venipuncture technique after obtaining consent from both T2DM patients and healthy 
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controls. This experiment was performed within 2 h after the withdrawal of blood. 
Blood tubes were centrifuged at 3500 rpm for 10 min to separate the plasma from the 
buffy coat and RBC. A volume of 50 µl of RBC was added to each solution of NaCl in 
increasing concentrations and incubated for 30 min at room temperature. After 
incubation, the tubes were centrifuged at 1500 rpm for 10 min and absorbance of the 
supernatant in each tube was measured in a spectrophotometer at 540 nm.  
The result of osmotic fragility test (OFT) was expressed as the concentration of NaCl 
causing 50% haemolysis and the median corpuscular fragility for fresh normal samples 
was taken between 4.0 and 4.45 g/L. Percentage of haemolysis for each solution was 
plotted against NaCl concentrations. The osmotic fragility curve was then compared 
between T2DM and healthy controls. This experiment required preparation of a series 
of hypotonic solutions with NaCl ranging from 0.1% to 0.9%. Dilutions of different 
concentrations of buffered NaCl (100g/L) were made from the stock solution as given in 
the table 2.6 below:  
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Table 2.6: Preparation of dilutions using different concentration of NaCl for 
measurement of osmotic fragility. 
Tubes 
Concentrations 
(g/L) 
1% NaCl (ml) 
Deionised water 
(ml)
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
0 
2.8 
3.2 
3.6 
4.0 
4.4 
4.8 
5.2 
5.6 
6.0 
6.4 
6.8 
7.2 
10 
0 
1.4 
1.6 
1.8 
2.0 
2.2 
2.4 
2.6 
2.8 
3.0 
3.2 
3.4 
3.6 
5 
5.0 
3.6 
3.4 
3.2 
3.0 
2.8 
2.6 
2.4 
2.2 
2.0 
1.8 
1.6 
1.4 
0 
2.11 Statistical analysis 
All the data from T2DM patients and age-matched controls from different experiments 
were analysed and compared using Student‘s t-test and ANOVA test. Data obtained are 
presented as mean ± standard error of the mean (SEM) A value of p<0.05 was taken as 
significant. A value of p<0.001 was taken as highly significant. 
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Chapter 3 
Measurement of intracellular calcium 
in neutrophils and lymphocytes of 
T2DM patients and healthy controls
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3.1 Objectives of this study 
To measure basal [Ca
2+
]i  and to investigate the effect of either thapsigargin or fMLP 
on [Ca
2+
]i in neutrophils and lymphocytes from T2DM patients and healthy age-
matched control subjects for comparison.  
3.2 Introduction  
It is known well that in T2DM condition where the host defence mechanism is highly 
compromised (Kumar and Clark, 2007). Impaired functions of granulocytes and 
lymphocytes and several other immunological dysfunctions have been reported in 
studies relating to diabetic patients and animals (Marhoffer et al., 1992; Alexiewicz 
et al., 1995). There are many on-going studies trying to elucidate the association 
between diabetes and leukocyte functions. Calcium plays a very important role as a 
second messenger in mediating cellular regulation (Berridge, 1995).  A disturbance 
in the intracellular free calcium concentration [Ca
2+
]i is a major cause of metabolic 
disorders and there is much evidence that Ca
2+
 plays an important regulatory role in 
the cascade of insulin-generated signals and β-cell function. An elevated or sustained 
level of calcium is the major reason to diminish cellular sensitivity to insulin and 
contributes to the pathogenesis of T2DM. In this chapter, [Ca
2+
]i was measured in 
lymphocytes and neutrophils of T2DM subjects and compared with healthy controls. 
Formyl-methionyl-leucyl-phenylalanine (fMLP) and thapsigargin-induced changes in 
[Ca
2+
]i of both lymphocytes and neutrophils were evaluated using spectrophotometric 
methods (Espino et al, 2009).  
3.2.1 Role of calcium in lymphocytes 
Calcium signals are crucial for various functions of all immune cells including 
differentiation, effector function, and gene transcription. [Ca
2+
]i ions are increased 
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through the sequential operation of two interdependent processes: depletion of 
endoplasmic reticulum Ca
2+
 stores as a result of binding of inositol trisphosphate 
(IP3) to IP3 receptors, followed by ‗store-operated‘ Ca
2+
 entry through plasma 
membrane Ca
2+
 channels (Berridge, 1995; Peterson et al, 1994).  
In lymphocytes, mast cells and other immune cell types, store-operated Ca
2+
 entry 
through specialized Ca
2+
 release-activated calcium (CRAC) channels constitutes the 
major pathway of intracellular Ca
2+
 increase. In lymphocytes, the main mechanism 
for the entry of extracellular Ca
2+
 across the plasma membrane is store-operated Ca
2+
 
entry (SOCE) through Ca
2+
 release-activated calcium (CRAC) channels. Opening of 
CRAC channels leads directly to the sustained increase of intracellular Ca
2+
 
concentrations resulting in both short-term and long-term functional consequences 
(Berridge 1995; Peterson et al, 1994). 
3.2.2 Role of calcium in neutrophils 
Neutrophils play a significant role in immune response during the initial stages of 
host response to infection via a series of processes which include chemotaxis, 
phagocytosis and the production of reaction oxygen species (ROS) (Roitt et al., 
1996; Vlahos et al., 1995). This leads to an activation of phosphatidylinositol 
cascade, resulting in inositol triphosphate (IP3) and diacylglycerol (DAG) production 
which is an activator of protein kinase C (PKC) (Hu et al., 1999). These processes 
are calcium dependent in which [Ca
2+
]i acts as a second messenger in most of signal 
transduction pathways. It is also shown that [Ca
2+
]i is actively involved in insulin 
signalling where it actively depends on intracellular calcium swings rather than large 
calcium swings resulting by influx from intracellular compartments (Clausen et al., 
1974; Jakubczak et al., 2006).  
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In T2DM, neutrophil dysfunction is considered to augment bacterial infection 
(Repine et al., 1980; Marhoffer et al., 1992) and cardiovascular disease (Berliner et 
al., 2000; McDonagh et al., 1997). Neutrophils from patients with T2DM also show 
signs of impaired phagocytosis, chemotaxis, adhesion and oxidase activity. 
Alterations in the level of [Ca
2+
]i is responsible for many functions of neutrophils. 
[Ca
2+
]i transients are essential for the release of neutrophil granule contents and 
oxidase activity as well as neutrophil adherence and chemotaxis (Jaconi et al., 1988; 
Lew, 1989; Levy et al., 1994a; Alteraifi & Zhelev, 1997) .There is also increasing 
evidence that [Ca
2+
]i levels are higher in most tissues in T2DM (Levy et al., 1994b). 
In T2DM, normalization of hyperglycaemia is associated with a lowering of [Ca
2+
]i 
to non-diabetic levels and an associated improvement in neutrophil function 
(Alexiewicz et al., 1995). 
The initial mechanism involved in the response of leukocytes to inflammatory 
stimuli is mobilization of [Ca
2+
]i. Activation of Polymorphonuclear leukocytes 
(PMNs) by chemoattractants like N-formyl-,methionyl-leucyl-phenylalanine (fMLP) 
induce changes in [Ca
2+
]i. This process is characterised by three major steps: a rapid 
increase, which is followed by a small sustained increase which returns to the initial 
levels in the final stage. Calcium release from internal stores is mediated by inositol 
1,4,5-triphosphate (IP). Response of [Ca
2+
]i is biphasic with a transient release of 
Ca
2+
 from intracellular stores (calciosomes) which is followed by a delayed influx of 
extracellular Ca
2+
 across the plasma membrane as it requires extracellular calcium 
[Ca
2+
]o. The principal second messengers for Ca
2+
 influx across the plasma 
membrane is possibly Ca
2+ 
release from intracellular stores and Ins(1,4,5)P3 and 
inositol 1,3,4,5-tetrakisphosphate (Ins1,3,4,5)P4 as neutrophils do not express 
voltage-operated Ca
2+
 channels (Kelly et al., 1989; Popko et al., 2003). 
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The mechanism of store-mediated calcium entry (SMCE) is not very well understood 
and several hypotheses have been proposed (Alvarez et al., 1992; Fasolato et al., 
1993; Randriamampita & Tsien, 1993; Sargeant et al., 1993). An integrated 
secretion-like coupling model involves trafficking of the Ca
2+ 
stores towards the cell 
surface and a physical interaction with the plasma membrane (Patterson et al., 1999; 
Rosado & Sage, 2000a). The actin cytoskeleton plays a major role in intracellular 
trafficking, however, cortical actin filaments hinder coupling of Ca
2+
 stores with the 
plasma membrane. Therefore, cytoskeletal remodelling is a key event in SMCE 
(Rosado & Sage, 2000b). It has been shown earlier that neutrophil actin 
polymerization is impaired in T2DM (Advani et al., 2002). As SMCE is dependent 
on cytoskeletal remodelling it is hypothesized that, in response to stimulation, Ca
2+ 
influx across the plasma membrane would be impaired in neutrophils from patients 
with T2DM.  
Calcium plays a central role in signal transduction for many responses in neutrophils 
(Sha'afi et al., 1981). An early  increase in [Ca
2+
]i ~ has  been recorded  after  
stimulation  of  neutrophils with a variety  of agents (Bengtsson  et al.,  1986; Pozzan 
et al., 1983). Neutrophil adhesion is a major event of the early inflammatory 
response that is characterized by the recruitment of neutrophils into areas of 
inflammation, which begins with the binding of these cells to endothelium followed 
by their transmigration into tissues (Albelda et al., 1994).  
Distinct phases have been characterized during neutrophil binding, including rolling, 
activation, and firm adhesion (Ley, 1996). The molecular basis for these phases is the 
up-regulation of various cell adhesion molecules that belong to three major families. 
These include the selectins (e.g., P-selectin, L-selectin, and Eselectin), the b2 
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integrins (e.g., CD11/CD18), and the immmunoglobulin super family (e.g., 
intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and platelet 
endothelial cell adhesion molecule-1) (Albelda et al., 1994).  
The main aim of this chapter of the study was to measure basal [Ca
2+
]i and to 
investigate the effect of either thapsigargin or fMLP on [Ca
2+
] homeostasis in 
neutrophils and lymphocytes of T2DM patients and healthy age-matched control 
subjects for comparison especially since derangement in [Ca
2+
]i  homeostasis is 
associated with several diseases.  
3.3 Methods 
As described in chapter 2 of this thesis. 
 
Table 3.1 Subjects recruited for this study 
 Healthy controls T2DM 
No of subjects 6 6 
Age group 30-60 years 30-60 years 
Gender 4 Male & 2 Female 5 Male & 1 Female 
Diabetic status Non-T2DM T2DM 
Treatment - Insulin 
Ethnicity European  European 
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3.4 Results 
3.4.1 Effect of fMLP on calcium release in neutrophils of T2DM and healthy 
controls. 
Basal [Ca
2+
]i in lymphocytes and neutrophils of age-matched control subjects was 
100±0.01 nM and 75.0±0.01 nM, respectively. Basal [Ca
2+
]i in lymphocytes and 
neutrophils of T2DM patients was 0.92±0.01 nM (n=16) and 0.87±0.01 nM (n=16), 
respectively. These values show no significant differences between basal [Ca
2+
]i for 
control and T2DM patients. Graphs were plotted to compare the difference of 
calcium release from neutrophils of T2DM patients and healthy controls and the 
results are presented in Figure 3.1.  
Figure 3.1 shows original time course chart recordings of [Ca
2+
]i level in neutrophil 
of T2DM patients and healthy age-matched controls following stimulation with 
fMLP. The data show that fMLP can elicit a large and transient increases in [Ca
2+
]i  
from neutrophils of both control and diabetic subjects. However, the release of Ca
2+
 
was much more prominent in neutrophils of control subjects compared to T2DM 
subjects. The results also show that [Ca
2+
]i reach a maximum level after 20-30 sec of 
fMLP stimulation followed by a rapid decline but remained slightly above the basal 
level. These experiments were repeated over 24 times for neutrophils of 6 T2DM 
patients and 6 control subjects and the peak responses for each were analysed and 
plotted as bar charts in Figure 3.1B.  The results show that neutrophils of T2DM 
patients contain significantly (p<0.05) less [Ca
2+
]i compared to neutrophils from 
healthy age-matched controls. 
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Figure 3.1 – (A) Original time course chart readings showing [Ca2+]i transients in human neutrophils of age-matched controls and T2DM 
patients following fMLP stimulation.  (B) Bar charts showing mean ±SD data for [Ca
2+
]i  from fMLP stimulated neutrophils of age-matched 
controls and T2DM human subjects (n=6), 
*
p<0.001 for diabetic compared to control. Note the significant elevation in [Ca
2+
]i for T2DM patients 
compared to control. 
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3.4.2 Effect of thapsigargin (TG) on calcium release in neutrophils of T2DM 
patients and healthy controls. 
Thapsigargin is a major Ca
2+
 mobilising secretagogue (Berridge 1995; Peterson et al, 
1994). It specifically acts on the endoplasmic reticulum (ER) in epithelial cells and 
release Ca
2+
. As such, TG was employed in this study to analyse [Ca
2+
]i release from 
WBC.  
Similarly, calculations were performed and graphs were plotted to compare the 
difference of calcium release between T2DM patients and healthy controls. A 
significant difference was observed when neutrophils were stimulated with 
thapsigargin under presence of normal calcium conditions. A decreased response to 
thapsigargin was observed in T2DM patients when compared with healthy controls 
(Figure 3.2).  
Original traces are representative of six independent experiments (Figure 3.2 A). 
Histogram represents the integral for 2.5 min of the calcium release, in healthy 
controls and T2DM patients, calculated as described in Methods section. Values are 
mean ± SD of six independent experiments 
*
P < 0.05 (Figure 3.2 B). The results 
clearly show that thapsigargin can evoke significant and sustained increases in 
[Ca
2+
]i  in neutrophils from T2DM patients and age-matched controls compared to 
basal [Ca
2+
]i. Moreover, the results also show that neutrophils from T2DM patients 
produced significant (P<0.01) less [Ca
2+
]i  compare to neutrophils from age-matched 
control subjects following thapsigargin stimulation.  
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Figure 3.2 - (A) Original time course chart readings showing [Ca
2+
]i transients in human neutrophils of age-matched controls and T2DM patients 
following thapsigargin stimulation.  (B) Bar charts showing mean ±SD data for [Ca
2+
]i  from thapsigargin stimulated neutrophils of age-matched 
controls and T2DM human subjects (n=6), 
*
p<0.001 for diabetic compared to control. Note the significant elevation in [Ca
2+
]i for T2DM patients 
compared to control. 
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3.4.3 Effect of thapsigargin on calcium release in lymphocytes of T2DM patients 
and healthy controls.  
Figure 3.3 (A) shows the effect of thapsigargin (TG) on [Ca
2+
]i from lymphocytes of 
T2DM patients and age-matched control subjects. The results show (A) time course 
original chart readings of Ca
2+
 release and (B) the mean±SD peak responses 
following TG stimulation.  
The graphs in Figure 3.3B were plotted to compare the difference of calcium release 
between T2DM patients and healthy controls. The results show that thapsigargin can 
evoke significant (p<0.05) and sustained increase in from neutrophils of healthy age-
matched control subjects compare to basal release. Analysis of the data show a 
significant (p<0.05) difference when lymphocytes from T2DM patients were 
stimulated with thapsigargin under presence of normal calcium conditions compared 
to healthy controls (see Figure 3.3 B).  
 Page 114 
 
 
 
Figure 3.3 – (A) Original time course chart readings showing [Ca2+]i transients in human lymphocytes of age-matched controls and T2DM 
patients following thapsigargin stimulation.  (B) Bar charts showing mean ±SD data for [Ca
2+
]i  from thapsigargin stimulated lymphocytes of 
age-matched controls and T2DM human subjects (n=6), 
*
p<0.001 for diabetic compared to control. Note the significant elevation in [Ca
2+
]i for 
T2DM patients compared to control. 
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3.5 Discussion 
The common links among several clinical disorders including T2DM and 
cardiovascular disease have been suggested in various studies (Gonzalez Flecha et al., 
1990; Levy et al., 1994a; Schaffer & Mozaffari, 1996). One of the most common 
reported clinical manifestations is insulin resistance. However, there is limited data 
available about the underlying molecular basis for insulin resistance and cardiovascular 
dysfunction. The major findings made in the present study are the significant and 
marked changes in [Ca
2+
]i in neutrophils and lymphocytes from T2DM patients 
compared to healthy controls. The measurement of Ca
2+
 concentration was determined 
by detection of the fluorescent dyes Fura 2. Bacterial peptide fMLP and thapsigargin 
were used for stimulation of lymphocyte and neutrophil. The results of this study show 
a significant decrease in peak [Ca
2+
]i after stimulation with either fMLP or thapsigargin, 
reflecting impaired activity of neutrophils and lymphocytes from T2DM patients when 
compared with healthy controls. 
Insulin secretion is a calcium-dependent biological process and an elevation of calcium 
is required for both first and second-phase insulin secretions. T2DM is associated with a 
shift from biphasic to monophasic insulin release, which might result from a functional 
impairment of Cav2.3 Ca
2+
 channels (Berridge, 1993). The threshold of blood glucose, 
which normally causes sustained second phase insulin release is increased. Elevated 
level of serum calcium is the reflection of extracellular calcium possibly in conjunction 
with impairments of voltage-gated Ca
2+
 channels (Berridge, 1993). There is also 
evidence of a link between serum calcium levels and cellular function relating to 
cytosolic calcium (Boris, 1988) .  
This altered metabolic response detected in granulocytes (neutrophil and lymphocytes) 
from T2DM patients under stimulation with fMLP may be a reflection of a disease-
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induced adaptive metabolic response. Defects in intracellular Ca
2+
 homeostasis have 
been implicated in the impaired mechanical performance of the diabetic heart (Roe et 
al., 1994). Deranged [Ca
2+
]i may also play a role in the development of other diabetic 
complications, such as nephropathy and cardiomyopathy (Pierce & Russell, 1997). It is 
suggested that albuminuria in T2DM patients is associated with a primary defect in 
[Ca
2+
]i homeostasis (Volzke et al., 2006). The results of the present study show an 
appreciable impairment of Ca
2+
 kinetics in neutrophils and lymphocytes from T2DM 
patients compared to control. Thus, decreased [Ca
2+
]i level in immune cells may be one 
of the mechanisms of impaired immunity in diabetic patients. Secondly, this may also 
be associated with constant infection and delayed wound healings normally associated 
with T2DM patients (Kumar and Clark, 2007). Lymphocytes play a major role in the 
development and production of antibodies in the body. Neutrophils are responsible for 
killing or engulfing foreign organisms (bacteria etc.) once they enter the body (Kumar 
and Clark, 2007).  
From the present results, it can be speculated that a correct response of granulocytes to 
extrinsic stimuli depends on the proper function of cell signalling pathways. A reduction 
in neutrophilic functional activity may contribute to higher susceptibility to and severity 
of infections in T2DM (Kumar  & Clark, 2007). Such alterations are strongly associated 
with cytosolic calcium disturbances. It is concluded that patients with T2DM have a 
decreased cytosolic calcium level in polymorphonuclear granulocytes after thapsigargin 
and fMLP stimulation.  This abnormality is possibly responsible for impaired 
neutrophilic function seen in these patients (McManus et al., 2001).  
The present study also shows that in neutrophils from patients with T2DM, despite 
elevated resting cytosolic-free calcium [Ca
2+
]i, stimulation gives rise to a significantly 
subnormal [Ca
2+
]i signal. The defect in neutrophil [Ca
2+
]i rise in T2DM is evident when 
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cells are incubated with either fMLP or thapsigargin. This suggests the presence of an 
abnormality that may affect more than one signalling pathway. Thus, in T2DM, the 
impaired [Ca
2+
]i signal results from a defect in influx of extracellular calcium across the 
plasma membrane and is likely owing to an abnormal store mediated calcium entry, 
which is a cytoskeletal-dependent process. There was a significantly greater response to 
fMLP in neutrophils from the controls than from the patient‘s with T2DM.  
Thapsigargin caused a similar change in [Ca
2+
]i as fMLP, with a significantly greater 
increase in control neutrophils and lymphocytes (Popko et al., 2003). 
The concentration (10
-6 
M) of thapsigargin used has been suggested to cause inhibition 
of Ca
2+
 entry (Geiszt et al., 1995). However, it is unlikely that the response in 
neutrophils from patients is owing to a differential sensitivity to thapsigargin, as the 
finding could be reproduced with fMLP. Previous work has shown that incubation of 
neutrophils, from healthy controls, with 10 nmolL
-1
 fMLP is associated with a 
significant increase in [Ca
2+
]i and that this can occur when cells are incubated in 
calcium-free medium (Espino et al, 2009).  
The demonstration of increased [Ca
2+
]i in resting neutrophils from patients with T2DM 
is consistent with previous findings in neutrophils and other tissues (Lew, 1989). 
Increased resting [Ca
2+
]i may be owing to reduced activity of membrane Ca
2+
-ATPase 
activity in T2DM (Levy et al., 1986). In contrast to the present study, in platelets and 
fibroblasts from patients with T2DM, increased Ca
2+
 influx has been observed (Ishii et 
al., 1991). However, the present observations in leucocytes are consistent with reports 
of a reduced [Ca
2+
]i response to increased glucose concentrations in endothelial cells 
(Salameh and Dhein, 1998) and cardiomyocytes (Yu et al., 1997b). Intriguingly, 
increased [Ca
2+
]i is associated with platelet hyper function in diabetes whereas the 
defect in neutrophil behaviour is one of impaired function (Ishii et al., 1991).  
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It is unclear whether abnormal calcium homeostasis in T2DM is primarily genetic or 
metabolic. Improvement in glycaemic control is associated with normalization of 
resting [Ca
2+
]i (Alexiewicz et al., 1995). On the other hand, a defect in Ca
2+
 handling by 
fibroblasts is most commonly observed in a subgroup of patients with T2DM with 
hypertension and microalbuminuria, suggesting a basic cellular defect (Solini et al., 
1996). In this study, subject groups differed in terms of BMI, blood pressure, lipids and 
insulin levels as well as level of glycaemia. There was, however, no correlation done 
between any of these parameters and the response of neutrophils to stimulation. The 
cause of the defect that was observed in patients with T2DM might be a reduced Ca
2+
 
influx across the plasma membrane secondary to impaired neutrophil cytoskeletal 
remodelling (Advani et al., 2002). Alternative hypothesis for the defect in Ca
2+
 
homeostasis in neutrophils and lymphocytes may be due to lipid abnormalities affecting 
membrane composition and possible insulin resistance (Pierce & Russell, 1997). Similar 
results have been obtained in cardiomyocytes from T2DM rats (Bracken et al, 2004). 
In conclusion, the results of this study, have clearly demonstrated a derangement in 
calcium homeostasis in both neutrophils and lymphocytes of T2DM patients compare to 
healthy age-matched control subjects. Either fMLP or thapsigargin can elicit marked 
and significant increases in [Ca
2+
]i from either neutrophils or lymphocytes of age-
matched control subjects. In contrast, in T2DM patients, either fMLP or thapsigargin 
elicited significantly less [Ca
2+
]i  from either neutrophils or lymphocytes compared to 
controls. The decreases in [Ca
2+
]i from neutrophils and lymphocytes in T2DM patients 
may be responsible for constant infections and delayed wound-healing, normally seen in 
T2DM patients. Therefore, altered intracellular calcium metabolism may represent a 
common, underlying abnormality linking the metabolic and cardiovascular 
manifestations of the diabetic disease process. Further studies are required to determine 
the molecular mechanisms responsible for this effect. 
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These include the measurement of Ca
2+
 from extracellular medium and its release from 
intracellular organelles including the endoplasmic reticulum and the mitochondria. 
Additionally, it is worthy to measure gene expressions for the different calcium 
transporting proteins in lymphocytes and neutrophils.     
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Chapter 4 
Analysis of red blood cell membrane 
proteins in T2DM patients compared to 
healthy controls using SDS-PAGE
 Page 121 
 
4.1 Objectives of this study 
To analyse RBC cell membrane proteins from T2DM patients and healthy age-
matched controls using SDS-PAGE electrophoresis and silver staining techniques.  
4.2 Introduction 
T2DM is a multifaceted syndrome which leads to the development of cardiovascular 
diseases (CVD) (Nishikawa et al., 2000). Significant evidence has demonstrated that 
T2DM is responsible for the production of reactive oxygen species (ROS) which 
contributes for the initiation and progression of atherosclerosis and other related 
complications (Saha et al., 2005). In recent years, there has been growing interest in 
characterising red blood corpuscle (RBC) membrane since structural and functional 
alterations of the membrane might also contribute to patho-physiology of the disease 
(Kahane et al., 1978). Cell membranes are fluid membrane structures which actively 
participate in the central regulation of different functions of the cell. Moreover, they 
are responsible for the maintenance of fluidity which is a prerequisite for their 
function, viability and growth. Zeta potential (ZP) is a characteristic signature for the 
diagnosis of haemolytic diseases, studies of membrane permeability, and other 
alterations leading to destruction of erythrocytes (Ohno et al., 1985).  
In this chapter, alterations of erythrocyte membrane proteins including spectrin, 
ankyrin, band 3, band 4.1 and glycophorin in T2DM patients and healthy controls 
were analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and quantitative estimation of protein bands was performed using scanning 
densitometry as described in chapter 2 
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4.3 Methods  
Methods for this chapter as described in chapter 2.     
Table 4.1 Subjects recruited for this study 
 Healthy controls T2DM 
No of subjects 9 9 
Age group 20-60 years 20-60 years 
Gender 5 Male & 4 Female 7 Male & 2 Female 
Diabetic status Non-T2DM T2DM 
Treatment - Medication & 
Insulin 
Ethnicity Caucasian Caucasian  
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4.4 Results  
Figure 4.2 shows the overall electrophoretic mobility and relative intensity of stained 
bands. The results reveal that the bands for proteins spectrin, ankyrin, band 3, band 
4.1, glycophorin were significantly (p<0.05) different between the two groups 
(Figure 4.4). 
 
 
Figure 4.1: SDS-PAGE protein patterns of T2DM patients following silver staining 
procedure using Fermentas Page Silver Staining Kit. Lane 1 represents molecular 
weight marker. Lane 3 and 5 represent controls and lanes 7 and 9 represent T2DM 
samples. These images are typical of 9 such experiments. 
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Figure 4.2: Analysis of protein bands performed by Bio-Rad Gel Doc analyser. Each 
electrophoretic protein band is expressed in terms of intensity (arbitrary units, AU). 
The peaks represent the intensity of each band in terms of AU units in this figure. 
Typical of 9 such experiments.    
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Figure 4.3: Sodium dodecyl sulfate–polyacrylamide gel (SDS-PAGE) 
electrophoresis patterns of protein extractions performed on Bio-Rad mini-gel 
system using Bio-Rad 12% Tris-HCl gel following silver staining technique. The 
first column on the left hand side represents molecular weight marker in kDa. Lanes 
1 and 2 represent healthy controls and lanes 3 and 4 represent T2DM patients. 
Typical of 9 such different experiments. 
 
The data presented in Figure 4.3 showed significant (p<0.05) increases in the 
intensity of bands of all proteins in T2DM patients compared to healthy controls 
which might indicate a genetic problem underlying the excess production of these 
proteins in T2DM. Following quantification of the different bands, the data are 
presented as a family of bar charts in Figure 4.5. The results have indicated 
significant (Student‘s t-test; p<0.05; n=9) increases in the amounts of all five 
proteins in erythrocyte membranes of T2DM patients compared to healthy controls. 
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Figure 4.4: Bar charts showing the levels of 5 different proteins in RBC membranes of healthy age-matched controls and T2DM patients.  
Data are mean±SEM, n=9, *p<0.05 for T2DM compare to controls. Note the significant increases for spectrin, ankyrin, band 3, band 4.1 and 
glycophorin compared to healthy controls    
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4.5 Discussion  
The membrane of the RBC plays a significant role in the structural and functional 
aspects of the cell and therefore any defects in the blood cell membrane could lead to 
various diseases including severe haemolytic anaemias. Unfortunately, present 
diagnostic tools are limited and the cause of these membrane defects is still unknown. 
The analysis of membrane proteins is challenging, as they are complicated to solubilise 
and also have the tendency to precipitate during analysis while the dynamic interaction 
between membrane and cytoskeleton of the RBC membrane makes it more difficult to 
analyse the proteins in its membrane. Therefore, for future analysis of patient with 
unknown deficiencies, detection of new potential biomarkers should be always 
confirmed by analysis including ELISA/radio immuno assays, immunohistochemistry 
or confocal immuno-fluorescence microscopy.  
Hyperglycaemia which results from uncontrolled glucose regulation is generally 
documented as an underlying link between diabetes and diabetic complications (Rolo & 
Palmeira, 2006). Chronic hyperglycaemia causes oxidation and non-enzymatic 
glycosylation (Maillard reaction) of proteins which also affects the erythrocyte 
membrane proteins (Bunn, 1981). Particularly, the slow turnover of the erythrocyte 
membrane proteins makes them more susceptible to hyperglycaemia. Glycosylation of 
erythrocyte membrane decreases the negative surface electric charge due to cleavage of 
terminal sialic acid components of glycophorin A, leading to accelerated ageing of 
erythrocytes (Raz et al., 1988).  It also leads to increased erythrocyte aggregation and 
accumulation of advanced glycation end products (AGEs), which are associated with 
erythrocyte deformability defects and microvascular complications of diabetes (Rogers 
et al., 1992). The present study was able to show some of the erythrocyte membrane 
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protein alterations that may result from altered glucose metabolism to produce diabetic 
complications.  
Erythrocyte membrane proteins perform various specific functions. For example, band 3 
is the most abundant erythrocyte trans-membrane protein to carry out anion exchange at 
the plasma membrane level (Kay, 1991). Other trans-membrane proteins serve as pumps 
or channels for the movement of ions and assist in the transport of glucose and other 
small molecules. Furthermore, cytoskeletal proteins provide structural integrity and are 
also important for the maintenance of the biconcave shape of the erythrocyte. 
Therefore, disorders of the erythrocyte membrane proteins may alter the surface electric 
charge and the mechanical properties of plasma membrane, including shape and 
deformability, which in turn reflect the elastic reserve of the erythrocyte when it 
receives shear stress forces while passing through either small vessels or capillaries. In 
conclusion, erythrocyte membrane protein alterations are linked to altered erythrocyte 
rheology. Several studies provide evidence of the association of haemorrheological 
abnormalities with diabetes mellitus which possibly participate in the pathogenesis of 
diabetic microangiopathy. Altered rheology of erythrocytes leads to increased 
aggregation, endothelial damage and capillary closure. This also applies on diabetic 
retinopathy, the most common of diabetic vascular microangiopathies (Babu and Singh, 
2004; Ernst and Matrai, 1986). 
There has been improved emphasis on the pathogenic mechanisms linking erythrocyte 
membrane protein alterations following altered erythrocyte rheology and further 
development of diabetic complications. Several studies described a variety of 
erythrocyte membrane protein alterations in diabetic humans or animals. Oxidation of 
spectrin has been demonstrated in diabetic erythrocytes (Schwartz et al., 1991). 
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Absence of spectrin has been reported in T1DM and increased ankyrin and band 6 has 
been reported in both T1DM and T2DM (Adewoye et al., 2011).  
In the present study, electrophoretic alterations of the erythrocyte membrane proteins 
are shown in T2DM patients compared to healthy controls. Detection of such alterations 
may help to clarify the pathogenic steps that contribute to the development of CVD in 
T2DM patients and they also might serve as a blood marker for the existence of diabetic 
microangiopathy or as a sign of increased risk to develop diabetic complications. In 
recent studies, alterations in the ultrastructure of red blood cell have been considered as 
a possible progression marker in T2DM (Straface et al., 2002).  There are several 
possible interpretations to these alterations in the RBC structure. Alterations of the red 
blood cell membrane might lead to accelerated ageing of erythrocytes in T2DM 
(Mazzanti et al., 1992). It has been reported that the proteins present in erythrocyte 
membrane have an increased susceptibility to lysis by endogenous enzymes in diabetes 
(Jones, 1984).  
However, in this study it has not been possible to find out whether the increased 
percentage of protein bands in T2DM patients is attributed to a glycosylation defect or 
to increased proteolysis. Abnormal low MW bands possibly arise due to increased 
proteolysis of original membrane proteins. The high MW band of above 255 KDa 
appeared due to a cross linkage event between spectrin and haemoglobin and has been 
previously found in membranes of oxidatively stressed erythrocytes. The formation of 
spectrin-haemoglobin cross linking represents a well-known oxidant damage of the 
senescent erythrocyte membrane (Snyder et al., 1983) and is reproduced in vitro by 
hydrogen peroxide treatment which is associated with echinocyte transformation, 
membrane rigidity, adherence and phagocytosis (Snyder et al., 1985). 
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In conclusion, the results presented in this study have shown that structural alterations 
of the erythrocyte membrane proteins, that occur as a result of oxidation and non-
enzymatic glycosylation of those proteins in chronic diabetes and which in turn affect 
the erythrocyte rheology, possibly are associated with the development of microvascular 
complications of diabetes, in particular diabetic cardiovascular disease. A lot of such 
protein alterations are shown exclusively in the present study. Their detection may serve 
as a blood marker for the development of diabetic microangiopathy or as a sign of 
increased risk to develop diabetic microangiopathy. Further studies are needed to assess 
whether pharmaceutical intervention to the rheology of erythrocytes can prevent or 
alleviate microvascular diabetic complications. Future research might explore the 
biochemical foundation of this difference and, possibly, its clinical significance. 
Therefore, an approach to study erythrocyte membrane proteins by SDS PAGE, 
quantification by scanning densitometry was used in this study which allowed 
identification and quantification of proteins in the RBC membrane. This may lead to a 
new proteomic approach to discover the unknown defects in erythrocyte membrane 
proteins and to obtain potential biomarkers, which may lead to an improved 
understanding of erythrocyte functioning in T2DM patients. Therefore, a more profound 
analysis of the erythrocyte membrane proteins is required, which can lead to the 
discovery of novel biomarkers and also provide an extension of the existing diagnostic 
tools. Proteomics technology is most suited for this research as it can provide 
simultaneous detection and quantification of proteins.  
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Chapter 5 
Analysis of various biochemical 
parameters in blood of T2DM patients 
and healthy controls
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5.1 Objectives of this study 
To measure the concentrations of cations, biochemical parameters and inflammatory 
markers in plasma and serum of T2DM patients and healthy age-matched controls for 
comparison. 
5.2 Introduction 
T2DM is a metabolic disease associated with a group of abnormalities including 
hyperglycemia, dyslipidemia, hypertension, elevated levels of biochemical and 
inflammatory markers in circulation. This condition predisposes an individual to a 
number of adverse consequences which include atherosclerotic cardiovascular disease, 
neuropathy, nephropathy and retinopathy (Kumar and Clark, 2007). T2DM and 
atherosclerotic CVD have many common antecedent factors that frequently coexist, 
which has given rise to the concept of ―common soil‖ (Jarrett & Shipley, 1988; Stern, 
1995). These factors are associated with increased concentrations of inflammatory 
markers in people with T2DM (Pickup et al., 1997; Nilsson et al., 1998). Inflammatory 
processes play a part in the cause of atherosclerotic CVD (Ross, 1999). Concentrations 
of acute-phase response markers and mediators of inflammation–cytokines such as 
tumour necrosis factor α (TNF-α) and interleukin-6 are increased in people with T2DM. 
This finding has led to the suggestion that raised concentrations of proinflammatory 
cytokines and the resultant acute-phase response may underlie much of the metabolic 
disease including glucose intolerance (Pickup and Crook, 1998).  
Moreover, patients with T2DM have an increased risk of developing extensive 
atherosclerosis and its sequelae including unstable angina pectoris, and acute 
myocardial infarction (Beckman et al., 2002). During the last few years, experimental 
data have emphasised the role of inflammation in atherogenesis. Clinical studies have 
revealed that this upcoming idea of the role of inflammation in atherosclerosis applies 
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directly to patients (Libby et al., 2002). Therefore the aim of this chapter of the study is 
to measure the concentrations of blood plasma cations and other biochemical 
parameters and inflammatory markers of T2DM patients compared to healthy age -
matched controls for comparison.  
5.3 Methods 
Materials and methods of this study are as described in Chapter 2 of this thesis.  
Table 5.1 Subjects recruited for this study 
 Healthy controls T2DM 
No of subjects 22 22 
Age group 30-60 years 30-60 years 
Gender 14 Male & 8 Female 12 Male & 10 Female 
Diabetic status Non-T2DM T2DM 
Treatment - Medication & Insulin 
Ethnicity Caucasian & Asian Caucasian & Asian 
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5.4 Results 
In this cationic study, sodium, potassium, calcium, iron, zinc and magnesium were 
measured in plasma of T2DM and healthy controls by a method described in chapter 2. 
A total of 22 T2DM patients and 19 healthy controls were involved in this particular 
study. The results in table 5.1 show that all the trace elements were observed to be 
significantly (p<0.05) higher in concentrations in T2DM patients when compared with 
healthy controls except for potassium which remains more or less the same for each 
group. The values are also expressed graphically in figures 5.1 to 5.7 for comparison.  
The results for the measurements of the different cations are presented in figure 5.1 to 
figure 5.7. The results show that the plasma of T2DM patients contains significant 
(p<0.05) more sodium, calcium, copper, zinc, and magnesium compared to plasma of 
age healthy age-matched controls. The results also showed that there was no change in 
potassium levels comparing control with T2DM patients. However, T2DM patients had 
significantly (p<0.05) less iron compared to age-matched healthy controls.  
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Figure 5.1: Bar chart showing plasma sodium (Na
+
) concentrations (mmol/L) in T2DM 
compared to controls. Values are expressed in terms of mean ± SEM, n=22, *p<0.05 for 
T2DM compared to control group. 
 
 
 
Figure 5.2: Bar chart showing plasma potassium (K
+
) concentrations (mmol/L) in 
T2DM compared to controls. Values are mean ± SEM, n=22. Note that there is no 
significant difference in K
+
 levels in both control and diabetic groups.  
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Figure 5.3: Bar chart showing plasma calcium (Ca
2+
) concentrations (mmol/L) in 
T2DM compared to controls. Values are mean ± SEM, n=22,
 
*p<0.05 for T2DM 
compared to control group. 
 
 
 
Figure 5.4: Bar chart showing iron (Fe
2+
) concentrations (mmol/L) in T2DM compared 
to controls. Values are mean ± SEM, n=22, 
*
p<0.001 for T2DM compared to control 
group. 
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Figure 5.5: Bar chart showing plasma copper (Cu
2+
) concentrations (mmol/L) in T2DM 
compared to controls. Values are mean ± SEM, n=22, *p<0.001 for T2DM compared to 
control group. 
 
 
 
Figure 5.6: Bar chart showing plasma zinc (Zn
2+
) concentrations (mmol/L) in T2DM 
compared to controls. Values are mean ± SEM, n=22, *p<0.001 for T2DM compared to 
control group.  
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Figure 5.7: Bar chart showing plasma magnesium (Mg
2+
) concentrations (mmol/L) in 
T2DM compared to controls. Values are mean ± SEM, n=22, *p<0.001 for T2DM 
compared to control group. 
 
5.4.1 Biochemical parameters 
Table 5.1 and figures 5.8–5.13 show the results of full blood count in plasma of T2DM 
patients and healthy age-matched controls. The results show higher concentrations of 
RBC, haemoglobin, HCT and lymphocytes in healthy controls when compared with 
T2DM patients and lower concentrations of WBC, platelets, MCV, MCH, neutrophils, 
monocytes and eosinophils in healthy controls when compared with T2DM patients 
(See Table 5.2).  
Figures 5.14-5.16 show the serum lipid profiles in plasma of control and T2DM 
patients. The results show high levels of serum lipid profiles including cholesterol, 
HDL-C, LDL-C and total cholesterol ratio in healthy age-matched controls when 
compared with T2DM patients. In contrast, the levels of triglycerides were found to be 
lower in healthy controls when compared with T2DM patients. 
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Figures 5.17-5.23 show the levels of plasma glucose, CRP, HbA1c, urea, creatinine, 
alkaline phosphatise and GTT in healthy controls and T2DM patients. The results show 
that levels of plasma glucose, C-reactive protein, HbA1c were significantly (p<0.05) 
higher in T2DM patients when compared with those without T2DM (healthy controls). 
The results also show significantly (p<0.05) high levels of urea, creatinine, alkaline 
phosphatase, GGT in plasma of T2DM patients when compared to plasma from age-
matched healthy controls. There were also significantly (p<0.01) low levels of total 
bilirubin, ALT, total protein, albumin, total calcium in plasma of TDM patients when 
compared with plasma from healthy age matched controls. 
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Table 5.2: Table showing the results of all the biochemical parameters measured in 
plasma of healthy controls and T2DM patients. All results are expressed as 
mean±SEM,
*
p<0.05 for T2DM compared to control group.  
Haematological parameters 
Full blood count 
Healthy 
control (n=19) 
T2DM (n=21) p values 
Red blood cells (10*12/L) 
White blood cells (10*9/L) 
Platelets (10*9/L) 
Lymphocytes (10*9/L) 
Monocytes (10*9/L) 
Neutrophils (10*9/L) 
Eosinophils (10*9/L) 
Haemoglobin (g/Dl) 
HCT (ratio) 
MCV (fL) 
MCH (pg) 
5.142±0.145 
6.425±0.360 
222.8±13.091 
2.284±0.131 
0.412±0.029 
3.4785±0.296 
0.2295 ± 
0.0421 
14.83±0.333 
0.434±0.008 
85.07±1.318 
28.98±0.473 
4.511±0.140 
8.542±0.380 
245.388±15.260 
2.040±0.168 
0.635±0.038 
5.464±0.307 
0.2311±0330 
13.311±0.317 
0.402±0.008 
89.72±1.311 
29.64±0.464 
 
0.05 
- 
- 
0.05 
0.05 
- 
- 
- 
- 
- 
Biochemical/Lipid parameters 
Serum lipid profile 
Healthy 
control (n=19) 
T2DM (n=21)  
Total Cholesterol (ratio) 
HDL-C (mmol/L) 
LDL-C  (mmol/L) 
Triglycerides (mmol/L) 
4.480±0.184 
1.268±0.094, 
2.584±0.188 
1.418±0.123 
3.965±0.181 
1.030±0.079 
1.921±0.200 
2.223±0.266 
- 
- 
0.05 
0.05 
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Total Cholesterol ratio 3.913±0.316 3.805±0.232 - 
Kidney function tests Healthy 
control (n=19) 
T2DM (n=21)  
Urea (mmol/L) 
Creatinine (umol/L) 
4.278±0.266 
74.695±2.770 
8.616±0.881 
106.66±12.004 
0.05 
0.05 
Liver function tests Healthy 
control (n=19) 
T2DM (n=21)  
Total bilirubin (umol/L) 
Alkaline Phosphatase (u/L) 
ALT (U/L) 
GGT (u/L) 
Total Protein (g/L) 
Albumin (g/L) 
11.565±1.449 
64.347±3.198 
31.090±8.359 
20.217±1.506 
79.304±0.723 
48.565±0.543 
18, 8±1.275 
89.722±10.497 
20.785±2.727 
69.111±17.683 
74.444±0.682 
45.111±0.675 
0.05 
0.05 
0.05 
0.05 
0.05 
- 
Total Calcium (mmol/L) 
Plasma Glucose (mmol/L) 
HbA1c (DCCT %) 
HbA1c (IFCCmmol/mol) 
CRP (mg/L) 
2.375±0.016 
4.726±0.189 
5.547±0.084 
37.238±0.940 
1.421±0.209 
2.374±0.02 
11.23±1.337 
8.277±0.407 
67.111±4.469 
8.441±2.438 
- 
0.05 
0.05 
0.05 
0.05 
 
5.4.1.1 Full blood count 
Analysis of full blood counts in plasma included measurements of RBC, WBC, 
platelets, lymphocytes, neutrophils, eosinophils, monocytes, mean corpuscular volume 
(MCV), mean corpuscular haemoglobin (MCH) and haematocrit (HCT) in both T2DM 
patients and healthy age-matched controls (Figures 5.8-5.13).  
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Figure 5.8: Bar charts A and B showing the concentrations of RBC and WBC in T2DM 
patients compared to controls, respectively. Data are mean ± SEM, n=22; *p<0.05 for 
T2DM compared with control group. Range of normal values is also shown in the figure 
for comparison.  
 
 
Figure 5.9: Bar charts A and B showing the concentrations of haemoglobin and 
platelets (PLT) in T2DM patients compared to controls, respectively. Data are mean ± 
SEM, n=22; 
*
p<0.05 for T2DM compared with control group. Range of normal values 
is also shown in the figure for comparison.  
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Figure 5.10: Bar charts A and B showing the concentrations of HCT and MCV in 
T2DM patients compared to controls, respectively. Data are mean ± SEM; n=22; 
*p<0.05 for T2DM compared with control group. Range of normal values is also shown 
in the figure for comparison.  
 
 
 
Figure 5.11: Bar charts A and B showing the concentrations of MCH and neutrophils in 
T2DM patients compared to controls, respectively. Data are mean ± SEM; n=22; 
*p<0.05 for T2DM compared with control group. Range of normal values is also shown 
in the figure for comparison.  
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Figure 5.12: Bar charts A and B showing the concentrations of lymphocytes and 
monocytes in T2DM patients compared to controls, respectively. Data are mean ± SEM; 
n=22; *p<0.05 for T2DM compared with control group. Range of normal values is also 
shown in the figure for comparison.  
 
 
 
Figure 5.13: Bar chart A showing the concentrations of eosinophils in T2DM patients 
compared to controls. Data are mean ± SEM; n=22. Note that there was no significant 
difference between the values. Range of normal values is also shown in the figure for 
comparison.  
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5.4.1.2 Serum Lipid Profile  
Analysis of serum lipid profiles included measurements of such parameters as 
cholesterol, triglycerides, HDL-C, LDL-C and total cholesterol ratio in both T2DM 
patients and healthy controls. The data are shown in figures 5.14-5.16. 
 
 
Figure 5.14: Bar charts A and B showing the concentrations of cholesterol and 
triglyceride in T2DM patients compared to controls, respectively. Data are mean ± 
SEM; n=22; *p<0.05 for T2DM compared with control group. Range of normal values 
is also shown in the figure for comparison.  
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Figure 5.15: Bar chart A showing the concentrations of total cholesterol in T2DM 
patients compared to controls. Data are mean ± SEM; n=22; *p<0.05 for T2DM 
compared with control group.  
 
 
 
 
Figure 5.16: Bar charts A and B showing the concentrations of HDL cholesterol and 
LDL cholesterol in T2DM patients compared to controls, respectively. Data are mean ± 
SEM; n=22; *p<0.05 for T2DM compared with control group. Range of normal values 
is also shown in the figure for comparison.  
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5.4.1.3 Glucose, CRP and HbA1c 
This analysis included measurement of plasma glucose, C-reactive protein and HbA1c 
in both T2DM patients and healthy controls. The data are shown in Figures 5.17-5.18. 
The results show significant (p<0.05) increases in the levels of glucose, CRP and 
HbA1c in plasma of T2DM compared to control.  
 
 
 
Figure 5.17: Bar charts A and B showing the concentrations of plasma glucose and 
CRP in T2DM patients compared to controls, respectively. Data are mean ± SEM; 
n=22; *p<0.05 for T2DM compared with control group. Range of normal values is also 
shown in the figure for comparison.  
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Figure 5.18: Bar charts A and B showing the concentrations of HbA1c (% and 
mmol/mol) in T2DM patients compared to controls, respectively. Data are mean ± 
SEM; n=22; *p<0.05 for T2DM compared with control group. Range of normal values 
is also shown in the figure for comparison.  
 
5.4.1.4 Kidney function tests  
Figure 5.19 shows the results for kidney function tests. The measurements included urea 
and creatinine in T2DM and healthy controls. The results have shown significant 
(
*
p<0.05) increases of both urea and creatinine in T2DM patients compared to controls. 
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Figure 5.19: Bar charts A and B showing the concentrations of urea and creatinine in 
T2DM patients compared to controls, respectively. Data are mean ± SEM; n=22; 
*p<0.05 for T2DM compared with control group. Range of normal values is also shown 
in the figure for comparison.  
 
5.4.1.5 Liver function tests (LFT’s) 
Figures 5.20-5.23 show analysis of Liver function tests and the measurements included 
total calcium, total bilirubin, alkaline phosphatase, ALT, GGT, total protein and 
albumin in both T2DM and healthy controls. The results show no significant change in 
total calcium between T2DM and control. However, the results also show significant 
(p<0.05) increases in alkaline phosphatase and GGT in T2DM patients compared to 
control.  
In contrast, there were significant (p<0.05) decreases in total bilirubin, ALT, AST, total 
protein and albumin in T2DM patients compared to age-matched controls. 
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Figure 5.20: Bar chart A showing the concentration of total calcium in T2DM patients 
compared to controls. Data are mean ± SEM; n=22. Note that there is no significant 
difference in the data.  Range of normal values is also shown in the figure for 
comparison.  
 
 
Figure 5.21: Bar charts A and B showing the concentrations of total bilirubin and 
alkaline phosphatase in T2DM patients compared to controls, respectively. Data are 
mean ± SEM; n=22; *p<0.05 for T2DM compared with control group. Range of normal 
values is also shown in the figure for comparison.  
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Figure 5.22: Bar charts A and B showing the concentrations of ALT and GGT in 
T2DM patients compared to controls, respectively. Data are mean ± SEM; n=22; 
*p<0.05 for T2DM compared with control group. Range of normal values is also shown 
in the figure for comparison.  
 
 
Figure 5.23: Bar charts A and B showing the concentrations of total protein and 
albumin of T2DM patients compared to controls, respectively. Data are mean ± SEM; 
n=22; *p<0.05 for T2DM compared with control group. Range of normal values is also 
shown in the figure for comparison.  
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5.5 Discussion  
There is now much evidence that risks for CVD are higher among T2DM patients 
compared to age-matched healthy control subjects. Other well-known risk factors 
including dyslipidaemia, hypertension, sedentary lifestyle, smoking and obesity add to 
this risk. In fact, 75-80% of mortality rate in T2DM patients are due to a combination of 
coronary heart disease, peripheral vascular disease and cerebrovascular diseases. 
Several research studies have provided evidence that patients with T2DM have several 
abnormalities in their blood and lipid profiles including U and E‘s, CRP, HbA1c, 
Glucose and various other biochemical parameters (Wilson et al., 2005). 
The results of this study have revealed marked and significant elevation in all the 
cations (except potassium) in plasma of T2DM patients compared to control. The results 
of cationic studies (Table 5.1) provide evidence that there is an alteration in the plasma 
concentrations of various cations including sodium, magnesium, calcium, zinc, copper, 
and iron in plasma of T2DM patients when compared with healthy age-matched 
controls. These interesting findings suggest that perturbations in cationic metabolism in 
T2DM are more pronounced and might lead to further complications. Further 
exploration of these data may provide fundamental new insights as to whether these 
differences are a cause or a consequence of T2DM.  
The present results are in total agreement with current evidence regarding the 
association of inflammatory markers with the development of metabolic disease, CVD 
and causes of mortality (Table 5.2). These prospective results support a possible role for 
inflammation in T2DM and they go with the hypothesis that T2DM might possibly be 
an expression of ongoing cytokine-mediated acute phase response which is initiated by 
the innate system of our body.  
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The present results also show that an elevation of plasma glucose (hyperglycaemia) is 
observed in T2DM patients when compared with those without T2DM. Glucose- related 
complications such as formation of advanced glycation end-products might be 
important in the pathogenesis of diabetic-late complications. In most of the previous 
studies, glycaemia and the duration of clinical T2DM did not appear to be very strong 
risk factors CHD. However, the reason for this has not been considerably understood.  
Elevated WBC count in T2DM patients might contribute to the development of vascular 
complications. Chronic inflammation might play a crucial role in the pathogenesis of 
CVD in T2DM patients. The close association between WBC and various complications 
of T2DM provides evidence that inflammation might be a common linking factor and 
consequently documented as a major risk factor for atherosclerosis (DSouza et al., 
2009). Mononuclear leukocytes are recruited to the site of endothelial injury and form 
foam cells in the plaque. Inflammatory markers including various cytokines like IL-6, 
TNF-α are released from activated leukocytes and cause endothelial dysfunction. An 
interaction between various risk factors and inflammatory responses lead to widespread 
vascular damage, endothelial dysfunction, and cause complications in T2DM patients. 
Further research is required to establish the relation between these factors and 
underlying mechanisms of diabetic complications.  
Abnormalities in lipid profile might be a result of unbalanced metabolic states of 
diabetic patients that include hyperglycaemia and insulin resistance (Haffner, 2000). 
Aggressive therapy of diabetic dyslipidemia can reduce the risk of CVD in T2DM 
patients. Primary therapy should be directed to lower the levels of LDL. Patients with 
T2DM have many lipid abnormalities including elevated levels of Low-density 
lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C) 
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and low levels of high-density lipoprotein cholesterol (HDL-C). The results of this 
study are found to be consistent with the literature (Kumar and Clark, 2007).  
The results of this study also reveal high prevalence of hypercholesterolemia, 
hypertriglyceridemia, high LDL-C, and low HDL-C levels which are well-known risk 
factors for CVD. Insulin affects apolipoprotein production in the liver and regulates 
enzymatic activity of lipoprotein lipase (LpL) and cholesterol ester transport protein. All 
the above factors are responsible for dyslipidemia in T2DM.  Insulin deficiency reduces 
the activity of haepatic lipase and therefore, several steps involved in the production of 
biologically active LpL might be altered in T2DM.  
This study shows that there is an elevated level of LFT‘s in T2DM patients when 
compared with those without T2DM. Possible explanations for elevated transaminases 
in insulin resistant states include oxidant stress as a result of lipid peroxidation, 
peroxisomal beta-oxidation, and inflammatory cells (Salmela et al, 1984; Erbey et al., 
2000). 
GGT is a nonspecific marker which is known to rise in patients with T2DM. In a cohort 
study of 7,458 non-T2DM men which was conducted for 12 years. It was determined 
that elevated GGT could predict development of T2DM (Perry et al., 1998). Similarly, 
the study in 1988 Ohlson et al have found elevated ALT levels in non-T2DM Swedish 
men to be an independent risk factor (Ohlson et al., 1988).  
Prospectively, increasing ALT concentrations were associated with a decrease in insulin 
sensitivity and T2DM risk. In this study ALT concentrations were found to be higher in 
healthy controls when compared with T2DM patients.  
The results for urea and creatinine prove to be significantly higher in T2DM patients 
when compared with healthy controls. This observation is in agreement with the study 
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conducted by Alder et al, 2003 who showed that elevated levels of creatinine and urea 
in T2DM patients might signify a pre-renal problem such as volume depletion. In 
T2DM patients, impairment of renal function is assessed through measurement of 
plasma concentrations of urea and creatinine. Plasma creatinine and urea are established 
markers of Glomerular Filtration Rate (GFR). Plasma creatinine is a more sensitive 
index of kidney function compared to plasma urea level. Creatinine fulfils most of the 
requirements of a perfect filtration marker. Plasma creatinine is also helpful in 
recognising when there is a drop in kidney function (Perrone et al., 1992). 
Previous studies measuring HbA1c as a predictor of CVD in T2DM patients have been 
largely confined to high-risk populations (Peters, 1997). Findings from earlier studies 
including Pima Indians, Japanese, and Chinese suggest that in pre-diabetic individuals, 
elevated levels of HbA1c predicts the progression to biochemical diabetes as 
determined by oral glucose tolerance testing (Little, 1994; Narayan et al., 1996; 
Yoshinaga and Kosaka, 1996). Association of HbA1c with incidence of cardiovascular 
events is largely attributed to coexistent risk factors. The findings of this particular 
study demonstrate the potential prognostic importance of this biomarker in clinical care.  
Measurement of CRP, a specific marker of inflammation, is an additional finding in this 
study. Levels of CRP have been observed to be significantly higher in T2DM patients 
when compared with healthy controls. CRP is a member of the pentraxin family of 
oligomeric proteins involved with pattern recognition in innate immunity. The 
biological mechanism through which CRP increases the risk of T2DM is not well 
understood. CRP is a marker of low-grade inflammation and influences both insulin 
resistance and insulin secretion indirectly as a result of heightened systemic 
inflammation. Positive association between CRP and T2DM reflects underlying 
endothelial dysfunction and sub-clinical atherosclerosis. Studies should be directed at 
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confirming these findings in animal models. It can be concluded that CRP is a risk 
marker for cardiovascular disease and could emerge as a mediator in atherogenesis.  
5.6 Conclusion  
The best approach to prevent potential CVD in T2DM patients is early recognition of 
risk factors and aggressive therapy. In this study, it is found that elevated plasma levels 
of several biochemical parameters and inflammatory markers were independent 
predictors of CVD in T2DM patients. The findings in this study support the hypothesis 
that low-grade systemic inflammation is an underlying factor in the pathogenesis of 
T2DM and also a common antecedent for both T2DM and CVD. The data from this 
particular study also provide further evidence that inflammatory markers might provide 
a method for early detection of CVD risk. These data might have many significant 
implications for the prevention and treatment of T2DM. Modification of lifestyle habits 
and management of systemic inflammation should be the major targets for prevention 
and treatment of CVD in T2DM patients. Pharmacological therapies with anti-
inflammatory properties might also play an essential role in T2DM induced CVD. 
Healthy diet, regular exercise, yoga and meditation, may also help in both reduction and 
prevention of T2DM-induced long term cardiac complications.    
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Chapter 6 
Analysis of osmotic fragility and 
advanced glycation end-products 
(AGEs) in RBC of T2DM patients and 
healthy age-matched controls 
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6.1 Objectives of this study 
To measure osmotic fragility of RBC, low molecular weight AGEs in seum and anti-
oxidant status in serum of T2DM patients compared to healthy age-matched controls. 
6.2 Introduction 
Biophysical features of red blood corpuscles (RBCs) play a crucial role in cell 
behaviour during blood flow. RBCs determine blood viscosity and blood flow through 
processes like cell aggregation and deformation and hence, they maintain effectiveness 
of blood circulation and normal physiological conditions in an organism.  
In this chapter, the biophysical and biochemical changes of erythrocytes including 
osmotic fragility, formation of advanced glycation end-products (AGEs) and anti-
oxidant status in T2DM patients are analysed and compared to healthy age-matched 
controls. 
In light of these different endogenous results of T2DM patients, this chapter of the 
thesis investigated the osmotic fragility of the RBC and low molecular weight AGEs 
and anti-oxidant status in serum of T2DM patients compared to healthy age-matched 
controls.  
6.3 Methods 
Materials and methods of this chapter are as described in chapter 2 of the thesis. 
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Table 6.1 Subjects recruited for this study 
 Healthy controls T2DM 
No of subjects 22 22 
Age group 30-60 years 30-60 years 
Gender 14 Male & 8 Female 12 Male & 10 Female 
Diabetic status Non-T2DM T2DM 
Treatment - Medication & Insulin 
Ethnicity Caucasian & Asian Caucasian & Asian 
 
 
 
6.4 Results  
6.4.1 Osmotic fragility  
Figure 6.1 shows the osmotic fragility curves of RBC in 5 T2DM patients compared 
with 5 healthy age -matched controls. The results show that there were increases in 
osmotic fragility (haemolysis) in the RBC of all the 5 T2DM patients as compared with 
healthy controls with increased concentration of NaCl up to 4.8 mM. Thereafter, the 
fragility increased in the RBC as NaCl concentration increased to 10 mM. Median 
corpuscular fragility (MCF) is calculated from the graph at which 50% of RBCs were 
haemolysed. The MCF in 2 T2DM patients was found to be present between 2.8-3.6 g/L 
NaCl concentration and 3 T2DM patients the values were  found to be present between 
4.8-5.6 g/L NaCl concentration while control remained at 4.4-5.2 g/L NaCl 
concentration. 
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Figure 6.1: Graph represents the osmotic fragility curve of RBC in T2DM patients 
compared with healthy control, n=5 for T2DM patients and 5 for controls. 
 
 
6.4.2 Advanced glycation end-products 
Low molecular weight AGEs in 50-fold diluted plasma were measured in triplicate on 
luminescence spectrometer. The fluorescence signals of samples were expressed as the 
relative fluorescence intensity in arbitrary unit (A.U) and multiplied by dilution factor 
and the data are presented in Figure 6.2. The results are expressed as mean (±SEM) for 
T2DM patients (368.93±66.14), n=22 and healthy controls (236.67 ±29.05), n=10. The 
data clearly show that the serum of T2DM patients contain significantly (p<0.05) more 
LMW AGEs compared to serum from healthy age-matched control subjects. 
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Figure 6.2: Bar charts showing low molecular weight plasma AGEs in T2DM and 
healthy controls. The results are expressed as mean (±SEM) of the samples (n=22 for 
T2DM and n=10 for controls); * p<0.05 for T2DM compared to control. Note the 
significant increases in LMW AGEs in the serum of T2DM patients compared to 
healthy age-matched controls. 
 
6.4.3 Antioxidant status 
Analysis of anti-oxidant assay was done according to method described in chapter 2 of 
this thesis. This series of experiments was performed at several dilutions of trolox 
standards in order to obtain a standard graph and absorbance was measured at 750 nm. 
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Figure 6.3: Standard curve for different concentrations of trolox at absorbance of 750 
nm. This curve is typical of 4-5 such different experiments. 
 
The results obtained in this study were not found to be accurate due to several reasons 
which might include the dilution of the samples, age of the samples, concentrations of 
trolox standards, high or low concentration of anti-oxidants in the samples. However, 
there was no significant difference observed in the absorbance readings between T2DM 
patients and healthy controls in this particular experiment.  
6.5 Discussion  
T2DM patients have a higher incidence of CVD compared with non-T2DM individuals. 
Atherosclerosis is considered as an inflammatory disease since the presence of humoral 
and cellular components of the immune response has been detected within the 
atherosclerotic lesion. Increased production of activated leukocyte-derived products 
such as ROS, enzymes, and pro-inflammatory mediators contribute to the development 
of atherosclerotic process (Ross, 1999; Libby, 2002).  
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The results of RBC membrane fragility experiments in this chapter of the study have 
indicated both an increase as well as decrease in the membrane fragility of T2DM 
patients when compared with those without T2DM. These reciprocal changes might be 
a result of disturbances in ions through the membrane and changes in the properties of 
membrane which leads to further changes in metabolic functions. Enhancement of 
glycosylation of membrane protein in DM might be one of the possible reasons for 
reduced membrane fluidity (Lux et al., 1978).  The degree of squeezing of RBCs 
depends on the elasticity of their membranes as they have to pass through blood 
capillaries of diameters smaller than themselves.  
Decreased RBC membrane elasticity, can lead to an increase in blood capillary 
resistance for RBC passage to carry out normal metabolism due to which toxicity occurs 
in few organs of the body (Ali et al., 2003). However, it is necessary to emphasize the 
urgent need for increasing investigations on the pathogenic mechanisms involved in the 
process of RBC fragility in order to prevent CVD in T2DM patients.  
Several animal and human studies have shown that AGEs have been implicated in the 
pathogenesis of long- term complications in T2DM patients (Peppa et al., 2003). AGEs 
react with extra cellular proteins and activate production of cytokines and transcription 
factors through binding to AGE receptors (Tan et al., 2004). Accumulation of AGEs 
predicts future development of cardiovascular complications in T2DM patients. 
Experimental evidence to date demonstrates that AGEs can alter the walls of the vessel 
through various mechanisms including modifications in permeability of extracellular 
matrix, release of inflammatory cytokines and growth factors, alterations of 
antithrombotic properties of vascular endothelium along with increased expression of 
adhesion molecules and chemokines on vascular cells (Chappey et al., 1997; Singh et 
al., 2001). 
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In this study, it was observed that there was an increase in the concentration of low 
molecular weight AGEs in T2DM patients when compared with healthy controls. 
Therefore, AGEs might constitute a specific target for treatment of CVD in patients 
with T2DM. The findings of this study are in agreement with some of the previous 
studies which have shown positive associations between plasma AGEs particularly non-
CML AGE, pentosidine, Amadori-albumin and microvascular complications but were 
limited in size of their population and cross-sectional designs (Salman et al., 2009; 
Miura et al., 2001; Schalkwijk et al., 2002).  
Several studies have demonstrated that increased levels of LMW AGEs were associated 
with macrovascular disease and suggested that fluorescent AGEs are not independently 
associated with presence of diabetic complications in T2DM patients. Other smaller 
studies have established an association between fluorescent serum AGEs and CAD in 
T2DM.  
It is clear that while AGEs appear to be capable of contributing to diabetic 
complications individually, advanced glycation is only one pathway by which injury 
may be induced in diabetes. LMW AGEs form through the incomplete digestion of 
AGE-modified protein and incorporation of AGE modifications. These accumulate in 
the circulation of T2DM patients. Indeed, LMW AGEs might have a higher toxic 
potential than those of larger AGE-modified proteins and react with AGE-receptors 
through circulation (Thomas et al., 2005). Hence, LMW fluorescence could be 
considered as a biomarker of measurement of toxic molecules with the ability to 
activate specific AGE receptors. Several factors including diet, inflammation, metabolic 
acidosis and dialysis modality might affect the levels of circulating AGEs in diabetic 
patients (Uribarri et al., 2003). 
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In diabetes, LMW fluorescence is induced as result of hyperglycemia and oxidative 
stress, but not exclusively via the Maillard reaction. Drugs that hinder the formation of 
AGEs also reduce LMW fluorescence, which suggests a close relation between the two. 
LMW fluorescence is elevated in experiment models only within a few weeks of disease 
and progressively accumulates in proportion to the duration of diabetes and with normal 
aging in control animals (Sharp et al., 2003). LMW fluorescence is also elevated in 
patients with diabetes, particularly those with impaired renal function or anemia 
(Thomas et al., 2005). These findings provide support for the association between 
LMW fluorescence and diabetes. The identification of the molecular source of LMW 
fluorescence remains a priority to elucidate the associations demonstrated in this 
research.  
Increased oxidative stress is observed in a system where the production of free radicals 
is higher and anti-oxidant mechanisms are impaired. In recent times, free radicals 
produced through oxidative stress have been implicated in the pathology of T2DM 
(Irshad and Chaudhuri, 2002; Tian et al., 2005; American Diabetes Association, 2006; 
Ashour et al., 1999). The most crucial factor for the increased production of free 
radicals is the condition of hypercholesterolemia which might induce damage through 
overproduction of superoxide radicals in mitochondria. Lipid peroxidation is initiated 
when superoxide is converted into hydro-peroxyls and diffuses through membranes 
(Baynes, 2000).  The most important risk factors and crucial steps involved in the 
pathogenesis of atherosclerosis are hypercholesterolemia and abnormalities in 
lipoprotein metabolism (Mallika et al., 2007; Maxfield and Tabas, 2005). In DM, 
hyperglycaemia leads to production of oxygen-free radicals through various processes 
including auto-oxidation of glucose, non-enzymatic glycosylation of proteins, and 
through activation of enzymes that produce oxidant species and subsequently oxidative 
stress (Atamer et al., 1998).  
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In conclusion, these preliminary results presented in this study have demonstrated that 
oxidative stress can be significantly increased in T2DM patients compared with non-
T2DM controls. These initial experiments could lead to further investigation of anti-
oxidant status in diabetic patients.  
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CHAPTER 7 
General discussion and scope for 
future studies
 Page 168 
 
7.1 General Discussion  
Within recent years, there has been an increasing interest in research on inflammation 
involving T2DM patients who have developed cardiovascular diseases (CVD) (Kumar 
and Clark, 2007). This project was originally designed to investigate the effect of age on 
different cardiovascular risk and inflammatory markers in T2DM patients compared to 
healthy controls. However, as the project developed and expanded in a logical manner 
and it was of paramount importance to measure the parameters associated with T2DM. 
Second, it was very difficult to obtain enough samples of blood from different age 
groups. It was only possible to measure blood samples from age-matched control and 
T2DM patients pooling all the data. Blood was obtained mainly from age-groups 40 
years and over in the study compared to the respective age–matched controls.  
The results in this study are presented in four different chapters focussing on 
measurement of intracellular free Ca
2+
 concentration [Ca
2+
]i
 
in lymphocytes and 
neutrophils in blood of T2DM patients compared to healthy controls, an analysis of 
RBC membrane proteins, an analysis of haematological and biochemical parameters in 
blood and finally measurement of low molecular weight advanced glycation end-
products (LMW-AGEs) in T2DM compared with healthy controls. Collectively, the 
results have demonstrated marked and significant changes in all the measured 
parameters in this thesis. Therefore, the general discussion of this thesis will be 
focussed on the four measured parameters.  
The results of Chapter 3 are significant as [Ca
2+
]i
 
are found to be affected in T2DM 
patients compared to healthy controls. Several previous studies have demonstrated 
elevated levels of [Ca
2+
]i in cells from diabetic individuals (Levy et al., 1989; Levy et 
al., 1994; Takaya et al., 1997). In this study, a decreased response to both fMLP and 
thapsigargin was observed in both neutrophils and lymphocytes of T2DM patients when 
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compared with healthy controls in normal calcium conditions. These findings suggest 
the presence of an abnormality in cellular calcium homeostasis probably affecting more 
than one calcium transport pathways in neutrophils and lymphocytes in blood of T2DM 
patients.  
The results of this study have demonstrated a significant lower response to both fMLP 
and thapsigargin for [Ca
2+
]i  in neutrophils and lymphocytes of T2DM patients 
compared to controls suggesting either a deficit in influx of extracellular calcium across 
the plasma membrane or a decrease in the release of calcium from intracellular stores or 
both. It is still not clear whether abnormal calcium homeostasis in T2DM is primarily 
genetic or metabolic. The findings of this study have indicated a possible role for 
Na
+
/Ca
2+
 exchanges in Ca
2+
 regulation in neutrophils and lymphocytes and their 
modulation in neutrophils and lymphocytes of blood of T2DM patients compared to 
controls. The original basis behind cellular Ca
2+ 
shifts in T2DM is not obvious. Genetic 
defects involved in the transport of Ca
2+
 across cell membrane might contribute to alter 
cellular Ca
2+ 
homeostasis. Altered Ca
2+ 
homeostasis at both cellular and sub-cellular 
levels can cause abnormal insulin secretion, increased vascular resistance, reduced 
muscle contraction, reduced enzyme secretion and altered response of vascular smooth 
muscle cells to Ca
2+ 
mobilising vasoactive hormones (Fleischhacker et al., 1999; Levy, 
1999; Berridge et al., 2000). Other metabolites including free fatty acids, triglycerides 
and cholesterol can also affect Ca
2+
-ATPase activity (Levy et al., 1994; Levy et al., 
1986).  
Evaluation of Ca
2+ 
homeostasis in populations that are genetically susceptible to 
development of T2DM should be performed to determine the primary defect of 
impairment in [Ca
2+
]i regulation. This study is more complicated as there are a number 
of similar abnormalities including ageing, hypertension and obesity that are associated 
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with impaired insulin action and insulin resistance (Boris, 1988; Draznin, 1993; Levy & 
Gavin, 1995; Orlov et al., 1995). Further studies in future on the molecular and genetic 
levels of altered Ca
2+ 
homeostasis in WBC might reveal the initial defect and its genetic 
component.  
The results presented in Chapter 4 of thesis are either contradictory or very interesting 
compared to previous findings. Several workers have found either less or more of the 
different RBC membrane proteins in their studies (Petropoulos et al., 2007, Adewoye et 
al., 2011). Nevertheless, the result of the present study have clearly demonstrated that 
the RBC membrane proteins including spectrin, ankyrin, band 3, band 4.1, and 
glycophorin were found to be present in significantly higher concentrations in T2DM 
patients when compared with healthy controls. Blood vessel is considered as a major 
target organ in T2DM. It is therefore, practical to assume that properties of RBC 
membrane might have certain abnormalities during disease progression such as CVD in 
T2DM patients (Kahane et al., 1978).  
Many studies have demonstrated erythrocyte deformability in several diseases including 
T2DM and CVD (Kahane et al., 1978; Saha et al., 2005; Ohno et al., 1985). However, 
very little is known about the content and quality of membrane proteins which 
contribute to this. SDS-PAGE analysis of RBC membrane proteins from T2DM showed 
weaker bands compared to healthy controls. These results suggest that the observed 
abnormalities might be a result of reduced erythrocyte membrane deformability which 
is associated with T2DM.  
RBC membrane proteins perform several functions including maintaining the 
membrane integrity, anion exchange, serve as channels for movement of cations, 
involved in transport of glucose, carbon dioxide and oxygen and moreover, they confer 
blood groupings (Kumar and Clark, 2007). Cytoskeletal proteins are crucial for the 
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maintenance of structure and integrity of the erythrocyte membrane. Thus, defects in 
RBC membrane proteins might result in alteration of surface electric charge, and 
mechanical properties of the membrane thus affecting erythrocyte rheology (Baba et al., 
1979; Petropoulos et al., 2007).  
There is increasing evidence regarding association of haemorheological abnormalities in 
T2DM patients leading to increased aggregation, endothelial damage, and capillary 
closure (Adak et al., 2008). These results are consistent with findings by Schwartz et al 
(1991) who demonstrated oxidation of spectrin in diabetic erythrocytes (Schwartz et al., 
1991). A study by Adewoye et al., (2001) showed the absence of spectrin in RBC of 
T2DM patients and increased ankyrin and band-6 in both T1DM and T2DM patients 
(Adewoye et al., 2011; Kaymaz et al., (2005) showed weaker actin and the  absence of 
band 4.5 and band 4.9 in diabetic cats (Kaymaz et al., 2005). Several possible 
interpretations/explanations can be drawn to these alterations in RBC proteins of T2DM 
patients. These include ageing of erythrocytes in diabetes (Mazzanti et al., 1992), the 
relation of AGEs with macrophages (Vlassara et al., 1987) and increased susceptibility 
of membrane proteins to lysis by endogenous enzymes in diabetes (Gaczynska et al., 
1993; Graham Lloyd, 1984). 
Therefore, it can be hypothesised that detection of such alterations in RBC membrane 
proteins of T2DM patients might contribute to the development of CVD and that the 
results of this study might serve as a blood marker for the existence of CVD risk in 
T2DM patients. 
In chapter 5, the results show that markers of inflammation in T2DM patients were 
clearly elevated when compared with healthy controls. This study has also shown a 
significant increase in several other factors in T2DM patients when compared with 
healthy controls. These findings support the hypothesis that low-grade systemic 
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inflammation is an underlying factor in the pathogenesis of T2DM. Furthermore, these 
findings might have important implications for the prevention and treatment of T2DM 
(Libby et al., 2002; Festa et al., 2003; Zozulinska and Wierusz, 2006).  Recently, C- 
reactive protein has emerged as an important independent predictor of CVD in both men 
and women (Ridker et al., 1997; Ridker et al., 2000). It is observed to be present in 
higher levels in diabetic subjects when compared with non-diabetic control subjects 
which suggests that inflammation might contribute to accelerated atherosclerosis in 
diabetes (Ford, 1999).  
Recent cross sectional data have also established that elevated levels of CRP are 
associated with obesity, insulin resistance and glucose intolerance. CRP is a marker of 
low-grade inflammation and it is involved both in insulin secretion and resistance 
through altered innate immune response due to heightened systemic inflammation 
(Pradhan et al., 2001; Pickup, 2004). Diabetic vascular complications induce tissue 
injuries which stimulate cytokine secretions from cells like macrophages and 
endothelium. The biological mechanisms behind this are not very well understood 
(Pickup et al., 1997; Pickup and Crook, 1998). In this study, it was observed that there 
was a higher level of HbA1c in T2DM patients when compared with healthy controls 
which suggests hyperglycaemia.  
High increase in triglyceride level was observed in T2DM patients when compared with 
healthy controls, which is a common feature of DM. Several research studies have 
suggested that this is due to an inhibition of lipolysis as a result of reduced action of 
insulin on adipocytes. This in turn leads to great increase in non-esterified fatty acids 
due to reduced hydrolysis of stored triglycerides. Increased triglycerides and LDL levels 
are risk factors for CVD (Garber, 2000; Nesto, 2008). 
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Impairment of renal function was observed in T2DM patients, which was assessed by 
the measurement of plasma concentrations of creatinine and urea in both T2DM and 
healthy controls. The results of this study were consistent with reports of several other 
workers (Alder 2003; Judykay 2007; Wagle 2010). Plasma creatinine and urea are 
recognized markers of Glomerular Filtration Rate (GFR) and in nephropathy, it is 
suggested that high levels of creatinine which is observed in diabetic patients might be 
due to impairment in the function of nephrons. It is well known that one long term 
complication of T2DM is nephropathy (Kumar and Clark, 2007). Similarly, high levels 
of urea could be a result of reduced filtering capacity of kidneys which leads to 
accumulation of waste products within the system of T2DM patients. Hyperuricemia is 
commonly associated with DM, obesity, hypertension and in the development of CAD 
(Kelley & Palella, 1991; Madsen et al., 2005; Short et al., 2005). 
Plasma glucose was found to be significantly higher in T2DM patients compared with 
healthy controls. One of the earlier studies showed that a higher concentration of 
glucose was observed in T2DM patients when compared with non-diabetic controls 
(D'Souza et al., 2009; Wagle, 2010). Increased liver function test (LFT) abnormalities 
were observed in this study in T2DM patients compared to controls. There was a higher 
incidence of LFT abnormalities in T2DM patients when compared with healthy 
controls. One of the most common marker, is elevated levels of ALT, a gluconeogenic 
enzyme which specifies impairment of insulin signalling rather than merely hepatocyte 
injury (O'Brien and Granner, 1991). Chronic elevations of transaminases in T2DM 
patients reflect underlying insulin resistance.  
Levels of trace elements and cations were observed to be higher in T2DM patients 
compared with healthy controls. Cations and trace elements are required especially for 
the maintenance of healthy metabolism in the body and either the lack or excess of these 
 Page 174 
 
elements can lead to numerous diseases in the body (Kumar and Clark, 2007). The 
results of this study have shown that the levels of various cations including calcium, 
magnesium, zinc, copper, and sodium were significantly elevated in T2DM patients 
compared to controls. These findings are in agreement with previous studies which 
support alteration of these cationic levels in T2DM patients when compared with 
healthy controls (Kazi et al., 2008; Mahmoud et al., 2008). The results of Zn levels in 
the present study are consistent with the findings of Mateo et al (1975) who showed that 
levels of Zn are equal or higher in diabetic patients compared to that of controls which 
might be due to heterogenecity of patients (Mateo et al., 1975; Melchior et al., 1989; 
Zargar et al., 1998). Various studied have shown similar results that diabetic patients 
have higher plasma levels of Zn (Golik et al., 1993; Rohn et al., 1993; Ruiz et al., 1998; 
Zargar et al., 1998). Plasma Zn varies according to metabolic status and hormonal 
changes and hence it is a poor indicator of zinc status. Hyperzincuria is consistent with 
other studies and has been associated with hyperglycaemia (Ekmekcioglu et al., 2001).  
The results of Cu levels are consistent with those reported by Noto et al., (1984) who 
showed high levels of Cu in older subjects (Noto et al., 1984). These results also 
support the findings by Walter et al., 1991 and Zargar et al., 1998 who demonstrated 
high levels of Cu in diabetic women on oral contraceptives and with retinopathy and 
hypertension (Walter et al., 1991; Zargar et al., 1998). Increased concentration of Cu is 
associated with several disorders related to structure of arterial walls, stress, infection 
and diabetes mellitus (Beshgetoor and Hambidge, 1998).  
The results of Mg levels are inconsistent with those findings of several other research 
studies which demonstrated that plasma levels of Mg are lower in diabetic patients than 
controls Mg levels are observed to be higher in T2DM patients compared with healthy 
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controls in this particular study which are consistent with other studies that already have 
been published (Fujii et al., 1982; McNair et al., 1978; Sjögren et al., 1988).  
The results of iron levels are consistent with those of other research studies. DM is 
associated with altered iron homeostasis in both human and animal models. Iron serves 
as a catalyst for lipid and protein oxidation and it is involved in generation of reactive 
oxygen species. It also contributes to diabetic nephropathy. Excessive iron is also 
implicated in the pathogenesis of T2DM and its complications (Thomas et al., 2004).  
Even though the data of this study are observed to be consistent with those of other 
research studies, it is very important to obtain more quantitative data from larger groups 
in order to fully elucidate the relationship between T2DM and various cations in the 
body. Analyses could also be performed between various cations in plasma and 
compare their levels in cells including erythrocytes and lymphocytes.  
Levels of total protein were observed to be lower in T2DM patients when compared 
with healthy controls which are characteristic of nephrotic syndrome that occurs due to 
long standing diabetes and is also the primary indication for dialysis. One of the 
common causes of hypoproteinemia is excessive protein discharge in urine (Hanoune et 
al., 1972; Ahmed, 2010).  
The results presented in Chapter 6 of this study have shown an increased level of low 
molecular weight AGEs in plasma of T2DM patients when compared with healthy 
controls. Incomplete digestion of AGEs-modified protein can result in the formation of 
low-molecular weight AGEs. These LMW-AGEs have a high toxic potential and LMW 
fluorescence increases with duration of disease which appears to be higher in patients 
with T2DM. LMW fluorescence is a marker of tissue fluorescence which is induced in 
DM due to a result of hyperglycaemia and oxidative stress, but not only because of 
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Maillard‘s reaction (Ahmed, 2005; Ahmed and Thornalley, 2007; DSouza et al., 2009; 
Ahmed, 2010). Excessive accumulation of AGEs underlies various complications in 
patients including diabetic neuropathy, nephropathy, vasculopathy and retinopathy 
(Peppa et al., 2003; Ahmed, 2005). AGEs have been implicated in the initiation and 
progression of CVD (Thomas et al., 2005; DSouza et al., 2009). LMW-AGEs can 
predict mortality in patients receiving chronic haemodialysis. (Roberts et al., 2006). 
Therefore, the possible involvement of LMW-AGEs in the mechanisms leading to 
atherosclerosis and inflammation in T2DM patients may need further investigation.  
The main findings of this study show that individual risk factors for both T2DM and 
CVD provide a common soil for the development of either of them or both. This study 
supports a positive association between various markers and T2DM and moreover, it 
supports the hypothesis that inflammation is closely involved in the pathogenesis of 
T2DM.  Clearly, T2DM is more than a risk factor for CVD in T2DM patients. The 
elevated levels of various risk factors and blood borne markers in T2DM patients lead 
to development of CVD. Further studies are needed to establish pathophysiological 
relationship between inflammation and T2DM. 
7.2 Conclusion 
This study was originally designed to investigate how T2DM can lead to CVD and 
subsequent to morbidity and mortality of the patients compared to healthy age-matched 
controls. In doing so, the project employed blood to measure a number of biochemical 
markers and mediators including cations in plasma, intracellular free calcium 
concentrations in WBC, osmotic fragility of RBC and proteins in RBC membrane 
which are associated with the development of T2DM.  The results show that 
inflammation is very strongly associated with micro-vascular complications and CVD 
in diabetes. Measurement of these inflammatory markers in T2DM patients is very 
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important for risk assessment of diabetic complications. Prevalence of T2DM is 
increasing worldwide. There is also an increase in the number of people with CVD 
among T2DM patients.  In order to prevent and to reduce the incidence of 
cardiovascular morbidity and mortality in high-risk diabetic patients, it is imperative to 
emphasize on routine measurements of these blood borne biochemical markers and 
mediators. Although this appears to be a challenging task, strict screening for an 
underlying sub-clinical CVD and aggressive prevention programmes would possibly 
achieve the target in T2DM patients.  
7.3 Limitations 
There are several limitations for this study. The sample size of this study could have 
been larger in terms of T2DM patients and healthy controls in all chapters. T2DM 
patients with diabetic complications including diabetic retinopathy, neuropathy, and 
nephropathy could also have been included in this study. Measurement of [Ca
2+
]i
 
could 
also have been performed in platelets of T2DM patients and controls.  
7.4 Scope for future studies  
 Future studies can involve the measurement of [Ca2+]i
 
in different blood cells 
including basophils, eosinophils and platelets of both T1DM and T2DM patients 
and compare them with healthy controls. In addition, it is also important to 
characterize the different transporters which are associated with cellular Ca
2+
 
homeostasis using specific agents.  
 Studies can also include the measurement of biochemical parameters and more 
inflammatory markers in large population groups and comparison can be done 
with various other populations. These include both T1DM and T2DM patients 
and diabetic patients who suffer from heart failure, coronary heart disease, 
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hypertension, arrhythmias, nephropathy, retinopathy and neuropathy compared 
to controls.  
 Further studies can involve an investigation of age-related changes on various 
measured biochemical parameters concentrating more on different age-group (eg 
15-39, 40-59, 60 and above) taking also into account factors like gender and 
ethnicity.  
 A study of how chronic T1DM and T2DM affect blood vessels and heart at both 
cellular and sub-cellular levels including development of hypertrophy and 
fibrosis could be performed. This will involve the use of animal models for both 
T1DM and T2DM to analyse fibrosis, remodelling and contraction. 
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Chemicals and Reagents 
1) Cold isotonic buffer 
145 mM NaCl  
5 mM KCl 
5 mM Hepes 
2) Hypotonic lysing solution 
15 mM KCl 
0.01 mM EDTA 
1 mM EGTA 
5 mM Hepes (4-2-hydroxyethyl-1-piperazine-ethanesulphonic acid) 
pH = 6.0 
3) RBC incubating solution 
Tris ATP - 5 mM 
KCl - 25 mM 
NaCl - 74 mM 
MgCl2 - 5mM 
EGTA - 0.1 mM 
Tris-HCl - 25 mM  
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